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ABSTRACT OF DISSERTATION 
 
THE ROLE OF ABCG2 IN DRUG ACTIVE TRANSPORT INTO MILK 
Drug active transport into milk is a major concern for breastfeeding mothers and 
healthcare providers. Studies from the literature indicated that breast cancer resistance 
protein (ABCG2) plays an important role in drug transfer into milk. There has been 
limited study on stereoselective interactions with ABCG2.  A mechanistic analysis of flux 
across cell monolayer model is a critical first step toward extrapolating in vitro results for 
predicting in vivo disposition (including distribution into milk), drug disposition or drug-
drug interactions.   
The objectives of this thesis were (1) to establish a “Chemical knockout model” in rat 
for studying drug accumulation into milk, (2) to investigate the impact of stereoselective 
interaction between ABCG2/Abcg2 and pantoprazole on drug transport in milk, (3) to 
understand in vitro monolayer flux model using experimental data and a mechanistic 
mathematical model.  
Quantitive PCR, Western blotting and immunohistochemistry results indicated that 
Abcg2 was up-regulated during lactation and localized on apical side of epithelial cells in 
mammary gland. In vitro and in vivo experiments confirmed that Abcg2 is responsible for 
nitrofurantoin active transport in rat milk and GF120918 was established as a chemical 
knockout model.  
Abcg2 interacts stereoselectively with pantoprazole isomers. A significant different 
apical flux between two pantoprazole isomers was observed in Abcg2-MDCKII cell line. 
The milk to serum (M/S) ratio of (-)-pantoprazole was almost 3 times as that of (+)-
pantoprazole in lactating rats. Administration GF120918 decreased M/S of (-)-
pantoprazole (p<0.001) but not (+)-pantoprazole (p>0.05).  
A stably transfected ABCG2/Abcg2 overexpressing MDCKII cell line was 
successfully created and used to explore the theoretical relationships in a monolayer flux 
model. Based on the profiles of pantoprazole isomer transport, a simple three 
compartment model for drug transfer into breast milk incorporating the permeability-
surface area products for passive diffusion (PSD), paracellular flux (PSPC) and apically 
efflux ABCG2 (PSA,E) transfection was developed.  The mathematical model was 
 
 
developed to more fully understand the interplay of paracellular, passive diffusion, active 
transport, and flux kinetic parameters (Km, Vmax, IC50 and Ki). This model provided useful 
insights into the meaning and limitation of parameters obtained from monolayer flux.  
KEYWORDS:  ABCG2, transporter, chirality, transwell model, lactation, 
mathematical modeling. 
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CHAPTER 1: Introduction  
A. The benefit of breastfeeding and breastfeeding trends in the United States 
Breast milk has been recommended by many advocacy groups as the 
optimal nutrition for infants, such as the American Academy of Pediatrics (AAP), 
the American Medical Association (AMA), the American Dietetic Association 
(ADA) and the World Health Organization (WHO).   An ideal feeding pattern for 
infants would include exclusive breastfeeding for the first 6 months of life and 
breastfeeding with complementary foods from 6 months until at least 12 months 
of age; such consideration would provide optimal nutrition and health protection 
for both infants and mothers (James and Lessen, 2009).  
Breast milk is considered to be most advantageous for providing protective 
nutrients for infants. Some components, including transforming growth factor 
(TGF)-β, interleukin (IL)-10 (Penttila, 2010), erythropoietin, and lactoferrin 
(Rodriguez-Palmero et al., 1999) can reduce the inflammatory response in the 
newborn intestine.  These special components from breast milk work individually 
or in concert to modulate the neonatal immature anti-inflammatory response. Milk 
appears to decrease the incidence of ear infections, diarrhea, lung infections and 
urinary tract infections in babies; such that breast-feeding babies are admitted to 
the hospital less often than the infants fed formula. Moreover, the composition of 
breast milk appears to change according to the newborn infant's needs for 
passive protection at the different ages. Some clinical evidence suggests its 
protective effect against age-related infectious gastroenteritis (Walker, 2010). 
Some elements in breast milk can actively stimulate development of the 
newborn's host defense systems to establish a continuous mucosal protection 
after breastfeeding is terminated (Walker, 2010). There is some evidence that 
breastfeeding improves cognitive development and has an important impact on 
children’s IQ, brain size and white matter development (Kramer et al., 2008; 
Isaacs et al., 2009). Furthermore, those who were breastfed are less likely to 
acquire adult illnesses such as type 1 and 2 diabetes (Kostraba et al., 1993; 
Pettitt et al., 1997; Gunderson, 2008), some cancers (Davis, 1998; Bener et al., 
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2001), asthma (Gdalevich et al., 2001; Chulada et al., 2003), hypertension, 
metabolic syndrome (Nobili et al., 2009) and obesity (Gillman et al., 2001; 
Armstrong and Reilly, 2002; Plagemann and Harder, 2005). For the mother, 
breastfeeding also improves health outcomes, including a reduced risk of breast 
and ovarian cancer (Titus-Ernstoff et al., 2009), type 2 diabetes (Villegas et al., 
2008), rheumatoid arthritis (Mason et al., 1995) and maternal postpartum 
depression (Ip et al., 2009).  
 
Figure 1-1  National trends in rate of breastfeeding. Data source: pre-1999, Ross 
Mothers Survey; 1999–present, CDC NIS (The figure was cited from (Grummer-Strawn 
and Shealy, 2009)) 
Notes: Ross Laboratory Mothers Survey (RLMS), a survey whose primary goal was to 
track usage of infant formula by manufacturing brand. CDC: the Centers for Disease 
Control and Prevention; NIS: the National Immunization Survey. 
Breastfeeding benefits not only the health of mother and infant but also 
provides societal and economic advantages as well as convenience of life issues 
of parenting (Rohde, 1981). These health benefits decrease acute and chronic 
illness in short-term and long-term for both mother and child help to reduce 
health care-related expenses. It has become an important public health strategy 
for decreasing infant and child morbidity and maternal morbidity, and helping to 
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control health care costs. During the last 39 years (1970-2009) the rate of 
breastfeeding had improved in the United States (Figure 1-1)(Grummer-Strawn 
and Shealy, 2009). Rates of initiation of breastfeeding more than doubled from a 
lowest rate of 26.5% in 1970 to 61.9% in 1982. This trend was slightly decreased 
from 1982 until the mid 1990s. In 1990 the rate of initiation of breastfeeding fell to 
51.5%; after that time point, the breast feeding rate again rose and reached 
74.2% in 2005. Trends in breastfeeding at 6 months have paralleled initiation 
trends. In order to drive the maximal benefit for mother, infant and society, new 
Healthy People 2010 set objectives to call for breastfeeding with targets of 75% 
initiation and 50% continuation at 6 months (Grummer-Strawn and Shealy, 
2009).  
B.Drug use during breastfeeding   
A societal concern of drug transfer into human milk has drawn more attention 
following the trend of increasing breastfeeding rate. It was reported the more 
than 90% of women take at least one medication during the first week after 
delivery (Bennet, 1988). Drug surveys have indicated that about 17% of the 
mothers who were still breast-feeding at 4 months had taken at least the 
equivalent of one daily dose of one drug.  Moreover, 5% of the mothers who 
continued to breast-feed were receiving medication for asthma, allergy, 
hypertension, arthritis, diabetes, and epilepsy or migraine (Bennet, 1988).  Drug 
use for infection, pain relief and other acute and chronic disease symptoms 
during breast feeding is very common (Hernadez et al., 2009). 
Most drugs and their metabolites in maternal blood pass the barrier of the 
mammary gland and distribute into the milk. They can modify the production, 
volume and composition of the milk to produce possible short- or long-term 
harmful effects on the infant. Significant drug-related symptoms in breast-fed 
infants [such as irritability, vomiting, sedation, respiratory depression and shock] 
have been reported in clinical cases. One extreme example of clinical case 
reports is the fatal opioid poisoning in a breastfed neonate whose codeine-
prescribed mother was a CYP2D6 (Cytochrome P450 2D6) ultrarapid 
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metabolizer (UM) (Madadi et al., 2009). CYP2D6 is a member of the cytochrome 
P450 system and it is one of the most important enzymes involved in the 
metabolism of xenobiotics in the body. The pathway of codeine and morphine 
metabolism is shown in Figure 1-2.  Although codeine has been recommended 
by the American Academy of Pediatrics as being compatible with breastfeeding, 
a polymorphism of breastfeeding mother in CYP2D6 added complexity to this 
case. Codeine is a prodrug and its analgesic properties are primarily dependent 
on its biotransformation into morphine by the cytochrome enzyme P450 2D6 
(CYP2D6). Its active product, M6G is almost exclusively catalyzed by the 
enzyme uridyl glucuronosyltransferase 2B7 (UGT2B7). Therefore, the breastfed 
infant of a mother who is CYP 2D6 UMs combined with the UGT2B7*2/*2 
genotype may result in increased in dose exposure level and as a result an 
increased risk of life-threatening CNS depression for the newborn (Madadi et al., 
2009). These observations prompted the Food and Drug Administration to issue 
a Public Health Advisory on the topic (Use of Codeine By Some Breastfeeding 
Mothers May Lead To Life-Threatening Side Effects In Nursing Babies) 
There also may be long term, more subtle developmental effects of drug 
exposure at early stages of life which are very difficult to monitor or ascribe 
cause and effect (Arendt, 1997; Khaksari et al., 2009). Likewise there may be 
consequences for mother and child if maternal pharmacotherapy is forgone.   For 
example, untreated depression may have a deleterious effect on the emotional 
development of their children and significant  depression, especially if 
complicated by delusions, may lead to the mother attempting suicide and 
infanticide (Gentile, 2005). Consequently maternal medication during lactation 
must consider not only benefit of breastfeeding but also health of mother and 
infant.  Doctors need to help mothers weigh the risks of prenatal exposure to 
drugs for their babies against the potential risks of untreated illness or to forego 
the benefits of breastfeeding. These therapeutic considerations include 
susceptibility to drug toxicity of the very young or premature infant, significant 
individual variations in drug response, the dose-response relationship with 
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respect to drug toxicity and the role of pharmacogenetics in both the mother and 
the infant (Berlin et al., 2009).  
 
Figure 1-2 The pathway of codeine and morphine metabolism. Figure is cited from 
(Thorn et al., 2009) 
While the above consideration is warranted, there are very few studies 
conducted in breastfeeding women and their infants to make an appropriate risk 
assessment for drug use in lactation.  A 2003 FDA analysis of the prescribing 
information of the 1022 drugs in the Physician’s Desk Reference illustrates the 
problem (Uhl et al., 2003).  Only 25% of drug labels had information of drug 
transport in human milk and/ or effects in nursing infants.  In addition, 16% of 
drug labels had information on drug excretion into milk in animals and more than 
half of them had no information at all.  The problem is not limited to older drugs. It 
was estimated that less than 10% of the new molecular entities approved 
between 1995 and 2002 gave any information on human milk transfer in their 
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regulatory filings (Uhl et al., 2003).  Therefore, considerable confusion in the 
scientific community regarding this issue exists (Friguls et al., 2010): should a 
woman breastfeed her baby while continuing to use prescription drugs and/or 
drugs of abuse? What is the mechanism of drug transfer into milk? What is the 
extent of drug exposure and does this present a significant risk to the newborn? 
The discussion of the mechanism of drug transfer into milk is one of the critical 
steps to address these questions.  
C.Physiological mechanisms of drug transfer into milk 
1.Physiology of mammary gland 
 
 
 
Figure 1-3 The development of structure of mouse mammary gland under the control of 
hormones in ontogeny. The proportion of epithelial cells in lactating are obviously 
increased than in non-lactating and involution. The solid green circle represents the 
nipple (N) from which the ducts originate. The ends of growing ducts form terminal end 
buds (TEB) during puberty. Mammary ducts (D) are shown as solid lines and the 
lobuloalveolar structures are presented as yellow circles (A). Epidermal growth factor 
(EGF) signals through the stroma and controls early ductal outgrowth. Together with 
estrogen, it also controls ductal elongation and branching during puberty. Progesterone, 
placental lactogens, prolactin, and the osteoclast differentiation factor signal alveolar 
proliferation and differentiation during pregnancy and possibly lactation. The figure was 
modified from Lothar Hennighausen’s paper (Hennighausen and Robinson, 2001).  
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Briefly, the mammary gland is comprised of epithelium and stroma. The 
functional unit of milk production is alveoli which are formed by two types of 
epithelial cells. The majority are luminal secretory cells which produce breast milk 
and secrete it into a central lumen.  These cells can form the barrier between the 
breast milk and the maternal circulation.  The development of the mammary 
gland is different from most of other organs. It estabolishes in embryo and further 
development, predominant differentiation and proliferation of mammary gland, 
occurs after birth and under the control of hormones (Figure 1-3). The embryonic, 
prepubertal, pubertal, pregnancy, lactation and involution stages are connected 
with sexual development and reproduction. Following initial embryonic and 
prepubertal stages, the growth and development of mammary gland is 
dependent on the stimulation of hormones. The steroid hormones control ductal 
and alveolar development. It has been proposed that progesterone through 
activating Wnt signaling pathway is essential for the cell proliferation of mammary 
gland (Brisken et al., 2000). Both estrogen and progesterone induce ductal side 
branching in mice (Xu et al., 2000). The proliferation and differentiation of 
secretory mammary gland epithelium are dependent on the interaction between 
prolactin and prolactin receptor (PrIR) (Ormandy et al., 1997) and the 
downstream Jak-Stat5 pathway. Jak-Stat5 signaling pathway controls cell 
proliferation, differentiation and specification in development of mammary gland.  
During a successful pregnancy, hormonal changes associated with pregnancy 
induce series changes in the maternal hypothalamus, stimulating maternal body 
development to prepare for lactation. The size and number of alveoli grows and 
develops under hormonal stimulation and intercellular gaps close for the 
preparation of lactation  (Neville and Watters, 1983). The inner structure and ratio 
of cell types in mammary gland undergoes significant change. The proportion of 
epithelial cells in lactation is obviously increased than in non-lactation (Figure 1-
3).  
2. Milk components and secretion pathways  
Drug is likely to be transported into milk via the same pathways which milk 
components secreted from serum or secretary cells into lactating mammary 
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gland. Therefore, to fully understand drug accumulation into milk it is helpful to 
examine the mechanism of milk formation itself. 
 Breast milk has evolved in mammals to enrich all necessary nutrients for the 
growth and development of the newborn. The various milk components include 
lipids, protein, carbohydrates, water, calcium and phosphorus, iron, zinc, copper, 
manganese, selenium, iodine, vitamins D, K, A, E, C, thiamine, riboflavin, niacin, 
pantothenic acid, pyridoxine, biotin, folate, and cyanocobalamine (Nichols and 
Nichols, 1981).  
From the cell biology of lactating alveolar cells in mammary gland, there are 
a number of potential barriers to the transfer of exogenous substances from 
blood to milk side: (1) vascular or stromal membranes; (2) basement membrane; 
(3) basal epithelial membranes, (4) paracellular junctional complexes, (5) Golgi 
membranes and (6) apical epithelial membranes (McManaman and Neville, 
2003). Some proteins in milk are synthesized and secreted by the epithelial cells 
themselves. The major amounts of lactation-specific proteins present in milk are 
synthesized in rough endoplasmic reticulum (Larson, 1979) and then secreting 
into the Golgi apparatus to finish post-translational modifications and ejected into 
the lumen with other milk components (Larson, 1979).  Substances derived from 
maternal circulation get into milk by overcoming the various barriers between 
blood and milk. The five pathways for solute to enter milk by transcellular and 
paracellular routes are summarized in Figure 1-4 (McManaman and Neville, 
2003). 
Pathway I: Aqueous solutes include the major milk proteins, 
oligosaccharides, and nutrients such as lactose, citrate, phosphate and calcium. 
They are secreted through an exocytotic pathway.  
Pathway II:  Primarily triglycerides and lipid-associated proteins are secreted 
by a process unique to mammary epithelial cells (Mather and Keenan, 1998).  
Pathway III: It is a transcytosis pathway and transports a wide range of 
macromolecular substances derived from plasma or stromal cells, including 
endocrine hormones such as prolactin, insulin and estrogen (Koldovsky, 1995; 
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Ollivier-Bousquet, 1998); serum proteins such as albumin, transferrin and 
immunoglobulins (Hunziker and Kraehenbuhl, 1998); and stromal derived agents 
such as secretory immunoglobulin A, cytokines and lipoprotein lipase (Goldman 
et al., 1996; McManaman and Neville, 2003). 
 
 
 
Figure 1-4  Diagram of mammary alveolus and alveolar epithelial cell showing pathways 
for milk secretion. Abbreviations: SV, secretory vesicle; RER, rough endoplasmic 
reticulum; BM, basement membrane; N, nucleus; PC, plasma cell; FDA, fat depleted 
adipocyte; JC, junctional complex containing the tight and adherens junctions; GJ, gap 
junction; ME, myoepithelial cell. MFG, membrane bound milk fat globule.  Figure is cited 
from (McManaman and Neville, 2003). 
Pathway IV: For the transfer of ions and small molecules, such as glucose, 
amino acids, and water across basolateral and apical plasma membranes. 
Pathway I and II are for secretion of endogenously generated substances. 
Pathway III and IV exist for transport of exogenous substances to milk. 
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Pathway V: Paracellular transport provides an entry of plasma components, 
leukocytes, serum and interstitial substances into milk (Nguyen and Neville, 
1998). Pathway V is typically open but becomes very restricted during lactation. 
This pathway is open during pregnancy, involution and in inflammatory states 
such as mastitis. 
D.The pathway of drug transfer into milk 
1. Paracellular transport 
Paracellular transport (Pathway V) plays minimal role in drug accumulation in 
milk. One would anticipate that some small, polar molecules are candidates for 
diffusion through the paracellular pathway since molecular size is the most 
relevant parameter relating to rate of diffusion through the restricted paracellular 
route. Pathway V is closed by the tight junctions between epithelial cells during 
lactation in humans and most other species except rabbit (McManaman and 
Neville, 2003) (Figure 1-4). Therefore drugs are transferred at a slow rate and in 
very low amounts by paracellular transport; hence, this pathway is generally 
considered negligible for most drugs.  
2. Transcellular passive diffusion 
Theoretically, passive diffusion is expected to be a common pathway for 
most endogenous or exogenous substances (including drugs, environment toxins 
and their metabolites) in blood circulation to pass through the barriers of alveolar 
epithelial cell and distribute into milk. Smaller, more lipophilic molecules partition 
into lipid bilayers and pass more readily through the epithelial membranes. The 
equilibrium between serum and milk tends to be rapid and there is no need for 
the assistance of transporters.  
The drug concentration in milk is proportional to the corresponding 
concentration in maternal serum based on the passive diffusion pathway. The 
parameter, milk to serum (M/S) ratio, which compares milk with maternal plasma 
drug concentrations, serves as an index of the extent of drug excretion in milk. 
Drug distribution resulting in passive diffusion between serum and milk can be 
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predicted or estimated by a diffusion model (Fleishaker, 2003) and calculated by 
Eq.1-1.  
                                                                                      Eq. 1-1                                   
                                              
where fu is the unionized fraction of drug in serum or milk, f is the free fraction of 
drug in serum or milk, W/S is the ratio of the drug concentration in whole milk to 
the drug concentration in skim milk, and the subscripts s and m represent serum 
and milk, respectively. 
 
Figure 1-5 M/S predicted vs observed in rabbit, rat and human for a number of drugs.  
Exceptions include: nitrofurantoin (NF), cimetidine (CM), acyclovir (ACV), ranitidine (RN) 
and ciprofloxicin (CP). 
Figure 1-5 shows that the results of passive diffusion model (M/SDif) to 
predict drug M/S ratios from a series of experiments which were conducted in 
lactating rabbits, rats and humans (Fleishaker and McNamara, 1988a; Fleishaker 
and McNamara, 1988b; McNamara et al., 1991; McNamara et al., 1992a; 
McNamara et al., 1992b). It illustrates the relationship observed M/S versus 
M/SDif for ten drugs: propranolol, phenobarbital, phenytoin, diazepam, 
acetaminophen, antipyrine, salicylic acid, caffeine, paraxanthine and cimetidine. 
The diffusion model predicted well the transport into milk for all drugs in rabbit 
and many of the drugs in rat and human. For some drugs, such as cimetidine 
and nitrofurantoin, the observed M/S in rat and human milk clearly exceeded the 
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diffusion prediction. The prototypical example is nitrofurantoin in rat and clinical 
studies. Oo et al. showed that an infusion of 0.5 mg/h nitrofurantoin resulted in an 
M/S in vivo that was almost 100 times greater than the value from the diffusion 
prediction (31.1± 4.0 v. 0.3 ± 0.1) in rat. In a clinical study, M/S determined by a 
ratio of the nitrofurantoin AUC in milk and serum was 22 times as the predicted 
M/S diff. (6.21 ± 2.71 vs. 0.28 ± 0.05) (Gerk et al., 2001a). CM and RN transfer 
into rat milk could be saturated and inhibited (McNamara et al., 1996). Taken 
together, these results suggest the presence of the active transport processes 
across the mammary epithelium that are involved in drug accumulation into milk 
(Oo et al., 2001).  
3. Transcellular active transport 
In some instances, physical and chemical properties such as size, charge, 
and hydrophilicity are impediments for drug passage across biological 
membranes (Klaassen and Aleksunes, 2010).  Pathway IV includes some solute-
specific mechanisms for the transport of ions and small molecules such as 
glucose and amino acids.  These processes require the presence of specific 
transporters on the basolateral or apical side of epithelial cells.  A number of 
transporters have been shown to be expressed in lactating mammary epithelial 
cells and are responsible for various components transport into milk. Some of 
them are likely to be involved in drug accumulation in milk as well.  
E.Transporter expression in lactation  
During lactating, the change of alveoli in mammary gland is not only in size 
and number but also in protein expression on epithelial cells for the preparation 
of lactation, including glucose, amino acid transporters. In order to exclude the 
effect of the changes of mammary gland in structure on the investigation of 
transporter expression during lactation, Alcorn et al first isolated a pure 
population of epithelial cells from human breast milk and reduction 
mammoplastic clinical samples to investigate 30 transporter expressions in 
lactating mammary gland by quantitative reverse transcription-polymerase chain 
reaction (Alcorn et al., 2002). In order to cover a broader array of transporter 
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expression in lactating mammary gland, Phil Empey (Thesis) used a similar 
approach to isolate a pure population of epithelial cells for subsequent gene 
expression profiling by microarray. From his dissertation work, the results of 
microarray analysis discovered that ABCG2, SLC15A2, SLC22A12, SLC6A14, 
and SLCO4C1 were significantly up-regulated during lactation (164-, 70-, 41-, 8-, 
and 2-fold, respectively). ABCC10, SLC10A1, SLC16A1, SLC22A4, SLC22A5, 
SLC22A9, SLC28A3, SLC29A1, SLC29A2, and SLCO4A1 had an expression 
level similar to, or greater than, levels in the kidney or liver (Table 1-1, from Phil 
Empey’s dissertation).   
PEPT2 is an oligopeptide transporter generally characterized as an apical 
uptake transporter (Shen et al., 1999) and if a similar location/function were also 
true for lactating mammary epithelium, an associated flux would more likely to 
diminish drug concentration in milk. SLC22A12 (an organic anion/urate 
transporter) and SLC6A14 (amino acid transporter) are also present at increased 
RNA expression level, but these transporters appear to play a less likely role in 
drug transport (Anderson et al., 2008; Ohtsu et al., 2010).  However, one 
investigation showed 1-Methyltryptophan, which is an inducer of immune 
surveillance against tumor cells by inhibiting indoleamine dioxygenase, is a 
substrate for SLC6A14 [ATB(0,+)](Karunakaran et al., 2008). Therefore, 
additional studies should be performed to investigate whether ATB (0, +) has a 
role in drug transport into milk. The significant up-regulation of SLCO4C1 is a 
novel finding.  SLCO4C1 has not been widely studied, but is considered to be an 
uptake basolateral transporter (Chu et al., 2007; Cheng and Klaassen, 2009).  
SLCO4C1 belongs to the organic anion transporting polypeptides (OATP) family 
of influx transporters expressed in numerous  tissues (liver, brain, intestine, 
kidney) and facilitate the tissue uptake of substrate drugs (Kalliokoski and Niemi, 
2009). A number of recent reports have shown that OATP uptake transporters 
(e.g, OATP1B1) on the basolateral membrane can function in concert with apical 
efflux transporters (e.g., P-gp, MRP2 and ABCG2) to facilitate the transcellular 
transport of drugs (Matsushima et al., 2005). The most important and established 
efflux transporter on apical side of epithelial cells in lactating mammary gland is 
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ABCG2. Therefore, a reasonable hypothesis is that SLCO4C1 coordinates with 
ABCG2 to regulate substrate movement into breast milk. However, unpublished 
data from our group studies (Kuei-ling Kuo) suggests that SLCO4C1 is on the 
apical instead of the basolateral membrane.  
 
 
 
 
 
 
 
 
1
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Table 1-1 Comparison of Affymetrix U133 plus 2.0 array transporter probeset expression levels in human LMEC (lactating luminal 
mammary epithelial cell) vs. MEC (mammary epithelial cell). Genes are grouped based on whether they are increased or decreased 
during lactation.  Probesets for the same gene were grouped into sections of the table sorted by fold change in expression (From Phil 
Empey’s dissertation). 
 
Gene     LMEC MEC Fold  
 Symbol Probeset ID p-Value Mean SD Mean SD Change 
Higher during lactation (p < 0.05, fold change >1) 
ABCG2 209735_at 3.69E-02 17536 5964 107 75 164.04 
SLCO4C1 222071_s_at 2.39E-03 3362 294 48 31 69.70 
SLC15A2 205316_at 3.62E-03 3936 421 96 47 40.80 
 
205317_s_at 2.16E-03 868 182 89 62 9.72 
 
240159_at 8.99E-04 243 31 76 10 3.18 
SLC22A12 237799_at 2.79E-02 184 80 24 19 7.84 
SLC6A14 219795_at 4.13E-02 3988 1193 1773 500 2.25 
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F. ABCG2 
1.General introduction of ABCG2  
The ATP binding cassette (ABC) transporter family is a large protein 
superfamily. ABC transporters are widely distributed in membranes of all 
organisms from bacteria to mammals, such as in the brush border membrane of 
intestinal cells, the canalicular and sinusoidal membrane of hepatocytes, the 
luminal and basolateral membrane in the proximal tubules of the kidney and in 
the endothelial cell of the brain capillaries (Kos and Ford, 2009; Wang et al., 
2009a; Klaassen and Aleksunes, 2010). They are responsible for transport of a 
wide variety of compounds through cell membranes against concentration 
gradient using the energy of ATP hydrolysis for the process of substrate 
translocation (Rocchi et al., 2000). The existence of ABC transporters can have a 
significant effect on the absorption distribution metabolism elimination (ADME), 
toxicity and the adverse drug-drug interactions of substrate drugs.  
ABCG2 is a member of ABC family subfamily G and it has been confirmed as 
an important transporter in mammalian defense system. ABCG2 is also named 
as mitoxantrone resistance-associated protein (MXR) or breast cancer resistance 
protein (BCRP) because it was first cloned from a multidrug-resistant breast 
cancer cell line (Doyle et al., 1998); however, subsequent studies indicate that 
BCRP is not a unique or special characteristic for breast cancer cells and many 
of these cells were found lacking BCRP expression (van Herwaarden and 
Schinkel, 2006). A growing body of evidence strongly suggests that ABCG2 is 
one of the more important efflux transporters having a strong impact on the 
pharmacokinetic profile, pharmacodynamics, and toxicity of drugs.  
The typical structure of the majority of mammalian ABC transporters contains 
2 types of structural domains: the hydrophobic membrane spanning domain 
(MSD) comprising several transmembrane α-helices and the hydrophilic, 
intracellular nucleotide binding domain (NBD) (Mao and Unadkat, 2005). The 
mRNA of ABCG2 encodes a 655 amino acid protein (72-kDa) that contains a 
single N-terminal ATP binding cassette followed by six trans-membrane 
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segments. Comparison of protein sequences with that of P-gp and MRP1, 
ABCG2 proteins are half transporters that are composed of a single NBD 
followed by one MSD. Hence, the structure of ABCG2 appears to be a half 
transporter and functions as a homodimer (Doyle and Ross, 2003) or 
heterodimers (Xu et al., 2004). Kage et al demonstrated that the breast cancer 
resistance protein (BCRP, ABCG2) forms an S-S homodimer (Kage et al., 2002) 
and Cys-603 is an important residue in the formation of the covalent bridge 
between BCRP monomers (Kage et al., 2005). Recently the results from 
mutation of Cys at different position of ABCG2 indicated that Cys-mediated 
covalent dimerization is not required for ABCG2 to function as a transporter and 
that Cys-603, Cys-608 may also be involved in BCRP dimmer formation (Figure 
1-6) (Shigeta et al., 2010).  
ABCG2 polymorphisms that alter expression or function of protein have been 
observed and it has been reported that variants of ABCG2 greatly impact the oral 
bioavailability and clearance of ABCG2 substrates (Ishikawa et al., 2005). Some 
studies have characterized the possible physiological relevance of the ABCG2 
polymorphism and functional variants (Mao and Unadkat, 2005). To date, 
sequencing of the ABCG2 gene from human samples has discovered over 80 
different, naturally occurring sequence variations (Ishikawa et al., 2005). In 
general, the studies of polymorphisms of ABCG2 have been focused on 
resistance of anticancer drugs. For example, a variant at position 482 which is 
responsible for the resistance to mitoxantrone, doxorubicin, and daunorubicin, 
reduces daunorubicin accumulation and retention, and causes an ATP-
dependent enhancement of the efflux of rhodamine 123 in the cloned transfected 
cells. At least three variant forms of ABCG2 have been documented on the basis 
of their amino acid moieties (i.e.,arginine, glycine and threonine) at position 482 
(Mitomo et al., 2003).  They have been reported causing change of drug 
resistance profile and substrate specificity.  
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Figure 1-6 Schematic depiction of the breast cancer resistance protein (BCRP) with 12 
cysteine residues indicated. Three of these residues, Cys-592, Cys-603, and Cys-608, 
are localized in the third extracellular domain (Shigeta et al., 2010). 
ABCG2 is abundant in the luminal membrane of endothelial cells of blood 
capillaries in the brain, epithelial cells of placenta, kidney, liver and intestine to 
limit endogenous or exogenous xenotoxins into body (van Herwaarden and 
Schinkel, 2006), and importantly in most of cancer cells where ABCG2 plays 
important roles to resist chemotherapy or acquire resistance during treatment.  
2. ABCG2 and drug transfer into milk 
As mentioned in previous section, nitrofurantoin and cimetidine are actively 
transported into human and rat milk, and result in drug accumulation much 
greater than predicted by the diffusion model.  However, the mechanism 
remained unknown until studies at the Netherlands Cancer Institute (Jonker et 
al., 2005; Merino et al., 2005b) which indicated that ABCG2 was strongly up-
regulated in the mammary gland of mice, cows and humans during lactation and 
was responsible for the active secretion of clinically and toxicologically important 
substrates into mouse milk, such as the dietary carcinogen PhIP, the anticancer 
drug topotecan and the antiulcerative cimetidine (Jonker et al., 2005).   
ABCG2 and P-glycoprotein are generally considered to be protective 
transporters.  In general, they play a role in barrier systems (e.g., blood brain 
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barrier, placenta, gut wall) that protect more vulnerable entities (e.g., brain, fetus, 
and whole body) from harmful xenobiotics.   Hence, the physiologic function of 
ABCG2 in lactating mammary epithelium is not fully understood, since high 
concentration of drugs and environment toxins in milk may be harmful to infants.  
Evolution would tend to favor physiology that is efficient and protects the 
developing newborn. ABCG2 transporting drug and toxin to milk would run 
counter to this tenet. The study of riboflavin suggests a possible physiological 
role for ABCG2 in lactating mammary epithelial cells.  As an important vitamin, 
riboflavin can be converted to the essential coenzymes which participate as 
electron carriers in many important redox reaction chains in body (Powers, 
2003); however, riboflavin cannot be synthesized by mammals.  Riboflavin is an 
ABCG2 substrate and is transferred into milk by ABCG2 (van Herwaarden et al., 
2007) which could imply that ABCG2 may be serve as a milk vitamin and nutrient 
transporter.   
G. In vivo model to study drug transport  
Knockout mouse models are the most popular in vivo approaches for the 
function study of transporter or other proteins (Kooij et al., 2009; Lagas et al., 
2009a; O'Byrne et al., 2009). The alteration of drug disposition following the 
knockout of a specific transporter provides compelling evidence for the 
significance of the transporter (Agarwal et al., 2010; de Waart et al., 2010; 
Kodaira et al., 2010). However, mammalian physiology is a complex, 
interconnected system and no one protein or pathway is truely independent. In 
some transporter knockout mice models, the mice cannot survive from disease or 
nutritive deficiency, such as deletion of the taurine transporter gene (taut) which 
results in all taut-/- mice succumbing to infections (Delic et al., 2010), whereas in 
other examples, the homeostasis is maintained in a relative normal state even if 
one important pathway has been impaired.  This would imply that the pathway 
associated with the transporter may not be the only one responsible for function 
or there are adjustments on compensatory mechanism. The body is under an 
integrated regulation control to maintain the normal physiologic function.  
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It has been observed that the expression of other proteins changes after 
knocking out a specific protein in several transporter knockout studies (Chu et al., 
2006; Kooij et al., 2009). For example, Mdr1a deficient mice express 3 times as 
much Abcg2 compared to wild-type mice (Cisternino et al., 2004); the level of 
Mrp4 mRNA and protein expression in liver and kidney of Mrp2 (-/-) mice 
increase approximately 6- and 2-fold, respectively (Chu et al., 2006). Whether or 
not these increased expressions of other transporters provide a compensatory 
mechanism in these knockout mice models will depend upon the particular 
substrates (or biochemical pathway).   Nonetheless, there may be unintended 
and unknown consequences following the knockout of a specific gene.  
Inhibition of transport of a compound by a specific inhibitor is often used for 
transporter studies in in vitro experiment, and a chemical knockout could be an 
alternative way to overcome shortcomings of a knockout mouse model if the 
function of a transporter in vivo can be completely inhibited. A critical criterion in 
selecting an inhibitor is specificity. Many inhibitors are nonspecific and they 
interact with several transporters and even drug metabolism enzyme (Matsson et 
al., 2009). The inhibitor specificities of P-gp, BCRP and MRP2 were shown to be 
overlapping. Moreover, P-gp and CYP3A4 have significant overlap in substrate 
specificity (Kim et al., 1999).  So the specificity of an inhibitor as a “chemical 
knockout” should be considered carefully when correlating the organ with 
multiple different transporter expressions, such as kidney and liver. GF120918 
(N-(4-[2-(1, 2, 3, 4-tetrahydro-6,7-dimethoxy-2-isoquinolinyl)ethyl]-phenyl)-9,10-
dihydro-5-methoxy-9-oxo-4-acridine carboxamide) is an inhibitor for both P-gp 
and ABCG2; however, P-gp is not expressed in mammary gland.  The rat is the 
most common animal model for drug development.  A functional blockade of 
rAbcg2 by a specific inhibitor (a “chemical knock out”) resulting in a decrease in 
active drug transport into milk would be a useful in vivo model for verification of in 
vitro experiments.  
H. In vitro models to study drug transport 
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Optimal pharmaceutical therapy delivers drug to the target site(s) in the body 
at concentrations adequate to obtain a positive pharmacological effect.  One 
factor affecting drug reaching the target site, as well as systemic exposure is 
drug transport into and out of cells (David T. Rossi, 2002). The presence of 
transporter(s) has been shown to affect the therapeutic consequence of many 
important drugs. Therefore, in order to decrease the cost in drug development 
and optimize the pharmacokinetic properties of drug candidates during the early 
stages, characterizing drug transporter interaction is a widely accepted strategy 
(White, 2000; Roberts, 2001).  Broadly, in vitro methods are the most common 
choice to evaluate key pharmacokinetic properties of drugs in pharmaceutical 
industry.  These in vitro systems tend to focus on drug metabolism enzymes and 
transporter (Yamashita et al., 2002; Schwab et al., 2003; Zhou et al., 2010). In 
general, the range of these available in vitro tools scale from relatively simple 
biochemical approaches to complex cell culture model.   
1. ATPase assay for ABC transporters  
ATPase assay is one of a limited number of traditional biochemical available 
methods for the assessment of drug transporter function (Stanley et al., 2009). 
The method is based on the realization that transporters utilize the energy from 
ATP hydrolysis for substrates translocation (Figure 1-7). It measures the 
utilization of ATP and indirectly provides an estimate of transporter mediated 
drug transport (Gannon et al., 2009; Robey et al., 2009).  For example, ATPase 
activity measured in the presence of orthovanadate represents non-P-gp ATPase 
activity and can be subtracted from the activity generated without orthovanadate 
to yield vanadate-sensitive ATPase activity (Schwab et al., 2003). In this method, 
isolation of intact membranes is important to estimate vectorial transport but it is 
controllable and easier than other biological systems (transwell monolayer or Sf9 
vesicles). It can be used for high throughput screening since we do not have to 
develop a specific assay for each drug.  However, this method is, at best, a proxy 
for actual directional transport (Stanley et al., 2009). Also some substrates that 
are transported do not stimulate ATPase activity and, hence, this approach would 
result in false negatives.  
22 
 
 
Figure 1-7 The mechanism of ATPase assay for ABC transporters. This figure is cited 
from the homepage of SOLVO Biotechnology Company 
(http://www.solvobiotech.com/Solvo%20Solutions/atpase_assays.html ) 
2. Monolayer flux model for transcellular transport assay  
Flux across a monolayer of cells grown on a porous plexiglass filter (i.e., 
sometimes referred to as Transwell after the name of the filter system) is the 
most popular method to study transporter. Monolayer flux model provides an 
efficient, low throughput pathway to screen new molecule entries in drug 
discovery (Balimane et al., 2004; Xiao et al., 2006), or study drug-drug interaction 
(Marchetti et al., 2007; Wang et al., 2009b) and drug transport mechanism 
(Wang et al., 2009b). It mimics in vivo environment by culturing specific cell lines 
on the permeable supports. These cells can polarize and form an integrated 
monolayer with tight junction on the support membrane. This model produces a 
separate apical or basolateral domain for the different purpose studies, uptake, 
efflux or secretion. Selection of an appropriate cell line is a key step to establish 
an appropriate model system. The cell lines which are often used for monolayer 
flux studies include the following:   
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Primary cell lines  
Primary cell culture involves the use of cells that are directly isolated from 
tissues or organs and may most closely mimic in vivo environment.  Cultures are 
established either as explants, using mixed cell populations from small fragments 
of tissues, or using purified populations of defined cell types. For the explant 
culture, one type cell could adapt in vitro environment quickly than other cell 
types by proliferating rapidly and outgrowing (Burdall et al., 2003).  It should be 
noted that explants culture may be significantly different from the original 
structure of tissue or organ. This is a particular problem with explants, and so 
primary cultures may be more desirable and controllable.  Primary culture 
typically involves the preparation of the cells every time and not as a continuous 
culture; hence, it tends to be labor intensive and may lack the necessary 
reproducibility to compare results across a series of experiments (Stanley et al., 
2009).  
Continuous culture cell lines 
 In order to overcome the disadvantages of primary cell culture and meet the 
preference for cell culture that is reproducible and easy to work with, several 
continuous cell lines have been established for drug transporter study. They also 
can be used as host (parent cell lines) to overexpress a single or double specific 
transporter(s) for further function study.   
CaCo-2 is a human colon tumor-derived cell line that has been widely used 
for the high-throughput screening of drug permeability and identification of 
substrates, inhibitors, and inducers of intestinal transporters (Sun et al., 2008).  
The CaCo-2 screening system has remained a popular in vitro model to test 
compounds for intestinal permeability and efflux liability for more than a decade 
(Press and Di Grandi, 2008). CaCo-2 was considered by the pharmaceutical 
industry for the development of cell culture systems that could mimic intestinal 
mucosa and thereby mimic drug absorption. The CaCo-2 cell line has a well-
differentiated brush border on the apical surface and tight junctions, and 
expresses typical small-intestinal microvillus hydrolases and nutrient 
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transporters. In addition, since differentiated CaCo-2 cells express various 
cytochrome P450 isoforms and phase II enzymes such as UDP-
glucuronosyltransferases, sulfotransferases and glutathione-S-transferases, this 
model could also allow the study of presystemic drug metabolism (Meunier et al., 
1995). The CaCo-2 is popular because it is of human origin, easy to maintain 
(Ohashi et al., 2009) and derived from a colon cancer. In addition, as a single cell 
line, it expresses the appropriate polarized phenotype as in vivo but it is free of 
mucus and underlying submucosal and muscular tissue, which could interfere 
with drug transport. 
LLC-PK1, the porcine kidney cell line, LLC-PK1, has been used as a model 
for drug-transport studies for around 15 years (Aszalos, 2004). LLC-PK1 cells 
have a polarized phenotype in culture and express some endogenous P-gp 
activity (porcine P-gp). The presence of porcine P-gp in LLC-PK1 cells may 
compromise the results of in vitro studies using this cell line (Yamazaki et al., 
2001). The main disadvantage of the LLC-PK1 cell line is it is non-human and 
non-rodent origin. However, this cell line is easy to work with and responds well 
to transduction with adenoviral vectors (Brimer et al., 2000).  
MDCKII (Madin-Darby canine kidney strain II cells), has been used as a 
model for drug-transport studies for around 20 years (Aszalos, 2004). This cell 
line has been widely used to establish transporter transfection model, such as P-
gp (Shirasaka et al., 2009; Tachibana et al., 2010), MRP2 (Lechner et al., 2010) 
and ABCG2 (Tournier et al., 2009). MDCKII cells grow fast, form relatively tight 
junction, produce interpretable data of relevance for clinicians (Keogh and Kunta, 
2006a) and with low expression level of MDR1,  MRP1 and  MRP2. MDCKII has 
been well characterized as a good host cell line for transfection.  
Overexpressing transporter cell lines 
The overexpressing transporter system is an effective tool for studying the 
activity of individual transport processes.  It brought into perspective the 
possibility to investigate transporter interaction with substrate on monolayer. 
Usually, the difference between efflux ratios on the transfected and parental cell 
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lines is regarded as transporter mediated active uptake or efflux process (van 
Herwaarden et al., 2007; Zhou et al., 2008; Lagas et al., 2009b).  To date, 
overexpressing transporter in a host cell line has been a widely accepted 
technique.  P-gp, MRP2, ABCG2 and other transporters have been 
overexpressed in CaCo-2, LLC-PK1 and MDCKI or II for different study 
purposes. The expression level and the function of specific transporter can be 
characterized and provide some pharmacokinetic insights, however, this method 
may not reflect the in vivo condition.  
3. Membrane vesicles with transporter protein 
Another popular method to study transporter is membrane vesicle of insect or 
mammalian cells which also introduces the overexpressing transporter system 
into a host cell line. Target transporter can be expressed on membrane of cells 
by either stable transfection (heterologously overexpressed) or baculovirus-
mediated expression in insect cells. In general, stable overexpression is most 
often chosen for mammalian cell lines, such as MDCKII, LLC-PK1 and CaCo2 
(Burger et al., 2005; de Wolf et al., 2008; Zhao et al., 2009; Zhang et al., 2010).  
Although it is possible to perform in insect cell lines (Kohler et al., 2000; Kempf et 
al., 2002); however, single insect cells are not easy to grow and the 
establishment of a monoclonal cell line is difficult following transfection.  Hence, 
there is a limited number of studies which include other proteins (such as 
receptor) overexpressed in Sf9 insect cells. In most of situations these cells were 
used as a population after selection and the percentage of expression cells 
would be estimated (Kohler et al., 2000; Kempf et al., 2002).  
Baculovirus-mediated expression in insect cells is a well-accepted approach 
to produce recombinant transporter protein. It is frequently used because it is 
relatively easy to use and the high likelihood of acquiring expected expression 
level of heterologous protein and the high probability of obtaining a biologically 
active protein. Insect cell is a popular alternative host to bacteria for expression 
of recombinant proteins. Several factors contribute to this widespread use, 
including the development of vectors with features that provide ease-of-use and 
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high expression levels of recombinant protein, post-translational modifications 
such as glycosylation and phosphorylation which mimic those modifications in 
mammalian cells. Hence, Baculovirus-mediated transporter expressing in insect 
cells could be used for mammalian transporter study of qualitative 
pharmacokinetic estimates (Pedersen et al., 2008; Lagas et al., 2009b; Vaidya et 
al., 2009).  
Membrane fractions can be isolated from overexpressing transporter in either 
mammalian cells or insect cells. The membrane fraction including functional 
transporter would form vesicles. Theoretically, the orientations of these vesicles 
are half and half (50% is “inside in” and 50% is “inside out”). Thus, efflux 
transporter study can take advantage of “inside out” membrane vesicle where the 
ATP binding site is exposed. The technique also changes the efflux study 
paradigm to one of vesicle accumulation, so that the experiment can be specific, 
ATP dependent and controllable.  
I. In vitro models to estimate kinetic parameters of drug transporters  
The most common in vitro models to estimate kinetic parameters of drug 
transporter are based on transporter overexpressing systems; either membrane 
fraction or whole cell system. Both approaches utilize overexpressing transporter 
into cell lines (mammalian or insect) to conduct a range of studies to determine 
Michaelis-Menten type kinetic parameters and Ki or IC50 values either directly or 
indirectly.  
1.Transporter ATPase (Km and Vmax) 
As mentioned previously, ATPase assay is a cost effective assay to identify 
interaction between test compounds and transporters since it is not necessary to 
establish a method for each compound. The membrane fractions are isolated 
from transporter over-expressing in Sf9 (Feng et al., 2008) or other mammalian 
cell lines (Robey et al., 2009; Cai et al., 2010). ATPase activities were calculated 
in terms of nanomoles of phosphate per milligram of total vesicle protein per 
minute of incubation time. Apparent affinity values (Km) of ATPase, could be 
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estimated from the concentration-response data by nonlinear regression (Feng et 
al., 2008).  Affinities of substrates for transporter can be ranked differently 
according to the range of Km of transporter ATPase (Feng et al., 2008). In some 
cases, the value of Vmax/Km is used to compare the transport property of different 
mutants of transporters (Cai et al., 2010). In addition, the parameter estimation of 
transporter ATPase avoids the culture of intact monolayer and basolateral 
transport limitation from Transwell.  However, Km and Vmax of transporter ATPase 
are not equivalent to the Km and Vmax of transporter-substrate complex. They 
provide a useful indication of activity of transporter but not real translocation 
parameters.  
2. Transporter from cellular transport (Km and Vmax) 
Intracellular accumulation of substrates is a popular method for the functional 
study of transporter to identify either uptake or efflux (Pan et al., 2009; Zheng et 
al., 2009; Agarwal et al., 2010; Pan et al., 2010). In some studies intracellular 
transport (also called cellular accumulation) is used to determine the kinetic 
parameters of efflux transporter, such as Km and Vmax of ABCG2 (Pollex et al., 
2010). In this method, it was assumed that the permeability of empty cell line (as 
nonsaturable transport or passive diffusion) was same as in a transporter 
overexpressing cell line. Time dependent transport and concentration dependent 
experiments were performed. The data were fit into nonlinear regression analysis 
to determine Km and Vmax of ABCG2.  
The driving forces for this transport process can be described in Figure 1-8. 
In this in vitro model there are a passive diffusion, an efflux transport on the 
membrane but no paracellular transport between cells. Although there is no 
passive diffusion presentation from basolateral as in Transwell model; they do 
have passive diffusion exposure on the membrane for efflux transport. The drugs 
or substrates to be effluxed out of cell must first diffuse into the cell. It should be 
recognized that the donor concentration of substrate is not the driving force for 
efflux transport process, but is the cellular concentration. As a result, functional 
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qualitative characterization may be acceptable; however, the Km and Vmax of 
transporter estimated from accumulation experiment may also be inaccurate.  
 
Figure 1-8 The model of drug accumulation in cell on plate. 
3. Cell monolayers (Km and Vmax)  
Transwell is a method used to estimate Michaelis-Menten type kinetic 
parameters (Km and Vmax ) of a substrate for a transporter (Breedveld et al., 2004; 
Petri et al., 2004). The substrate obtained from the receiver side of the Transwell 
is detectable by HPLC or LC-MS.  In Figure 1-9, there is an example in which the 
K1/2 (Km) of pantoprazole was obtained from Transwell data (Breedveld et al., 
2004) and estimated to be 100-200 µM. However, several issues with this 
approach need to be fully understood before the information can be utilized 
effectively. First consideration is one of correlating flux with concentration.  For 
vectorial drug transport from basolateral to apical side or apical side to 
basolateral, the driving force for efflux transporters is the drug concentration in 
the cell, not donor concentration. Second consideration, is the realization that as 
with any process, the overall flux rate is controlled by the slowest step in a series.   
Permeability associated with diffusion across the basolateral side (PSD) may be 
the limiting step controlling the appearance of drug in the apical compartment, 
thus masking the apical flux process.  Bentz et al reported the steady-state 
Michaelis-Menten analysis of P-glycoprotein mediated transport through a 
confluent cell monolayer cannot predict the correct Michaelis constant (Km) 
(Bentz et al., 2005). Kalvass and Pollack demonstrated that PSD on the 
basolateral membrane limits the apical directional transport of substrate so that 
ERA (the apical efflux ratio  can be defined as the ratio of the initial rate of flux in 
the B-to-A direction in overexpressing cell line divided by the initial rate of flux in 
 
 
 
 
  
  
PSD PSefflux 
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the B-to-A direction in parent cell line ) of substrate in Transwell should not 
exceed 2 (Kalvass and Pollack, 2007). Therefore, understanding the mechanism 
of drug transport in Transwells is a critical step to estimating Michaelis-Menten 
type kinetic parameters (Km and Vmax) of transporter using this approach. 
 
 
Figure 1-9 Saturation kinetics of pantoprazole transport by Bcrp1 in the MDCKII cell line. 
The difference in transport of pantoprazole in MDCKII-Bcrp1 and MDCKII-Parental cell 
lines at t = 4 h is plotted against the pantoprazole concentration (in μM). Inset, 
Lineweaver-Burk transformation of these results. The apparent K1/2 value at t = 4 h is 
0.1–0.2 mM (Breedveld et al., 2004) 
4.Kinetic parameters (Km and Vmax) from Sf9 vesicles 
 
Figure 1-10 The model of efflux transporter in Sf9 membrane vesicle. 
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As described previously, Baculovirus-mediated expression in insect cells has 
become well-established for the production of recombinant transporter proteins 
(Figure 1-10). Overexpressing transporter in Sf9 cells is convenient, fast and 
controllable.  For efflux transporters, inside-out Sf9 membrane vesicles expose 
ATPase site of transporter and substrate concentration directly so that ATP 
dependent substrate accumulation can be quantitiated.   Because of these 
advantages, estimation of Km and Vmax for efflux transporters from Sf9 vesicles 
has been widely used (Breedveld et al., 2004). The disadvantage of Sf9 vesicle 
experiment is assay limitation. The amount of substrate accumulation in vesicle 
is very low and hence, requires highly sensitivity of assay. The samples from 
vesicle experiment are difficult to detect by HPLC or even LC-MS methodology. 
As a result, a radiolabeled substrate is frequently used for the detection of 
uptake. However, most target substrates are not commercially available as 
radiolabeled. Some investigators use inhibition experiments to indirectly 
characterize parameter values such as the inhibition constant (KI) (Lagas et al., 
2009b). Another consideration is the lipophilicity of the compound.  For highly 
lipophilic drugs, the ability to discern the affinity of compound could not be 
uniquely defined because of the high background accumulation due to diffusion.   
In those cases as well, competition experiments may be employed as an indirect 
estimate of affinity, as in the estimation of gimatecan affinity for human ABCG2 
(Marchetti et al., 2007).  
J. The understanding and mathematical model of efflux in Transwells 
Since the initial paper using a monolayer flux model was published in 1980’s, 
Transwells have been extensively employed in many studies for individual 
purpose. The discussion about the underlying mechanism of drug transport 
across cell monolayers has greatly deepened our understanding (Lentz et al., 
2000; Tam et al., 2003; Kalvass and Pollack, 2007). A large number of Transwell 
studies have focused on P-gp substrate screening using the CaCo-2 system. The 
various complex observations associated with Transwell experiments have 
caused investigators to consider a number of factors involved in kinetic 
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processes and establish the kinetic models to understand the Transwell model 
(Roerig et al., 2004; Janneh et al., 2009). Naruhashi et al have examined 
whereas  the unstirred water layer can be the rate-limiting step for transport of 
drugs with high membrane permeability in Caco-2 cells and affect the apparent 
permeability of drug transport (Naruhashi et al., 2003). Therefore, investigators 
should be cautious in evaluating the contributions of a transporter in the case of 
drugs with high apparent permeability.The passive permeability may also have 
influence on results of drug transport mediated by P-gp. Some compounds, such 
as nicardipine, may pass through the cell membrane faster than P-gp can 
transfer it.  Thus, the high passive diffusion can mask drug flux across the apical 
membrane via P-gp and resulted in that efflux ratio does not affect active 
transport (Lentz et al., 2000). Also Liu et al indicated that the filter membrane is a 
permeability barrier for the low mass balance compounds (Liu et al., 2009). It is 
very important to define the hydrodynamic conditions in these small chambers 
with use of in vitro experimental apparatus (Transwell or Snapwell) for transport 
experiments (Naruhashi et al., 2003).  To date, a relatively comprehensive 
approach to explain flux in monolayer system has been presented as a kinetic 
efflux model (Kalvass and Pollack, 2007) and Caco-2 cell monolayer theoretical 
model (Sun and Pang, 2008).  
1. Kalvass and Pollack kinetic model 
 
 
Figure 1-11 Kalvass’s three-compartment model consistent with efflux attenuating the 
initial rate of flux in the A-to-B direction. PSA,inf and PSA,eff, represent the passive 
permeability–surface area product of the apical membrane, whereas, PSB,inf and PSB,eff 
represent the passive permeability–surface area products of the basolateral membrane. 
PSefflux represents the permeability–surface area product of efflux activity. It is assumed 
PSA,inf = PSA,eff = PSA and PSB,inf = PSB,eff = PSB (Kalvass and Pollack, 2007). 
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Kalvass et al (Kalvass and Pollack, 2007) constructed the three 
compartments kinetic model based on the efflux transporter P-gp in monolayer 
system (Figure 1-11). Compared with previous P-gp kinetic models (Lentz et al., 
2000; Adachi et al., 2001), it is a system with relative complete and derived from 
first principles. It considers all the interactions in the system, such as passive 
diffusion on both membranes (apical and basolateral) and efflux on apical side, 
the role of cellular concentration in determination of Km, the relationship between 
various efflux ratios (ERA: apical efflux ratio (PS0,B→A/PSB→A) or steady-state 
(CA,0/CA); ERB: basolateral efflux ratio (PSI,A→B/PSA→B ) or steady-state (CB,I/CB); 
ERα : asymmetry efflux ratio (PSB→A/PSA→B) or steady-state (CA/CB) and ERC: 
cellular efflux ratio (PSI,A→C/PSA→C ) or steady-state (CC,I,/CC))and efflux activity.  
Permeability-surface area product was introduced to the mathematic model. 
It derived the theorectical relationships between PSefflux and experiment 
parameters, such as Michaelis-Menten constant (Km), 50% inhibitory 
concentration (IC50) and the degree of efflux inhibition (Φi). This model is helpful 
in illuminating our interpretation of the apical efflux in the monolayer Transwell 
model. Overall, it makes the following points: 
1). Apical efflux would attenuate the basolateral directional flux and enhances the 
apical directional flux. However, neither attenuation nor enhancement of flux is 
proportional to the efflux activity.  
2). The flux should not be used to calculate the Km or IC50 directly since the 
substrate concentration and inhibitor concentration do not relate to flux directly 
and the flux is not proportional to PSefflux. 
3). Measuring the effect of efflux on permeability in the B to A is uninformative 
because it is minimally sensitive to PSefflux by passive diffusion on basolateral 
side. Therefore, the maximal ERA is approaching to 2. ERA is not a right 
parameter to estimate the efflux activity. 
However, some assumptions upon which this model is based may produce a 
significant bias of observation significantly:  (1) it did not consider the effect of 
paracellular permeability (PSPC) on the kinetic parameters and assumed the 
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PSPC can be ignored; (2) it did not consider the effect from unstirred water layer 
and filter permeability. For P-gp substrates with high lipophilic property, the high 
passive permeability and unstirred water layer may become limiting step or mask 
the active flux on the membrane. While insightful, the model of Kalvass and 
Pollac (Kalvass and Pollack, 2007) has some shortcomings that came to light 
while analyzing the pantoprazole – ABCG2 flux data and compelled us to explore 
a more complex mechanistic model.  
2.Theoretical Caco-2 model 
Caco-2 is widely accepted for assessment of permeability to oral drug 
absorption.  Usually it is used to test whether compounds are substrates of efflux 
transporter, especially P-gp (Sun and Pang, 2008). As mentioned earlier, Caco-2 
also expresses various CYP 450 isoforms and phase II enzymes, so the 
theoretical model of Caco-2 cell monolayer is a comprehensive system which 
described both the kinetic parameters from transporter as other monolayer 
systems (MDCKII or PK-LLC) and also metabolic contribution from cellular 
enzymes (Sun and Pang, 2008).  
 
 
Figure 1-12 Sun’s three compartment CaCo-2 model. Schematic presentation of the 
Caco-2 cell-based system by a catenary model comprising the basolateral (baso), cell, 
and apical (ap) compartments. V, f, and C denote volume, unbound fraction, and the 
concentration of drugs of each compartment, respectively; M denotes formed 
metabolite(s). CLd1 and CLd2,CLd4, and CLd3 denote the influx and efflux and passive 
diffusion clearance on the basolateral and apical membrane, respectively. CLinflux and 
CLefflux represent the transporter-mediated influx and efflux intrinsic clearances on the 
basolateral membrane; CLabs and CLint,sec denote transporter-mediated intrinsic 
clearances of absorption and efflux on the apical membrane, respectively; CLint,met is the 
metabolic intrinsic clearance. Under nonlinear conditions, CLinflux,CLefflux,CLabs and 
CLint.sec, and CLint,met may be replaced by the Vmax/(Km + Cu), where Cu is the unbound 
drug concentration(Sun and Pang, 2008). 
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In Sun and Pang’s three compartment Caco-2 model (Figure 1-12), apparent 
permeability, Papp (is called effective permeability in the paper) and efflux ratio 
ERα (is called EfR in the paper) were also introduced as in Kalvass’s kinetic 
model. They added two more detailed elements to the model, volume and 
unbound fraction of each compartment. Also, a parameter, clearance was used 
to represent the drug “in or out ” the cell membranes either by transporters 
mediated efflux or influx, or cellular enzymes mediated metabolic intrinsic 
clearance. Compared with other kinetic models, this Caco-2 system considered 
both sink and nonsink conditions; no assumptions were made for nonsink 
condition. They established an “improvised equation” which reflects the 
relationship between flux and passive diffusion and active transport; also Vmax, 
Km and the number of binding site were also introduced to express active 
transport. The effect of high or low passive diffusion on apparent permeability 
and efflux ratio was discussed in the paper. However, there was no consideration 
of paracellular permeability either in this model. In the improvised equation, the 
donor concentration but not cellular concentration of substrate was used to 
calculate Vmax and Km. The cellular concentration of substrate is significantly 
different from donor concentration so this calculation can result in deviation from 
the right value. For the efflux ratio, they conducted same implication equation as 
Kalvass’s model (Eq. 1-2 is equal to Eq.1-). 
 
                                                                                                                                                           Eq.1-2                                                                                                                                          
 
                                                                                                                           Eq.1-3                                                                                                                                                          
In this CaCo-2 model the cellular metabolism was another factor which 
contributes to the observation of drug efflux or influx on either direction.  Briefly, 
cellular metabolism can affect the apparent permeability of each direction but the 
effects on both directions (AB and BA) are same, so the efflux ratio remains 
unchanged.   
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Overall, both Kalvass and Sun’s theoretical models were based on the efflux 
transporters, P-gp, and both provided insights into flux across a monolayer 
system in Transwell.  Both recognized that the Transwell monolayer model is not 
just a single barrier but two barriers in series; and both utilized a three 
compartment model to better reflect the interaction between substrate and 
membrane barriers. The description of apparent permeability, efflux ratio, passive 
diffusion, active transport, intracellular metabolism and saturation process 
indicated the complexities of the system. Due to the large number of parameters 
to be ascribed and that saturation may involve in more than one process 
(transporter and enzymes), these models are typically limited to theoretical 
considerations and are difficult to fit actual observations.  
K.  Chirality and effect on drug disposition 
1.Molecular chirality  
In 1848, Louis Pasteur separated the first isomers of fasfasic acid into its left-
handed (levo-tartaric acid) and right-handed (dextro-tartaric acid) forms by using 
a hand lens and a pair of tweezers. This experiment established the theory of 
chirality in chemical molecules: the compounds contain chiral center and one is 
related to another as non-superimposable mirror images. Ten years after Pasteur 
first discovered enantiomers of tartaric acid, he indicated that the mold 
Penicillium glaucum destroyed two enantiomers of ammonium tartrate differently 
and established that enantioselectivity is exist in biological environment and 
proteins can recognize the molecular asymmetry (DE, 1993). Since then, 
stereoselectivity of compounds has been documented to give rise to differences 
in drug metabolism, pharmacokinetics and toxicity (Prost and Thormann, 2003; 
Ha and Follath, 2004; Afshar and Thormann, 2006; Sun and Scott, 2009).  
By definition, enantiomeric compounds are composed of the same chemical 
entity and have the same structural formulas, but differ with respect to their three-
dimensional structure. Some stereoisomers could have two or more chiral 
centers which have 4 or more non-superimposable mirror images, such as 
diastereoisomers. Chirality exists not only in chemical molecules, but also in the 
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biological world. Many endogenous substances, such as proteins and amino 
acids have chirality feature. The recognition between two enantiomers of 
endogenous or exogenous substances and chiral macromolecule, such as an 
enzyme, receptor or transporter, could result in different outcomes. In some 
situations stereoselectivity is required for biological function and the higher 
affinity enantiomer dominates the reaction, or the metabolic or transport pathway. 
2. Effect of chirality on drug disposition 
It has been estimated that about 50% of therapeutic drugs are currently 
administered as a racemate, a mixture of equal proportions of two enantiomers 
(Andersson and Weidolf, 2008). When administered as a racemate, two 
enantiomers can display a qualitative and quantitative difference in 
pharmacokinetic processes (absorption, distribution, metabolism and excretion). 
Molecular chemical properties, such as lipophilicity, total hydrogen bond strength 
and dipole/polarize-ability are related with passive diffusion. The passive 
transcellular membrane transport is  generally identical between two enantiomers 
(Sugano et al., 2010). By contrast, the active transport tends be significantly 
affected by chirality. The interaction of three dimensional structures of active 
transporter and chiral substrates can cause different transport profiles.   
To date, a large number of studies have focused on enantiomer drugs 
stereoselective interaction involving CYP450 in many drug pharmacokinetic, 
pharmacodynamic and toxicology areas (Campo et al., 2009; Choong et al., 
2010; Schmitz et al., 2010; Tenberken et al., 2010). Steroselective interactions 
may make some drug utilization problematic (e.g., antiarrhythmics), especially 
drugs that have a narrow therapeutic index.  Drug response is dependent on 
many processes including administration route, first-pass effect, inhibition of 
enzymes and polymorphisms, receptor sensitivity, etc.  Stereoselectivity 
contributes to the problem of individual variability to many of these processes (Ha 
and Follath, 2004) .  
In recent years, the studies have shown that steoroselective interactions not 
only occur with metabolic enzymes (Gunaratna and Kissinger, 1998), but also 
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with transporters (Bhatia et al., 2008). For example, efflux transporters P-gp and 
MRPsexhibit enantioselectivity in the absorption and efflux of cetirizinein in 
CaCo-2 monolayer. The results indicated that  enantiomers interaction with P-gp 
and MRP2 caused potential drug-drug interaction and might significantly 
changed the cetirizine pharmacokinetics (He et al., 2009). Moreover, several in 
vitro and in vivo evidences indicated an enantioselective drug transport at the 
human blood-brain barrier and implied that significant enantioselective activity of 
P-gp might be clinically relevant (Choong et al., 2010). As an important efflux 
transporter, ABCG2 is involved in the disposition of many drugs in body and has 
a significant impact on drug pharmacokinetic and pharmacodynamic profile.  
However, to date, there are no reports demonstrating steroselective interaction 
between substrate drugs and ABCG2.  
L. Pantoprazole 
Pantoprazole (Protium and Protonix) is a proton pump (H+/K+-ATPase) 
inhibitor (PPI) which binds specifically and irreversibly to the proton pump to 
reduce gastric acid secretion [150]. Pantoprazole is a prodrug which is more 
stable than other substituted benzimidazole PPI drugs in neutral to moderately 
acidic environment and is active and tends to accumulates in an acid 
environment (Sachs, 1997). It is more effective than H2-antagonists in the 
treatment of moderate to severe gastro-oesophageal reflux disease (GERD) 
(Schoenfeld et al., 1999; Scott et al., 2002). The mechanism of action of 
pantoprazole on proton pump is shown in Figure 1-13. The prodrug form is 
ampholytic in that three nitrogen atoms can accept or donate protons.  Briefly, 
pantoprazole accumulates under an acidic environment; then is catalysed and 
converts to active principal, cyclic sulfenamide. This active principle has an ability 
to react with key cysteines present in the gastric acid pump (Kohl et al., 1992; 
Huber et al., 1995).    
38 
 
 
Figure 1-13 Acid activation of pantoprazole and inhibition of the gastric proton pump by 
binding of the active principle to a cysteine SH group of the enzyme (Huber et al., 1995).  
Pantoprazole is completely metabolized to inactive metabolites M1, M2 and 
M3 by the cytochrome P450 isoforms CYP2C19 (> 80%) and most of rest of 
them by CYP3A4 (Andersson, 1996; Noubarani et al., 2010) and rest of them by 
a conjugating enzyme, a cytosolic sulfotransferase (Meyer, 1996). The time 
course of covalent interaction of pantoprazole with the acid pump is prolonged 
compared to the time the compound is in plasma (Huber et al., 1995).  
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Pantoprazole is rapidly eliminated from plasma and almost completely 
metabolized in the human liver. The initial metabolic step is oxidation via CYP450 
system and then it undergoes further metabolism as shown in Figure 1-14. M2, 
the main metabolite of pantoprazole, is formed by demethylation at the 4-position 
in the pyridine ring to give a hydroxyl group, then conjugated with sulphate. Both 
M1 and M3 are sulphate conjugates in an analogous fashion to M2. There are 
additional oxidation and reduction of the sulphoxide group to sulphone for 
forming M1 and M3 (Figure 1-15). None of these metabolites are active (Huber et 
al., 1995).  
 
Figure 1-14 Pattern of pantoprazole metabolites in human plasma (M2: main metabolite; 
pantoprazole sulphone: minor metabolite: relative plasma concentrations: M2>M1>M3> 
sulphone) (Huber et al., 1995).  
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Figure 1-15 Biotransformation of pantoprazole in the human liver (Huber et al., 1995). 
 
 
Figure 1-16 The structure of pantoprazole isomers. 
Pantoprazole is a typical ABCG2 substrate that has been widely used as a 
specific inhibitor of ABCG2. PAN is a chiral benzimidazole sulfoxide (Figure 1-
16). Currently it is administered as a racemic mixture. In human study, the 
pharmacokinetics of PAN enantiomers was different in extensive metabolizers 
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(EMs) and poor metabolizers (PMs). In EMs, the serum concentrations of (-)-
PAN were slightly higher than (+)-PAN. In PMs, the concentrations of both PAN 
isomers were higher than in EMs. The half life of (+)-PAN is 2.67-3.77 times 
longer than that of (-)-PAN (Tanaka et al., 1997). It demonstrated a 
stereoselective interaction between pantoprazole enantiomers and metabolic 
enzymes. In rat pharmacokinetic study, the mean area under the curve value of 
(-)-PAN was 1.5 times greater than (+)-PAN after oral administration of racemic 
PAN. It suggested stereoselective pharmacokinetics of pantoprazole isomers are 
due to the steroselective metabolism that contributed by all the metabolic 
pathways (Xie et al., 2005). In addition, the chiral inversion was observed after 
administration of (+)-PAN in rat but not (-)-PAN (Masubuchi et al., 1998).  
M. Summary 
Breastfeeding is considered to be the best choice of nutrition for most infants, 
with numerous benefits to infant, mother and society. Drug use during 
breastfeeding is common.   Limited information on drugs disposition in lactation 
adds uncertainty and concern for both lactating mother and caregiver.  Most 
drugs and their metabolites readily diffuse into milk; however, some drugs are 
actively transported into milk, leading to accumulation in milk. To fully understand 
drug accumulation into milk as a critical first step in risk assessment, it is 
necessary to establish experimental paradigms and mathematical models to be 
able to put observations into a more integrated form.  ABCG2 is an efflux 
transporter on the apical side of epithelial cell in lactating mammary gland that is 
responsible for drug active transport into milk. Clinical studies and knockout mice 
studies have confirmed the role of ABCG2/Abcg2 in nitrofurantoin, cimetidine, 
Phip(toxin 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine) and other 
xenobiotics accumulation in milk. In this dissertation we propose to investigate 
the possible role of interaction between substrate and transporter on drug 
accumulation in milk using both in vivo and in vitro experimental paradigms 
focusing on the following aspects:  
a) To determine the role of Abcg2 in drug accumulation in rat milk.  
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b) To establish a “chemical rAbcg2 knockout” for drug active transport 
into milk.  
c) To understand the stereoselective interaction between ABCG2 and 
substrate by in vitro and in vivo experiments.  
d) To fully understand cell monolayer flux data by using a mechanistic 
mathematic model.    
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CHAPTER 2:The plan of study and hypothesis 
ABCG2/Abcg2 appears to play a major role in the bioavailability and 
systemic clearance as well as contribute to the active transport into milk for a 
number of drugs. The following hypothesis and specific aims are designed to fully 
understand the interaction of substrates with ABCG2/Abcg2 and its role in drug 
accumulation into milk.  
 
Overall Hypothesis: ABCG2 substrates accumulate in milk, resulting in high M/S 
ratios 
 
Hypothesis 1:  Drugs which are rAbcg2 substrates will accumulate in rat milk.    
To validate the rat as a suitable animal model for assessing the role of Abcg2 in 
drug transfer into milk, the following three aims will be pursued: 
 Specific Aim 1a:  Quantitate the expression and localization of Abcg2 in 
lactating mammary gland in rat compared to non-lactating mammary gland 
or other organs (kidney and liver). 
 Specific Aim 1b:  Characterize the transport of nitrofurantoin in a rAbcg2-
MDCKII cell line.  
 Specific Aim 1c:  Validate an in vivo model in lactating rat using 
GF120918, a chemical inhibitor of ABCG2, to block the transfer of 
nitrofurantoin into milk. 
Genetic knockout mice have been used to confirm the role of ABCG2 in drug 
accumulation in milk. The benefits of using the rat as an animal model for drug 
development also apply to understanding drug accumulation in milk (e.g., similar 
drug accumulation in milk between rat and humans, ease of sample collection 
and the potential compensatory mechanisms associated with genetic knockout 
mice).  To establish a clear role for Abcg2 in drug accumulation in rat milk and to 
validate the chemical knockout rat Abcg2 model could be valuable tools for drug 
development.   
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Hypothesis 2: ABCG2 substrates accumulate in milk with high M/S ratio and 
interact stereoselectively with ABCG2/Abcg2. 
To further challenge the use of the rat as a suitable animal model and to 
explore the stereoselectivity of ABCG2, the following three aims will be pursued: 
 Specific Aim 2a: Characterize the M/S ratio of pantoprazole isomers in 
lactating rats. 
 Specific Aim 2b: Test the ability of a passive diffusion model to predict the 
M/S ratios of pantoprazole isomers in rat.  
 Specific Aim 2b: Utilize the “chemical knockout” Abcg2 rat model to 
characterize the differential influence of Abcg2 on the distribution of 
pantoprazole isomers into milk. 
ABCG2 is highly expressed in mammary gland of mice, cows and humans 
during lactation, and is responsible for the active secretion of clinically and 
toxicologically important substrates. Pantoprazole, a typical ABCG2 substrate 
has been used as a competitive inhibitor to identify other ABCG2 substrates. 
However, pantoprazole has a very low M/S at 0.022 in one  clinical report (Plante 
et al., 2004). Pantoprazole is an ABCG2 substrate that exists as a racemic 
mixture. Although chirality has been described as an important characteristic for 
a number of enzymes and receptors, there have been few reports of 
stereoselective interactions with transporters. The objective of this series of 
experiments is to determine if there is a stereoselective interaction between 
pantoprazole and ABCG2 and, if present, does the stereoselectivity manifest 
itself in the M/S ratios of pantoprazole isomers.  
Hypothesis 3:  Pantoprazole transport properties are consistent across species 
(rat and human).  
To fully assess interspecies differences ABCG2 transport, the following two 
aims will be pursued: 
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 Specific Aim 3a: Characterize pantoprazole isomers transport in 
ABCG2/Abcg2-expressing MDCKII cell line. 
 Specific Aim 3b: Compare transport property parameters of rat Abcg2 and 
human ABCG2.  
To effectively utilize animal model data to predict human exposure, a clear 
understanding of similarities and differences across species is warranted.   We 
have advocated for the use of the rat as an animal model, hence a comparison of 
transporter kinetic parameters is required.  In addition to kinetic assessments, it 
is also of interest to compare the extent to which stereoselective differences 
between enantiomers exist across species. 
Hypothesis 4:  Drug transport in ABCG2-MDCKII monolayer in Transwells can 
predict drug accumulation in milk.  
To fully develop an overall conceptual framework for pantoprazole interaction 
with ABCG2, the following two aims will be pursued: 
 Specific Aim 4a:  Develop a mechanistic model and characterize the 
impact of assumptions of the model with respect to cell monolayer flux 
data (Transwell).   
 Specific Aim 4b:  Evaluate the parameters from Transwell such as PSD, 
PSPC, ERα, ERA, Km, Vmax, IC50 and Ki based on mathematical three 
compartments model.  
In general, there is no broadly accepted in vitro exposure system to mimic in 
vivo environment.  However, several in vitro methods offer the unique possibility 
to focus the question and derive a more specific inference as to the role of a 
specific drug characteristic or protein (e.g., transporter) feature.  Although the 
use of cell monolayers of transporter transfected cell lines grown on Transwell is 
widespread, a clear understanding of parameters from such data remains a 
challange. The purpose of this section of the thesis is to build a mechanism 
based model and explore the limits and implications of the model utilizing 
pantoprazole isomers as model substrates.  
Copyright © Lipeng Wang 2010  
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CHAPTER 3: GF120918 as a chemical Abcg2 knockout 
model to study nitrofurantoin transfer into milk 
3.1 Summary 
Genetic knockout mice studies suggested ABCG2/Abcg2 translocates 
nitrofurantoin at the mammary – blood barrier resulting in drug accumulation in 
milk. The purpose of this study was to establish the role of Abcg2 in nitrofurantoin 
accumulation in rat milk using GF120918 as a “chemical knockout” equivalent.  
The inhibitory effect of GF120918 was verified in MDCKII cells stably expressing 
rat Abcg2 with Hoechst 33342 and nitrofurantoin flux in transwells.  Nitrofurantoin 
was infused (0.5 mg/h) in the absence and presence GF120918 (10 mg/kg in 
DMSO) to Sprague Dawley lactating female rats using a balanced crossover 
design.  Administration of GF120918 increased nitrofurantoin concentration in 
serum (from 443±51 to 650±120 ng/ml) and decreased concentration in milk 
(from 18.1±0.9 to 1.9±1.2 μg/ml), resulting in corresponding mean values for M/S 
of 41.4±19.1 vs. 3.04±2.27 in the absence and presence of GF120918 (p<0.05), 
respectively.  There was a decrease in the systemic clearance with GF120918 
(2.8±0.5 L/h/kg) compared to vehicle controls (4.1±0.5 L/h/kg; p<0.05).  Western 
blot analysis revealed good expression of Abcg2 and no P-gp expression in 
mammary gland while immunohistochemistry confirmed the apical expression of 
Abcg2 in lactating mammary gland epithelia.  Nitrofurantoin active transport into 
rat milk can be inhibited by GF120918 resulting in a 10-fold lower M/S.  Although 
GF120918 inhibits both Abcg2 and P-gp, the high expression of Abcg2 and the 
absence of detectable P-gp expression in lactating mammary gland validates an 
important role for Abcg2 in nitrofurantoin accumulation in rat milk.  GF120918 is 
particularly useful as a rat “chemical knockout” model to establish ABCG2’s role 
in drug transfer into milk during breastfeeding.  
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3.2 Introduction 
Most xenobiotics are transferred into milk by passive diffusion and the extent 
of their accumulation in milk (as measured by milk to serum concentration ratio, 
(M/S)) can be predicted by in vitro measurements of drug binding and ionization 
in milk and serum as well as lipid partitioning into milk (Fleishaker et al., 1987; 
Fleishaker and McNamara, 1988a).  Such an approach successfully predicted 
the M/S for a number of drugs (Fleishaker and McNamara, 1988b); however, this 
approach was unable to estimate the large M/S observed for drugs like 
nitrofurantoin (Gerk et al., 2001a).  In fact, the observed ratios for nitrofurantoin in 
the human and rat were 20 and 100 times greater (Gerk et al., 2001a; Oo et al., 
2001), respectively than could be accounted for by passive diffusion alone, 
clearly implicating an active transport process. 
The transport of nitrofurantoin across a murine mammary epithelial cell 
culture model has been shown to be saturable and sodium dependent in the 
basal-to-apical direction (Toddywalla et al., 1997; Gerk et al., 2002).   Merino et 
al described that nitrofurantoin was efficiently transported by murine Bcrp1 and 
human BCRP by using polarized cell lines (Merino et al., 2005b).  Importantly, 
they also demonstrated that the milk-to-plasma ratio of nitrofurantoin was almost 
80 times higher in wild-type compared with Bcrp1 knockout lactating female mice 
(Merino et al., 2005b).  Nitrofurantoin, therefore, was identified as an excellent 
BCRP/Bcrp1 substrate that is translocated at the blood–mammary barrier 
resulting in its accumulation in milk.  
A growing number of studies have shown compensatory mechanisms in 
genetic knockout mouse models. The most impressive evidence was from recent 
literature.  In Bcrp (-/-) mice, several transporters, like Abca5, Abcb4, Abcc2, and 
Abcc4, were significantly up- or down-regulated, the most pronounced differential 
expression observed with Abcg5 and Abcg8, which showed a 20- to 100-fold up-
regulation in Bcrp (-/-) mice (Huls et al., 2008).  Therefore, compensatory 
mechanisms in transport function in genetic knockout mice may complicate the 
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interpretation of drug metabolism and disposition studies as well as active 
transport into milk.    
In present study, we systematically evaluated the role of Abcg2 (Bcrp) in 
nitrofurantoin accumulation in rat milk. GF120918 pretreatment was administered 
to generate a “chemical knockout” equivalent of Abcg2 in lactating rat and 
nitrofurantoin was employed as the prototypical Abcg2 substrate.  The results 
obtained from these studies provide new insights into the utility of the rat model 
for ABCG2 substrates in drug active transport into milk and other drug 
metabolism and disposition studies. 
3.3 Materials and Methods 
Chemicals 
 Nitrofurantoin and furazolidone were purchased from Sigma Chemical Co. 
(St. Louis, MO). N-(4-[2-(1,2,3,4-tetrahydro-6,7-dimethoxy-2-isoquinolinyl)ethyl]-
phenyl)-9,10-dihydro-5-methoxy-9-oxo-4-acridine carboxamide (GF120918) was 
a gift from GlaxoSmithKline (Research Triangle Park, NC). Hoechst-33342 was 
from Invitrogen (Carlsbad, CA). All organic solvents (HPLC grade) and PEG400 
were purchased from Fisher (Pittsburgh, PA) and all other chemicals were 
obtained from Sigma (St. Louis, MO) unless specified otherwise. 
Animals 
Five adult female lactating Sprague-Dawley rats (250 to 350 g) with 1 or 3 
day old pups were purchased from Harlan Laboratories (Indianapolis, IN). 
Animals were maintained under a 12 h/12 h light/dark cycle and had access to 
food and water during the experiments. The rats were acclimatized for at least 1 
week before the experiment. All procedures were approved by the University of 
Kentucky Institutional Animal Care and Use Committee. 
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      Expression and Functional Characterization of Rat Abcg2 in MDCK-II 
Cells 
Total RNA was isolated from a frozen liver of a Sprague Dawley rat using 
RNAeasy kit (Qiagen, Valencia, CA) and reverse transcribed to cDNA using oligo 
dT primers and Thermoscript RT PCR kit (Invitrogen, Carlsbad, CA). Rat Abcg2 
cDNA was amplified using forward (5’-
CCGCTCGAGGCATAGATCCTAAAGATGTCTC-3’) and reverse 5’-
CTAGTCTAGAGGAGTACTATCAATAGTCCTTTC-3’) primers and Phusion DNA 
polymerase enzyme (NEB, Ipswich, MA). The PCR product was cloned into the 
pcDNA3.1 vector (Invitrogen) between XhoI and XbaI restriction sites.  The 
Abcg2 sequence in this vector was confirmed (Davis Sequencing, Davis, CA) 
and it had 100% homology with the published rat Abcg2 sequence (Gene Bank 
accession number AB105817). MDCKII cells were maintained in MEM with 
Earle’s salts (Mediatech, Manassas, VA) with 5% FBS (GIBCO/Invitrogen) and 
1X Penicillin Streptomycin (Invitrogen) at 37ºC in 5% CO2. Cells were transfected 
with pcDNA3.1 or pcDNA3.1-rAbcg2 using Fugene 6 transfection reagent (Roche 
Diagnostics, Indianapolis, IN) according to the manufacturer’s instructions.  After 
48 hours, cells were selected with 800 μg/ml G418 (Invitrogen) for 10 days.  
Abcg2 expression was confirmed by Western blot analysis with polyclonal 
anti-ABCG2 antibody from Kamiya Biomedical Company (Seattle, WA). Rat 
Abcg2 function was assessed using the Hoechst-33342 (10 µM) accumulation 
assay (Leggas et al., 2006). Single clones were isolated by fluorescence-
activated cells sorting (FACS) (MoFloTM, DakoCytomation, Fort Collins, CO) on 
the basis of reduced accumulation of the Hoechst 33342 dye. The clone with the 
highest functional activity was chosen for in-vitro studies.  
Inhibition of rAbcg2 by GF120918  
To assess the utility of GF120918 as a chemical inhibitor of rat Abcg2, first, 
we incubated MDCKII-rAbcg2 cells with Hoechst 33342 in the presence and 
absence of 1 µM GF120918.  Briefly, cells were incubated with dye-containing 
medium at 37°C for 45 minutes. GF120918 was added at the indicated 
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concentrations 10 minutes before the dye incubation. All flow cytometry assays 
used 10 µM Hoechst 33342 (Leggas et al., 2006).  Secondly, the effect of 
GF120918 on nitrofurantoin directional transport was evaluated using MDCKII 
cells expressing rat Abcg2 or empty vector (pcDNA3.1). Cells were seeded on 
microporous membrane filters (3.0-µm pore size, 24-mm diameter; Transwell 
3414; Corning Glassworks, Corning, NY) at a density of 1.0×106 cells per well. 
Cells were grown for 4 days to achieve TEER (transepithelial electrical 
resistance) >200 Ω∙cm2 and medium was replaced every other day. Prior to the 
experiment, the medium at both the apical and basolateral side of the monolayer 
was replaced with 2 ml of OpitiMEM medium (Invitrogen) without serum, and 
either 1 µM GF120918 or vehicle-only (0.1% DMSO) with 10 µM nitrofurantoin 
containing 0.2 µCi/ml [3H]-Mannitol.  Cells were incubated at 37oC in 5% CO2. To 
ensure the tightness of each monolayer, 50 µl aliquots were collected to assess 
the paracellular flux of [3H]-Mannitol into the opposite compartment. We required 
that layers restricted mannitol transport to <1% of the total radioactivity per hour. 
For nitrofurantoin transport, 140 µl aliquots were taken at 0.5, 1, 2 and 3 hours. 
Samples were stored at -80 oC until the time of analysis by HPLC assay.  
In-vivo Studies 
The jugular and femoral veins of Sprague-Dawley lactating female rats were 
cannulated under ketamine/xylazine anesthesia on day 10 to 12 post partum. 
After a day of recovery, each dam (n = 5) was randomized to receive an 
intravenous infusion of nitrofurantoin in PEG400 (0.5 mg/0.25ml/h) for 5 hours 
either with pretreatment of the inhibitor (GF120918, 10 mg/kg in DMSO) or with 
equivalent volume (about 0.15 ml DMSO) of vehicle administered intravenously 
over 10 min and crossed over on the second day to complete both phases (Gerk 
et al., 2001b; Edwards et al., 2005).  One ml normal saline was given hourly to 
prevent dehydration during infusion. The dams were separated from the pups 
prior to the infusion. Blood samples were drawn hourly for the last 4 h of the 
infusion. The blood samples were protected from light, allowed to clot, 
centrifuged to harvest serum, and frozen at -80°C until analysis. Milk samples 
were obtained by manual manipulation under light anesthesia (ketamine) at the 
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end of the infusion, protected from light, and also frozen at 80°C until analysis. 
Mammary gland and kidney samples were harvested from a separate group of 
lactating rats on day 16 to18 post partum, frozen in liquid nitrogen, and stored at 
-80°C until analysis. 
Nitrofurantoin HPLC Analysis 
To each aliquot (70 µl) of serum, 15 µl of a 5 µg/ml furazolidone HCl was 
added as an internal standard and was precipitated with 85 µl of cold methanol, 
vortexed for 5 min, and then centrifuged at 16,000g for 10 min at 4°C. Fifty 
microliters of the supernatant plus 50 µl mobile phase was mixed for 10 seconds 
and injected onto the HPLC. To each aliquot of milk, 25 µl of a 25 µg/ml 
furazolidone HCl was added as an internal standard to 50 µl milk sample and 
was precipitated with 200 µl of cold methanol, vortexed for 5 min, and then 
centrifuged at 16,000g for 10 min at 4°C. Then, 50 µl of the supernatant was 
mixed with 50 µl mobile phase and injected onto the HPLC. The HPLC system 
consisted of a Lichrosorb 5 RP18 125 × 4.0-mm column (Phenomenex, 
Torrance, CA) and eluted with 20% acetonitrile: 80% 25 mM potassium 
phosphate buffer (pH 3.0) at 1.0 ml/min. UV absorbance was measured at 
366 nm. Peak height ratios (nitrofurantoin/furazolidone) were used for 
comparison with the standard curve. The standard curve range for nitrofurantoin 
in serum was 62.5 to 4000 ng/ml. The milk samples were diluted if the 
concentration was greater than the linear range for the standard curve (0.725 to 
29 µg/ml). Aliquots of nitrofurantoin in OptiMEM medium were directly injected 
onto the HPLC. The standard curve range was 7.8 to 2000 ng/ml. All standard 
curves demonstrated an intra- and inter-day variability of less than 10% and r2 
>0.99. 
Western Blot Analysis for P-gp and Abcg2 
Crude membrane fractions were prepared from lactating mammary gland 
and kidney. Briefly, the tissue samples were homogenized in Dounce Buffer (Tris 
buffer pH 7.6 at 4ºC, 0.5 mM magnesium chloride) with protease inhibitors 
(Complete Mini EDTA-free tablets, Roche Diagnostics, Indiapolis, IN) and the 
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tonicity restored to 150 mM with sodium chloride.  Following centrifugation at 
1200 g for 5 min at 4ºC, the supernatant was removed and EDTA was added to a 
final concentration of 5 mM.  The sample was then centrifuged further at 100,000 
g for 1 hour at 4ºC to pellet the crude membrane fractions.  Pellets were 
resuspended in resuspension buffer (0.2 M mannitol, 0.07 M sucrose, 50 μM Tris 
HCl, 1 μM EDTA). Rat Abcg2- and pcDNA3.1 (empty vector)-MDCKII cell pellets 
were resuspended in RIPA buffer (50 mM Tris pH 8.0, 150 mM NaCl, 1% NP40, 
0.5% deoxycholate, 0.1% SDS, protease inhibitor cocktail), rotated for 30 
minutes at 4oC, then centrifuged at 13000 rpm for 20 minutes at 4ºC. 
Supernatants were collected for immunoblot. Protein concentrations were 
measured using the BCA Protein Assay kit (Pierce, Rockford, IL).   PNGase F 
(New England Biolabs, Ipswich, MA) was used for deglycosylation of rat Abcg2 
following manufacturer instructions.  Briefly, 60 μg (lactating mammary gland), 
100 μg (kidney) and 7 μg (pcDNA3.1 expressed MDCKII cell and Abcg2 
expressed MDCKII cell) of membrane fractions were incubated with 10X 
denaturing buffer supplied and PNGase F (4 μl) at 37 °C for 2.5 h. Then the 
samples were mixed with 2X SDS-loading buffer and reducing buffer at 37°C for 
30 minutes as the non-PNGase treatment group. Western blotting was performed 
as described previously (Edwards, 2005). P-gp expression was determined using 
the C219 (mouse anti-human P-gp; 1:100) monoclonal antibody which was 
obtained from Signet Laboratories (Dedham, MA) and Abcg2 was determined 
using the PC-138 (1:1000) antibody which was obtained from Kamiya Biomedical 
(Seattle, WA). Antibody binding was detected using a horseradish peroxide 
linked IgG (H+L) (goat anti-rabbit) and IgG (H+L) (rabbit anti-mouse) antibodies 
(1:20000) obtained from Pierce, Inc. (Rockford, IL). The bands were visualized 
using a SuperSignal Pico Chemiluminescent substrate detection kit (Pierce, 
Rockford, IL). 
Immunohistochemistry for Abcg2 localization in lactating mammary 
gland 
Six-micrometer sections of paraffin blocks were cut using microtomy.  After 
deparaffinization and rehydration, endogenous peroxidase was blocked with 
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H2O2 in methanol for 20 min. The sections were blocked using an avidin biotin 
blocking kit (Vector Laboratories, Burlingame, CA), and PC-138 (1:1000) was 
applied for kidney and lactating mammary gland. For non-specific staining 
control, rabbit IgG (Invitrogen) was applied to the slide instead of PC-138 
(1:1000). The sections were incubated overnight at 4oC with amplifier. 
Subsequently, the slides were washed in PBS-T and then incubated with 
biotinylated anti-rabbit antibody (1:600 dilutions) and HRP-conjugated avidin-
biotin-complex (Vector Laboratories, Burlingame, CA). The antibody binding sites 
were visualized by incubation with DAB-H2O2 solution to develop a brown color 
and counterstained with hematoxylin, dehydrated, and coverslipped.  
Pharmacokinetic calculations and statistical analysis 
     Systemic clearance was calculated using the following formula.  
 
                                                                                                                  Eq.3-1 
      Where Cs is the average concentration of nitrofurantoin in serum from 3 to 5 
hours. 
     M/S was calculated by:   
      
 
                                                                                                                            Eq. 3-2   
  Where Cm is concentration of nitrofurantoin in milk at 5 hours.   
All data are expressed as mean ± standard deviation (SD). Analyses were 
performed to estimate intergroup differences using the One-way ANOVA. A p 
value of <0.05 was considered statistically significant.  
3.4 Results 
Functional characterization of rat Abcg2 expressed in MDCKII cells and 
GF120918 as an inhibitor of rat Abcg2   
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The full-length rat Abcg2 complementary DNA was expressed in MDCK-II 
cells. The functional activity of Abcg2 was characterized and high activity clones 
were selected using FACS based on the ability to limit the accumulation of the 
prototypical human and mouse ABCG2 substrate, Hoechst 33342.  Rat Abcg2 
clone was selected and validated as shown (Figure 3-1 A). The phenotype of 
this clone could be reversed with GF120918 (Figure 3-1 B).  Furthermore, the 
effect of GF120918 on the transport of nitrofurantoin by rat Abcg2 was 
investigated in MDCKII-rat Abcg2 and MDCKII-empty cells. These MDCKII-rat 
Abcg2 cells demonstrated 7.5-fold increase in apically directed transport and a 
55% decrease in basolateral transport of nitrofurantoin (Figure 3-1C), which was 
largely reversed by GF120918 treatment (Figure 3-1D).  These results show the 
creation of a MDCKII–rat Abcg2 expressing cell line was successful and that 
GF120918 is an inhibitor of rat Abcg2. 
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Figure 3-1 Functional characterization of MDCKII-rat Abcg2 expressed cells. The 
Hoechst 33342 accumulation of MDCKII cells with either empty vector (black unfilled) or 
rAcbg2 clone cells (shaded) (Panel A). Cells were analyzed by flow cytometry following 
incubation of the ABCG2 substrate Hoescht 33342 in presence (black unfilled) and 
absence (shaded) of 1 µM of the ABCG2 inhibitor, GF120918 (Panel B). The amount of 
nitrofurantoin appearing in the receiver compartment across MDCKII-empty vector and 
MDCKII-rAbcg2 monolayers grown on Transwells (Panels C and D). Panel C depicts 
the flux of nitrofurantoin from the basolateral to apical (●■); apical to basolateral (○□) in 
MDCKII-empty (●○) and MDCKII –Abcg2 (□■);  Panel D depicts the transport of 
nitrofurantoin from the basolateral to apical in MDCKII-empty (●○) and MDCKII –Abcg2 
(□■) in MDCKII-  
 
Expression of rAbcg2 and P-gp in lactating mammary gland and rAbcg2 
expressed MDCKII cells 
Abcg2 and P-gp expression in rat lactating mammary gland were assayed by 
Western blot. In contrast to the kidney (positive control), P-gp was not detected in 
lactating mammary gland (Figure 3-2A).  Abcg2 expression was detected in 
lactating mammary gland, kidney and Abcg2 expressing MDCKII cell line (Figure 
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3-2B and 3-2C); however, the native Abcg2 bands were different sizes in the 
mammary gland (~72kd), rat Abcg2 expressing in MDCKII cell line (~80kd) and 
the kidney (~80kd).   Following deglycosylation (Figure 3-2B and 3-2C), all of the 
native bands were reduced to approximately 60 kDa.  Immunohistochemistry 
showed the localization of Abcg2 in rat lactating mammary gland (Figure 3-3). 
Abcg2 was strongly expressed on the apical side of epithelial cells in lactating 
mammary gland. As a positive control, Abcg2 staining was mainly observed in 
the renal proximal tubules in kidney. Abcg2 staining was not found in the 
nonspecific staining control.  
Infusion Studies 
Results from the nitrofurantoin infusion study in lactating rats are shown in 
Figure 4. The concentration of nitrofurantoin in serum reached steady-state at 2 
hours following the initiation of the infusion and was maintained through 5 hours.   
Linear regression revealed that the slope (plasma concentration versus time) 
was not significantly (p<0.05) different from zero over this timeframe, however 
there was a trend for the GF120918 treatment to increase nitrofurantoin 
concentration with time.  The presence of GF120918 resulted in a higher 
concentration of nitrofurantoin in serum (Figure 3-4A). The systemic clearance of 
nitrofurantoin in lactating rats was 4.12 ± 0.5 L/h/kg and was significantly 
decreased to 2.78 ± 0.5 L/h/kg (p<0.05, Figure 3-4B) by coadministration with 
GF120918.  Higher nitrofurantoin serum concentrations and lower milk 
concentrations (Figure 3-4A) in GF120918 treated group resulted in a 
substantial reduction (93%) in the M/S of nitrofurantoin from 41.5 ± 19.1 to 3.04 ± 
2.27 (Figure 3-4C). 
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Figure 3-2 Western blot analysis of P-gp and Abcg2 expression. Crude membrane 
fractions were prepared for all the samples. P-gp expression in rat kidney and lactating 
mammary gland (Panel A). The expression of native and deglycosylated rAbcg2 in 
lactating mammary gland, kidney (Panel B), vector (pcDNA3.1), and rAbcg2 expressed 
MDCKII cell line (Panel C). 
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Figure 3-3 Immunohistochemical detection of Abcg2 (magnification, 63x) in rat lactating 
mammary gland (nonspecific staining control) (Panel A), rat kidney (positive control) 
(Panel B) and rat lactating mammary gland (Panel C). 
 
 
 
Figure 3-4 Concentration versus time profile (Panel A) for serum (●■) and milk (○□) 
following nitrofurantoin infusion (0.5 mg/hr) in GF120918 (10 mg/kg) treated (□■) or 
control lactating rats (●○).  Nitrofurantoin systemic clearance (Panel B) and M/S (Panel 
C). Asterisks represent data points that are significantly different from control. * P<0.05.  
Data is presented as mean ± SD).   
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3.5 Discussion 
In the present study, we have utilized GF120918 as an inhibitor of Abcg2 in 
order to assess its role in drug transfer into rat milk. GF120918 was originally 
developed as a second-generation P-gp inhibitor (Tan et al., 2000).   It belongs to 
the family of acridone carboxamide derivatives (Warmann et al., 2002; 
Boumendjel et al., 2007) and has an IC50 value of ~30 to 300 nM on the cellular 
accumulation of phosphine technetium complexes by human P-gp in Sf9 cells 
(Luker et al., 1997).  GF120918 is also a potent ABCG2 inhibitor with IC50 values 
of ~300 nM on efflux or accumulation in cell lines transfected with human ABCG2 
(Ahmed-Belkacem et al., 2005; Pan et al., 2007).  Based on our results, 
GF120918 (1 μM) appeared to effectively inhibit the efflux of Hoechst 33342 and 
nitrofurantoin from rAbcg2 expressing MDCKII cell line, thus confirming that 
GF120918 is an effective in vitro inhibitor of rat Abcg2.    
Following a 10 mg/kg dose, GF120918 significantly increased the serum 
concentrations of nitrofurantoin by decreasing its systemic clearance.   Previous 
investigators have noted the systemic clearance of nitrofurantoin to be mediated, 
in part, by Abcg2-dependent processes (Merino et al., 2005b; Wang and Morris, 
2007).  Following oral and intravenous administration of nitrofurantoin, the area 
under the concentration time curve in Bcrp1 knockout mice was 4-fold and 2-fold 
higher, respectively, than in wild-type mice (Merino et al., 2005b), due to reduced 
first pass and hepatobiliary excretion of nitrofurantoin. Zhang et al have also 
shown that Bcrp1 limited the fetal distribution of nitrofurantoin and had a minor 
effect on the systemic clearance of the drug in the pregnant mouse (Zhang et al., 
2007).    
In previous work in our lab, the P-gp substrate, nelfinavir, was dosed to 
lactating rats with GF120918 (Edwards et al., 2005).  GF120918 had no effect on 
M/P (the ratio of drug concentration in milk to in plasma) but did change brain to 
plasma ratio.  Nelfinavir, like other human immunodeficiency virus protease 
inhibitors are well established substrates of P-gp (Kim et al., 1998; Lee et al., 
1998; Washington et al., 1998).  These protease inhibitors have been shown to 
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be inhibitors, but not substrates of Abcg2 (Gupta et al., 2004).  This evidence 
suggests that P-gp does not play a role in drug transfer into rat milk.  By contrast, 
nitrofurantoin has not been shown to be a substrate of other major efflux 
transporters, such as P-gp, Mrp1 and Mrp2 (Merino et al., 2005b; Wang and 
Morris, 2007).  Hence, the affect GF120918 on the clearance and M/S of 
nitrofurantoin is not mediated by P-gp, but due largely to Abcg2 inhibition.   It 
should be noted, however, a study of membrane transporters in MDCKII-hMDR1 
using GF120918 to inhibit digoxin and loperamide efflux implicated a possible 
basolateral transporter(s) which could be inhibited by GF120918 (Acharya et al., 
2008).  The identity or function of basolateral transporter(s) on lactating 
mammary epithelial cells and their potential impact on M/S has not been 
established.  
 Consistent with mammary gland expression in other species (Merino et al., 
2005b), our western blotting results show Abcg2 is highly expressed in the 
lactating rat.  P-gp appears to be transcriptionally down-regulated during lactation 
(Alcorn et al., 2002) and protein expression was not detectable in the lactating rat 
mammary gland (Figure 2A). All of the native Abcg2 bands were reduced to 
approximately 60 kDa following deglycosylation.  This observation is consistent 
with the result previous work suggesting that ABCG2 contains N-linked 
oligosaccharides, probably at both of the putative glycosylation sites (Litman et 
al., 2002).  The native Abcg2 bands in kidney and rAbcg2 - MDCKII cell line had 
a larger size (approximately 80 kd) than the mammary gland (approximately 
70kd), suggesting rat Abcg2 may have tissue or cell specific patterns of 
glycosylation.  
Consistent with the Western blot analysis, immunohistochemistry clearly 
indicated that Abcg2 is strongly expressed on the apical side of epithelial cells in 
lactating mammary gland.  Apical expression also confirms the role of Abcg2 in 
actively transporting nitrofurantoin out of the epithelial cells and into rat milk.  
The rat is a frequently used animal model in drug development and may be a 
better animal model under certain experimental paradigms (e.g., multiple 
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samples, crossover study design).  Furthermore, drugs identified as 
accumulating in rat milk by active transport are consistent with human literature 
(McNamara et al., 1991; McNamara et al., 1992a). Hence, evidence gathered to 
date suggest that the rat is a good model for identifying which drugs might 
undergo active transport into human milk.  
As noted in the introduction, genetic knockout models are useful tools to 
demonstrate transporter function with the assumption that the only difference 
from wild-type is the abolishment of expression of the intended protein.   
However, knockout models have been found to undergo additional changes 
which might further complicate interpretation.  For example, brain microvessels 
from Mdr1a deficient mice express 3 times more Abcg2 RNA than  microvessels 
of  wild-type mice (Cisternino et al., 2004).  Although the accumulation of Abcg2 
substrates, mitoxantrone and prazosin was significantly increased in the 
presence of GF120918 in both wild-type and P-gp deficient mice there was 
significant difference between them (Cisternino et al., 2004).  Whether or not this 
increased expression and activity of Abcg2 is a compensatory mechanism for the 
lack of Mdr1a at the mouse blood-brain barrier remains to be elucidated.    There 
are other compensatory functions which also may be present in genetic knockout 
animals.  In Mrp2 (-/-) mice, Mrp4 mRNA and protein expression in liver and 
kidney were increased approximately 6- and 2-fold, respectively (Chu et al., 
2006).   In Mrp2-deficient rats [TR (-)], Mrp3 was significantly up-regulated in the 
liver (approximately 6-fold) and kidney (approximately 3.5-fold) compared with 
wild-type controls.   Likewise, the expression of the Ugt1 enzyme was increased 
in the liver and kidney of TR (-) rats by approximately 3.5- and 5.5-fold (Johnson 
et al., 2006). Therefore, alterations in drug disposition using knockout animals 
must be interpreted cautiously because of the possibility of compensatory 
changes in other transport proteins.  
The inhibition of Abcg2-associated nitrofurantoin accumulation by GF120918 
in the lactating rat (“chemical knockout”) provides support for the use of this 
alternative to the genetic knockout model for establishing the role of Abcg2 in 
drug active transport into milk.  GF120918 has been tested in phase I clinical 
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trials and was confirmed to have little toxicity (Planting et al., 2005; Kuppens et 
al., 2007).  Various studies have shown that GF120918 can be tolerated in 
humans and animals at concentrations sufficient to inhibit ABCG2.  Hence, 
GF120918 is suitable for in vivo  animal and perhaps even clinical studies (Mao 
and Unadkat, 2005).    
In summary, Abcg2, but not P-gp is expressed in lactating mammary 
epithelia and appears to be responsible for nitrofurantoin active transport into rat 
milk. The rat appears to be a good animal model for identifying those drugs that 
would accumulate in human milk.  GF120918 appears to be an effective in vivo 
inhibitor (“chemical knockout”) tool for confirming the role of Abcg2 in milk 
transfer. These data are especially valuable for the design of studies of ABCG2 
substrates during breastfeeding using the rat as animal model.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Copyright © Lipeng Wang 2010 
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CHAPTER 4: Stereoselective drug accumulation in milk: 
ABCG2 interaction with pantoprazole 
4.1 Summary 
Drug active transport into milk is a major concern in breastfeeding. Recent 
evidence has confirmed Abcg2, a xenobiotic transporter, plays a critical role in 
drug transfer into rat milk which is consistent with human study.  Although it is 
estimated that about half of all therapeutic agents are chiral, there have been few 
reports of stereoselective interactions with transporters. The purpose of this 
study is to investigate the interaction of pantoprazole isomers with Abcg2 in drug 
accumulation in milk by in vitro and in vivo experiments. For in vitro experiments, 
Abcg2/vector-MDCKII cells were seeded in Transwell. Pantoprazole isomers (30 
µM) were loaded on apical/basolateral side and pantoprazole flux was analyzed 
by HPLC.  Jugular and femoral veins of Sprague-Dawley lactating rats were 
cannulated and each dam (n = 5) received an i.v. infusion of pantoprazole 
mixture in saline for 8h with/out Abcg2 inhibitor (GF120918) and crossed over on 
the second day. Samples were analyzed by LC-MS with chiral column. The 
results indicated pantoprazole isomers were transported in an identical fashion in 
empty-MDCKII cell lines, whereas a significant difference in flux was observed in 
Abcg2-MDCKII cell line. In the in vivo experiments, the steady state was 
achieved after 2 hour infusion and the administration of GF120918 apparently 
increased both pantoprazole isomer concentrations in serum, but no statistical 
difference was observed. (+)-PAN (0.57±0.1) had a higher systemic clearance 
than (-)-PAN (0.44±0.12) (p<0.01). Milk to serum ratio of (-)-PAN (1.36±0.20) was 
almost 3 times as great as that of (+)-PAN (0.54±0.09).  Administration of the 
Abcg2 inhibitor (GF120918) decreased M/S of (-)-PAN to 0.50±0.08 (p<0.001) 
and (+)-PAN to 0.38 ±0.07 (p>0.05).  Abcg2 interacts stereoselectively with 
pantoprazole isomers in both in vitro and in vivo studies. Pantoprazole 
stereoselectivity for Abcg2 appears to be responsible for a difference in the 
accumulation of substrate isomers in milk and may have consequences for other 
aspects of stereoselective drug disposition.  
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4.2 Introduction 
Chirality is a central feature of biology and its existence is essential for many 
life processes.   Specific three dimensional structure-activity relationships in the 
environment of living systems are required for effect (e.g., enzymes, receptors, 
transporters, and DNA) (Smith, 2009), which implies that enantiomers of drugs or 
substrates may elicit a different response or outcome.  It is estimated that about 
half of marketed therapeutic agents are chiral with most available as 50/50 
mixtures of their enantiomeric forms (Andersson and Weidolf, 2008).  The final 
decision to market a drug as an enantiomerically pure form or a racemic mixture 
is made following consideration of all the medical, financial and social risk 
benefits (Nunez et al., 2009).    
Stereoselective metabolism, the transport of chiral drugs as well as genetic 
polymorphisms of CYP450 and receptors complicate drug dosing and influence 
pharmacokinetics, pharmacodynamics, and toxicity (Katsuki et al., 2001; Tateishi 
et al., 2008; Miura and Uno, 2009).   It is especially critical for those drugs that  
have a narrow therapeutic index (e.g., warfarin) (Takahashi, 2008).  Additionally, 
there is a report that two enantiomers of chiral drug can have reverse 
stereoselective regulation on transporter expression (Shen et al., 2007).  As a 
result of these revelations of the significance of chirality on pharmacodynamic 
and pharmacokinetic profiles, there has been increasing concern over the use of 
racemates, and other steroisomeric mixtures, as drugs.  
As a widely distributed efflux transporter in such tissues as kidney, liver, 
blood-brain barrier, placenta, stem cells and mammary gland,  ABCG2 (ATP 
binding cassette transporter isoform G2) exhibits a broad substrate specificity 
transporting hydrophobic, anionic, and cationic drugs (Mao and Unadkat, 2005). 
It can significantly influence the absorption, distribution, elimination and toxicity of 
substrate drugs (Oostendorp et al., 2009).  
The role of ABCG2 in xenobiotic distribution into milk has been identified 
(Jonker et al., 2005; Merino et al., 2006b). A working hypothesis of the present 
work provides that all ABCG2 substrates accumulate in milk resulting in relatively 
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high M/S ratios (the ratio of drug concentration in milk to serum); higher than that 
predicted by simple diffusion.   However, a clinical case report with pantoprazole 
(PAN) would appear to challenge this hypothesis (Plante et al., 2004).   PAN has 
been described as a typical ABCG2 substrate (Breedveld et al., 2004), and yet, 
the authors found an M/S value of 0.022 for racemic PAN in one volunteer 
(Plante et al., 2004).  It is unclear whether the low M/S ratio for PAN is a result a 
more limited ability of PAN to act as a substrate for ABCG2, PAN’s rapid diffusion 
across membranes, PAN’s extensive serum protein binding, or some other 
explanation.  
PAN undergoes enantioselective hepatic metabolism in both humans and 
rats (Tanaka et al., 2001; Xie et al., 2005).  Poor metabolizers of S-mephenytoin 
(a CYP2C19 substrate) were less able to metabolize (+) PAN than (–) PAN 
(Tanaka et al., 2001).  There are no reports of PAN isomers interacting with 
transporters (e.g., ABCG2).   Moreover, there do not appear to be any reports on 
stereoselective drug accumulation in milk.  
A chemical knock-out Abcg2 rat model, in which the function of Abcg2 is 
inhibited by GF120918, has been established (Wang et al., 2008).  The major 
goals of the present work was to take advantage of this unique model to 
investigate the stereoselective interaction in pantoprazole enantiomers active 
transport in milk and to further examine the ABCG2 substrate milk accumulation 
hypothesis by comparing that to predicted M/S from passive diffusion model. 
4.3 Materials and methods:  
Chemicals  Protonix I.V (Pantoprazole sodium, 50:50 stereo mixtures) was 
obtained from Altana (Konstanz, Germany) and zonisamide sodium was 
purchased from Sigma-Aldrich (St. Louis, MO). The isomers of PAN were 
obtained from Altana Pharma AG (Konstanz, Germany). GF120918 was a gift 
from GlaxoSmithKline (Research Triangle Park, NC). All the organic solvents 
[high-performance liquid chromatography (HPLC) grade] were purchased from 
Thermo Fisher Scientific (Waltham, MA). 
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Animals 
 Five adult female lactating Sprague-Dawley rats (250–350 g) with 1- or 3-
day-old pups were purchased from Harlan Laboratories (Indianapolis, IN). 
Animals were maintained under a 12/12-h light/dark cycle and had access to 
food and water during the experiments. The rats were acclimatized for at least 1 
week before the experiment. All the procedures were approved by the University 
of Kentucky Institutional Animal Care and Use Committee. 
Flux study 
 Rat Abcg2 and empty vector (pcDNA3.1) expressed in Madin-Darby Canine 
Kidney II Cells has been established in our lab (Wang et al., 2008). Cells were 
seeded on microporous membrane filters (3.0-µm pore size, 24-mm diameter; 
Transwell 3414; Corning Inc., Corning, NY) at a density of 1.0 x 106 cells/well. 
Cells were grown for 4 days to achieve transepithelial electrical resistance >200 
· cm2, and media was replaced every other day. Before the experiment, the 
media at both the apical and basolateral side of the monolayer was replaced with 
2 ml of OptiMEM media (Invitrogen, CA) without serum and  either the apical or 
basolateral side was loaded with 25 µM PAN isomers containing 0.2 µCi/ml 
[3H]mannitol (Perkin Elmer, Norton, OH). Cells were incubated at 37°C in 5% 
CO2. To assess tight junctions of each monolayer, 50 µl aliquots were collected 
to assess the paracellular flux of [3H] mannitol into the opposite compartment. 
For PAN isomers transport, 140-µl aliquots were taken at 1, 2, 3 and 4 h. 
Samples were stored at -80°C until the time of analysis. 
In vitro M/S.   
M/S ratios for PAN isomers transfer into milk is governed by passive diffusion 
and can be predicted from an in vitro passive diffusion model (Fleishaker et al., 
1987; Fleishaker and McNamara, 1988b):  
 
                                                                                                       Eq.3-1 
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where fu is the unionized fraction of drug in serum or milk, f is the free fraction of 
drug in serum or milk, W/S is the ratio of the drug concentration in whole milk to the drug 
concentration in skim milk, and the subscripts s and m represent serum and milk, 
respectively.  
The S/W ratios, a measure of the milk fat partitioning of PAN isomers, were 
determined following LC-MS analysis of the each PAN isomer concentrations in 
blank rat whole milk and skim milk into which isomer had been added. The 
unionized fraction in serum and skim milk, a measure of the pH partitioning of 
drug between serum and milk, was calculated from the pKa of each isomer and 
from the pHs of serum (pH 7.45) and milk (pH 6.8)(Alcorn and McNamara, 2002). 
The unbound fraction of PAN isomers in milk and serum were determined by 
equilibrium dialysis of these fluids against a 0.133 M phosphate buffer (milk pH 
6.8 and serum pH 7.45) in plexiglass dialysis cells (single place, 0.5 ml cells). 
After 8 hours equilibrium at 37oC, samples were taken from both donor and 
recipient sides. These concentrations were determined by LC-MS.  
In vivo studies 
 The jugular and femoral veins of Sprague-Dawley lactating female rats were 
cannulated under ketamine/xylazine anesthesia on days 10 to 12 postpartum. 
After 24 hours of recovery, each dam (n = 5) was randomized to receive an i.v. 
infusion of PAN in saline (0.4 mg/ml/h) for 8 h either with pretreatment of the 
inhibitor (GF120918, 10 mg/kg in DMSO) or with equivalent volume 
(approximately 0.15 ml of DMSO) of vehicle administered i.v. 10 minutes before 
infusion and all animals were crossed over on the second day to complete both 
phases (Wang et al., 2008). One milliliter of normal saline was given hourly by 
i.v. infusion to prevent dehydration during infusion. The dams were separated 
from the pups 4 hours before the infusion. Blood samples were drawn every 2 
hours during the infusion. The blood samples were protected from light in 
separator tubes (BD Microtainer, Franklin Lakes, NJ), centrifuged to harvest 
serum, and frozen at -80°C until analysis. Milk samples were obtained by manual 
manipulation under light anesthesia (ketamine) at the end of the infusion, 
protected from light, and also frozen at -80°C until analysis.  
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Sample preparation 
 To each aliquot (50 µl) of serum, 10 µl 0.2 M NaOH and 20 µl of 10 µg/ml 
zonisamide sodium (internal standard) were added and the proteins were 
precipitated with 1ml Ethyl acetate, vortexed for 1 min, and then centrifuged at 
2,400 rpm for 15 min at room temperature. The clear layer was collected into 
another clean glass tube (~0.8 ml) and dried under nitrogen in a 40oC water bath.  
Samples were then reconstituted in 50 ul mobile phase (15% Acetonitrille and 
85% water but without formic acid).  To each aliquot of milk, the same amount of 
NaOH and zonisamide sodium were added to 25 µl of milk sample, protein was 
precipitated with 1 ml of cold methanol, vortexed for 30 seconds, and then 
centrifuged at 14,000g for 10 min at 4°C. The clear layer was collected to a clean 
glass tube (~0.9ml) and dried under nitrogen in a 40°C water bath.  Samples 
were reconstituted in 200 µl water and mixed very well. Then 1 ml ethyl acetate 
was added, the samples were vortexed and centrifuged (same as serum samples 
extraction).  The collected clear layers were dried under nitrogen in a 40oC water 
bath and reconstituted in 50 µl mobile phase.  This method was adapted from 
Bharathi (Bharathi et al., 2009). PAN isomers in phosphate buffer samples from 
in vitro predicted M/S ratio experiment were reconstituted in 1 ml water and 2 ml 
ethyl acetate, vortexed and centrifuged at 2400rpm for 15 minutes. The 1.8 ml 
organic layer was collected and dried under nitrogen at 40oC water bath and 
reconstituted in 50 µl mobile phase.  
Pantoprazole HPLC analysis 
 Concentrations of total PAN were assayed by HPLC on a Luna RP18 125 x 
4.0-mm column (Phenomenex, Torrance, CA) and eluted with 40% 
acetonitrile/60% 10 mM potassium phosphate buffer, pH 7.2, at 0.5 ml/min. UV 
absorb  at 290 nm. Aliquots of PAN in Opti-MEM medium were directly injected 
onto the HPLC. The standard curve range was 7.8 to 2000 ng/ml. All the 
standard curves showed an intraday and interday variability of <10% and r2 > 
0.999. 
Pantoprazole isomer analyses by LC-MS 
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 A Varian 1200L Triple Quadrupole mass spectrometer (Walnut Creek, CA) 
equipped with an electrospray ionization (ESI) source and a Varian MS 
Workstation (6.42) data system was employed. The interface was adjusted to the 
following conditions:  positive ion mode; spray needle voltage, 5000V; shield 
voltage, 600V; capillary voltage, 40V; drying gas (Nitrogen) temperature, 
300oC.  MS/MS spectra were obtained for selected precursor ions through 
incidental collision with neutral gas molecules (Argon) at 2.0mTorr in the collision 
cell of the mass spectrometer. The collision energy was set at 8.50V. The 
parameters of the selected reaction monitoring transitions for the [M+H]+ to 
selected product ions were optimized with the following typical values for the 
analytes and internal standard: PAN m/z 384 to 200 and the internal standard 
zonisamide m/z 213 to 132.  The LC conditions were as follows. The column was 
a Lux 5 µl Amylose-2 150 x 4.60-mm Chiral column (Phenomenex, Torrance, 
CA). The initial mobile phase consisting of acetonitrile: water: formic acid 
(15%:85%:0.02%) was delivered by dual Varian ProStar 210 pumps (Walnut 
Creek, CA), at a flow rate of 0.3 ml/min.  A gradient program was utilized; the 
acetonitrile phase was increased to 90% over 12 minutes and held constant for 
an additional 6 minutes.  The acetonitrile phase was returned to 15% over 1 
minute and held constant for an additional 11 minutes for a total run time of 30 
minutes. Twenty microliters of the sample was injected onto the LC-MS. Serum 
and milk concentrations of PAN were quantified according to standard curves.  
Pharmacokinetic Calculations and Statistical Analysis. Systemic clearance 
was calculated using the following formula:  
 
                                                                                                                            Eq.3-2 
 where CS is the average concentration of PAN in serum from 2 to 8 h. M/S 
was calculated by:  ( 
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                                                                                                                           Eq.3-3 
where CM is concentration of PAN in milk at 8 h.                             
All the data are expressed as mean ± S.D. Analyses were performed to 
estimate intergroup differences using two-way ANOVA analysis of variance with 
Bonferroni Post test for multiple comparisons. A p value of <0.05 was considered 
statistically significant.  
 
4.4 Results 
Pantoprazole isomers transport in rat-Abcg2 expressed in MDCKII cell 
line.  
The expression level and function of rat Abcg2-MDCKII were confirmed by 
Western blot, flow-cytometry and nitrofurantoin transport in previous studies 
(Wang et al., 2008).  At 25 μM, the flux for both isomers and in both directions 
approached steady-state after 3 hour in empty vector and Abcg2-MDCKII cells.  
Initial rates were calculated during first hour.   The flux for both PAN isomers in 
both directions was identical in empty MDCKII cells (Figure 4-1A).  The 
asymmetry efflux ratios (ERα) of (+)- and (-)- PAN in parent cell line at the one 
hour time point were 0.90 and 0.95, respectively.  In Abcg2-MDCKII cell line, the 
initial flux rate for basolateral to apical flux was considerably greater than the flux 
in the opposite direction.   The mass transport of (+)-PAN from basolateral to 
apical side across monolayer appeared greater than (-)-PAN (Figure 1B), 
whereas the flux from apical to basolateral was greater for the (-)-PAN relative to 
the (+)-PAN.  The ERα of (+)- and (-)-PAN at the one hour time point were 5.15 
and 1.51, respectively in Abcg2-MDCKII cell line.   These stereoselective 
differences in initial rates were maintained as the profiles approached steady 
state of (+)-and (-)-PAN were 3.82 and 1.77, respectively. 
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Figure 4-1 The amount (mean±SD, n=3) of PAN isomers appearing in the receiver 
compartment of MDCKII-empty vector and MDCKII-rAbcg2 monolayers grown on 
Transwells at donor concentration of 25 uM.  PAN isomers: minus (open symbol) and 
plus (closed symbol) from the basolateral to apical (squares) and apical to basolateral 
(circles) in MDCKII-empty (panel A) and MDCKII-rAbcg2 (panel B) 
Predicted M/S ratios of pantoprazole isomers 
Table 4-1 contains individual parameter estimates that contribute to the 
diffusion model prediction of M/S (M/Spredicted) of the PAN isomers. The fraction of 
unionized approximated 1 for both PAN isomers since their pKa is lower than the 
pH of both rat milk (6.8) and serum (7.45). The free fractions of PAN isomers 
were determined by equilibrium dialysis using serum concentrations in rat 
infusion study.  The serum free faction of (+)-and (-)-PAN were 2.33% and 
2.38%, respectively.  PAN isomers have lower binding in skim milk (74% and 
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73%, respectively). The fat partitioning of each isomer was reflected in the S/W 
ratio which was 0.75 and 0.77 for the (+)- and (-)-PAN, respectively.  M/S ratio 
predicted by the diffusion model was 0.12 for (+)-PAN and 0.11 for (-)-PAN.  
Table 4-1 M/S Ratio Observed M/S Ratio Predicted for PAN isomers in lactating Sprague-
Dawley rats.* P<0.01. Data is presented as mean. 
M/S Ratio and property or rat no. 
 
(+)-PAN (-)-PAN 
Diffusion Model Parameters 
  pKa 3.9 3.9 
f
u
,serum ~1 ~1 
f
u
,milk ~1 ~1 
f serum (%) 2.33 2.38 
f milk (%) 25.96 27.08 
S/W ratio 0.75 0.77 
   Predicted M/S (M/S Predicted) 0.12 0.11 
200% M/S Predicted 0.24 0.23 
50%  M/S Predicted 0.06 0.06 
(M/S Observed)/(M/S Predicted) 4.43* 11.95 
   
Observed M/S (M/S Observed) 
  1 0.45 1.22 
2 0.43 1.34 
3 0.62 1.68 
4 0.64 1.40 
5 0.54 1.17 
   Mean 0.54* 1.36 
SD 0.10 0.20 
Lower 95% Cl of mean 0.42 1.11 
Upper 95% Cl of mean 0.65 1.61 
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In vivo study-pantoprazole isomers accumulate in rat milk.  
The lactating rats were infused with racemic PAN and each isomer 
concentration in serum and milk were measured by LC-MS. Chromatographs of 
PAN isomers and zonisamide are shown in Figure 4-2.  The standard curve was 
linear from 80 to 5,000 ng/ml in serum, 10 to 5000 ng/ml in milk and 25-1000 
ng/ml in phosphate buffer. All the standard curves showed an intraday and 
interday variability of <10% and r2 > 0.99 (Appendix D-2) .  
 
Figure 4-2 Enantiomeric separation of PAN (156 ng/ml) and internal standard 
zonisamide (4 µg/ml).  Panels A and C represent a chromatogram of internal standard 
alone in one PAN standard serum (156 ng/ml) and blank serum respectively.  Panels B 
and D represent a chromatogram of PAN isomers in one PAN standard serum (156 
ng/ml) and blank serum (lower attenuation), respectively. 
The mean PAN isomer concentration time profiles in serum are shown in 
Figure 4-3.   In the dosing vehicle treatment, both PAN isomers appeared to 
achieve steady-state serum concentrations by 2 hour time point in the 
A 
B 
C 
D 
IS 
IS 
(+)-PAN (-)-PAN 
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intravenous infusion protocol with (-)-PAN (1,625 ng/ml) slightly higher than (+)-
PAN (1,204 ng/ml).   The treatment of GF120918 appeared to increase the 
serum concentration of both PAN isomers, in particular for (-)-PAN which 
increased 37%.   In the control group, (+)-PAN (0.57±0.1) had greater systemic 
clearance (Figure 4-4) than did (-)-PAN (0.44±0.12).   The two-way ANOVA 
analysis of variance indicated a significant isomer and treatment effect, but no 
interaction.   
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Figure 4-3 PAN isomer concentrations (Mean±S.D., n=5) in serum in lactating Sprague-
Dawley rats at 2, 4, 6 and 8 hour infusion (0.4 mg/ml/h) following administration of 
dosing vehicle alone (DMSO) or GF120918 (10 mg/kg) 
PAN isomers were distributed differently into milk in the rat.   At 8 hours, the 
milk concentration of (-)-PAN (2,260 ng/ml) was considerably higher than (+)-
PAN (644 ng/ml).   The milk concentrations were lower for both isomers and the 
difference between the isomers diminished [(-)-PAN (1,098 ng/ml) and (+)-PAN 
(525 ng/ml)] following GF120918 administration.   The M/S ratios for PAN 
isomers are shown in Figure 4-5.  In control (DMSO) group, M/S ratio of (-)-PAN 
was nearly 3 times that of (+)-PAN.   Administration of GF120918 decreased M/S 
ratios of (+)-PAN from 0.54±0.09 to 0.38 ±0.07 and (-)-PAN from 1.36±0.20 to 
0.50±0.08. The two-way ANOVA analysis of variance indicated a significant 
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isomer and treatment effect, as well as a significant interaction between isomer 
and treatment. The mean observed M/S was 4.43 fold for (+)-PAN and 11.95 fold 
for (-)-PAN greater than the M/S Predicted (Table 4-1) and the 95% confidence 
intervals around the M/S did not overlap the 50 to 200% range of the M/S 
predicted.  
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Figure 4-4 The systemic clearance of PAN isomers following administration of dosing 
vehicle alone (DMSO) or GF120918 (10 mg/kg). Data are presented as paired values 
from individual rats.   
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Figure 4-5 The M/S ratios of PAN isomers following administration of dosing vehicle 
alone (DMSO) or GF120918 (10mg/kg).  Data are presented as paired values from 
individual rats.   
4.5 Discussion 
ABCG2 is a widely distributed efflux transporter and plays an important role 
protecting body against endogenous or exogenous xenobiotics.  The role of 
transporter on absorption, distribution, metabolism and excretion (ADME) of 
drugs has been documented in ABCG2 substrate flux studies (Kruijtzer et al., 
2002).   There is a growing concern regarding the role of ABCG2 in drug-drug 
interactions as well (Giacomini et al., 2010; Huang and Woodcock, 2010). 
 ABCG2 is also found on the apical surface of lactating mammary epithelial 
cells (Jonker et al., 2005). The physiological function of ABCG2 in lactation is 
uncertain; however, riboflavin has been shown to be a substrate and ABCG2 
may be functioning as a nutrient transporter (van Herwaarden et al., 2007).  A 
number of investigators have demonstrated the importance of this transporter in 
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the accumulation of drugs in milk (Jonker et al., 2005; Perez et al., 2009).  
Nitrofurantoin and cimetidine, both ABCG2 substrates, accumulates in human 
and rat milk (Oo et al., 1995; McNamara et al., 1996; Gerk et al., 2001a; Oo et 
al., 2001).   Others have clearly demonstrated the role of mAbcg2 in drug transfer 
into milk using knockout mice (Jonker et al., 2005; Merino et al., 2005b).   Other 
ABCG2 substrates which appear to accumulate in milk include: topotecan, 
acyclovir, dietary carcinogens, ranitidine and ciprofloxicin (Jonker et al., 2005; 
Merino et al., 2005b; Merino et al., 2006a; van Herwaarden et al., 2007; Vlaming 
et al., 2009) 
A testable supposition would hold that all ABCG2 substrates accumulate in 
milk, resulting in relatively high M/S ratios, greater than that predicted by simple 
diffusion.   A clinical case report with PAN would appear to challenge the premise 
(Plante et al., 2004).   PAN is highly protein bound (>98%) in human serum 
(Andersson and Weidolf, 2008) and rat serum (Xie et al., 2005).  Data in the 
current work confirms that the protein binding of both PAN isomers in rat serum 
is extensive.   PAN has a modest octanol to water partitioning (Badwan, 2002) 
and hence, the fat partitioning is higher (reflected in a lower S/W value) than 
many drugs.  The unionized fractions were assumed to be identical for the two 
isomers.  As a result, M/S ratios predicted by diffusion for both isomers were low 
and virtually identical.  The observed M/S were 4.4 fold [(+)-PAN] and 12.5 fold [ 
(-)-PAN] higher than predicted by diffusion and the 95% confidence intervals 
around the observed M/S did not overlap the 50 to 200% range of the predicted 
M/S (Table 4-1) clearly suggesting a potential role of a transporter for PAN 
accumulation in milk. We have previously utilized this approach as a predictor for 
a significant role of a transporter in drug accumulation in milk (Alcorn and 
McNamara, 2002; Edwards et al., 2003). The observed M/S ratios of (+)-PAN 
and (-)-PAN in the rat were 20-60 times higher than the M/S from the lone human 
report (Plante et al., 2004).  The explanation for the species difference remains 
unclear.  
Stereochemistry is an important aspect of biology and plays a role in many 
aspects of drug disposition (Bhatia et al., 2008) and yet there are few studies 
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examining stereoselective transport of drugs.   PAN is marketed as a racemic 
mixture whose stereoselective disposition has been characterized (Masubuchi et 
al., 1998; Tanaka et al., 2001); however, the interaction of its isomers with 
transporters (e.g., ABCG2) has not been described.  It is unclear whether 
differences in stereoselective disposition could play any role in the distribution of 
PAN into milk.  The present work characterized PAN isomer flux using rat Abcg2 
in vitro models as well as PAN isomer distribution into rat milk.   
Previously our laboratory had established a stably expressed rat Abcg2 in 
MDCKII cell line, a cell line commonly used in transport studies (Bartholome et 
al., 2007; Marchetti et al., 2007; Weinglass et al., 2008).  MDCKII cells are 
believed to express fewer endogenous xenobiotic transporters compared to 
Caco-2 cells, although some research groups have demonstrated that several 
xenobiotic transporters are present in MDCKII cells, such as p-gp and MRP2 (Su 
et al., 2004).  Hence, a number of substrates, including nitrofurantoin exhibit 
directional transport in parent cell line (Kim et al., 1998; van Herwaarden et al., 
2007; Wang et al., 2008).  Interestingly the PAN isomers transported from apical 
to basolateral or from basolateral to apical overlaped completely in MDCKII 
empty cell line; the ERα values were close to unity for both PAN isomers.  This 
would suggest that PAN was not a substrate for any of the endogenous 
transporters in MDCKII; hence, PAN may serve as a model ABCG2 substrate for 
a certain mechanistic flux studies. 
As a typical ABCG2 substrate, PAN has been used as a competitive ABCG2 
inhibitor to identify other ABCG2 substrates or to study drug-drug 
interaction(Breedveld et al., 2004; Yokooji et al., 2007; Adkison et al., 2009) Our 
in vitro experiment demonstrated a rat Abcg2 mediated apically directed 
transport of PAN and indicated pantoprazole is a substrate of rAbcg2, which is 
consistent with the reports that pantoprazole is a substrate for human and mouse 
ABCG2/Abcg2 (Breedveld et al., 2004; Breedveld et al., 2005; Suzuki et al., 
2009). Furthermore, in rat expressing MDCKII cell line, Abcg2 demonstrated 
stereoselective interaction with pantoprazole. The flux of the (+)-PAN appears to 
be greater than the (-)-PAN isomer (Figure 4-1B).   However, a more detailed 
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analysis of the in vitro transport data (Chapter 5) suggests that the (-) isomer is, 
in fact, the better ABCG2 substrate; possessing a greater affinity and overall 
apical efflux permeability (PSAE) for rAbcg2.  The greater flux of (+)-PAN arises 
due to the interplay between the two membranes (basolateral and apical) in 
determining the overall flux.  At lower concentrations, PAN (both isomers) flux 
across the apical membrane (due to rAbcg2) is so rapid that the overall rate 
limiting step is diffusion across the basolateral membrane.   At 25 µM 
concentration, the higher affinity (-)-PAN isomer saturates rAbcg2 at the apical 
membrane, slowing overall flux across the monolayer.   Hence, (+)-PAN 
appeared to be a better rAbcg2 substrate than (-)-PAN (Figure 4-1) when in 
reality the opposite is true.   A more insightful, mechanistic model is required to 
fully interpret flux data (theoretical part, Chapter 6) and such an analysis reveals 
(-)-PAN to be a better rAbcg2 substrate (Chapter 5: in vitro model).  
In the chemical Abcg2 knockout rat model, co-administration of GF120918 
decreased the systemic clearance of nitrofurantoin (Wang et al., 2008).  In the 
present study of PAN isomers, (-)-PAN had a slightly lower systemic clearance 
compared to (+)-PAN but there was no statistical difference. This observation is 
consistent with the report that (-)-PAN had relative longer serum elimination half-
life and mean residence time in rat study (Masubuchi et al., 1998).  The 
administration of GF120918 had no significant effect on PAN isomer systemic 
clearance, which would indicate that Abcg2 does not play a major role in the 
elimination for the systemic clearance of PAN.   In a human study, roughly 80% 
of an oral or intravenous dose is excreted as metabolites in urine; the remainder 
is found in feces and appears to originate from biliary secretion (Huber et al., 
1996a). The parent drug is predominantly metabolized by CYP2C19 and to a 
lesser extent by CYP3A (Radhofer-Welte, 1999).  The pharmacokinetics of PAN 
is unaltered in patients with renal failure, but the rate of metabolism was 
significantly decreased with severe liver cirrhosis patients (Huber et al., 1996b), 
which indicates systemic clearance of PAN is largely determined by hepatic 
metabolism of PAN.  
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The metabolism of PAN isomers in mammary epithelial cell appears to be 
minimal (no evidence of metabolism in milk samples).  The in vivo M/S of (+)-
PAN was almost 1/3 that of (-)-PAN in DMSO group and the in vivo M/S of both 
isomers converged to a similar value (0.4-0.5) following the administration of 
GF120918, suggesting Abcg2 contributes to PAN distribution in rat milk with 
Abcg2 serving as a major contributor for (-)-PAN accumulation.   
Based on the results of in vitro and in vivo studies, we confirmed that Abcg2 
recognizes three dimensional structure of PAN.  This difference may play a role 
in the tissue distribution profile for PAN.  However, it is likely that such 
differences would result in minimal differences in the overall pharmacodynamic 
profiles of PAN.  PAN is an acid gradient dependent accumulation prodrug and 
both isomers are converted to the same active principle, planar sulphenamide.  
Cyclic sulphenamide has an ability to react with key cysteines present in the 
gastric acid pump (Huber et al., 1995).  The chirality is lost in the conversion from 
prodrug to active form; hence, for PAN, stereoselective differences in disposition 
may have limited pharmacologic or clinical effects.  
In conclusion, the present work has demonstrated a clear difference in the 
transport of the isomers of PAN by rAbcg2 with (-)-PAN a better substrate than 
(+)-PAN.   Moreover, PAN stereoselectivity for Abcg2 appears responsible for a 
difference accumulation of substrate isomers in milk and may have 
consequences for other aspects of stereoselective drug disposition.  The current 
work also supports the hypothesis that ABCG2 substrates will accumulate in 
milk, but does not explain the previous clinical observation of a low M/S ratio.  
Additional studies will be needed to clarify this apparent species difference. 
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CHAPTER 5: Data based efflux transport transwell 
model: pantoprazole interaction with rAbcg2/ABCG2 
5.1 Summary 
CaCo-2 and efflux transporter over-expressing cell lines seeded in Transwell 
have been broadly used for new molecule entity screening (NME), drug 
disposition and drug-drug interaction studies which involved efflux transporters, 
such as P-gp, ABCG2 and MRP2. The interactions between compound and 
monolayer in Transwell as a NME screening tool have driven more attention than 
before. In recent years, investigators have employed mathematical models to 
explain the various experimental observations. Kalvass’s efflux theoretical model 
and Sun’s CaCo-2 model expanded our understanding of Transwell flux data and 
have identified the limitation of some parameters. However, these models also 
have their limitations as well.  
In this section, we characterize the interactions between pantoprazole 
isomers and rat Abcg2/ human ABCG2 in Transwell system.  Both pantoprazole 
isomers are Abcg2/ABCG2 substrates. There were stereoselective transport of 
pantoprazole isomers in monolayer of both Abcg2 and ABCG2 expressed in 
MDCKII cell lines with (-)-PAN having a greater affinity. There was a modest 
difference observed in kinetic transport parameters between rat Abcg2 and 
human ABCG2. (-)-pantoprazole is a better substrate than (+)-PAN for both 
species. The observation of PAN isomers transport in Abcg2 expressing in 
MDCKII cell line is consistant with the in vivo result from rat study in Chapter 4.  
Having identical chemical properties (diffusion controlled), the pantoprazole 
isomers provide an ideal platform to compare the kinetic parameters derived from 
Transwell experiments. It is important to use cellular concentration instead of 
donor concentration to estimate kinetic parameters of transporters, e.g., PSA,E, 
Km and Vmax. The theoretical mechanistic model provided a comprehensive 
understanding of pantoprazole isomers transport in Abcg2/ABCG2, verified the 
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theory behind the experimental paradigm and helped reinforce our understanding 
of the monolayer flux experiments.  
5.2 Introduction 
Efflux transporters such as P-gp, MRP2 and ABCG2 are localized in 
numerous tissues throughout the body and play important roles in drug 
absorption, distribution, metabolism and excretion (Giacomini et al., 2010).  
These transporters can be major determinants of the pharmacokinetic, efficacy 
and safety profiles of drugs. In order to identify transporter substrates from new 
discovery libraries or investigate the impact of drug-drug interaction on drug 
metabolism and pharmacokinetic of marketed drugs or those in development, an 
in vitro method is required that is convenient, specific, high-speed and cost 
effective.  
Flux across a Caco-2 or P-gp-overexpressing polarized epithelial cell lines 
have become one of the most popular in vitro methods to characterize substrate 
– transporter interactions. Experimental monolayer models produce an 
environment that mimics the in vivo state, permitting cultured cells to polarize and 
grow on porous membranes that provide an independent access to apical and 
basolateral plasma membrane domains.  Vectorial transport across cell 
monolayers has been well established and used routinely in pharmaceutical 
industries world-wide (Balimane et al., 2004; Balimane and Chong, 2005).   
However, a mechanistic explanation and quantitative description of transport or 
inhibition data from transwells remains limited (Kalvass and Pollack, 2007).   The 
US Food and Drug Administration and the International Transporter Consortium 
are trying to develop guidance to assist drug development scientists in 
conducting informative in vitro and follow-up clinical studies, for example, to 
establish decision trees for the study of P‑glycoprotein or BCRP substrate 
interactions and inhibitor interactions (Zhang et al., 2008; Huang and Woodcock, 
2010). 
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Our laboratory has studied the transfer of drugs into milk in rats, rabbits and 
humans.  While diffusion plays a major role in drug appearance in milk, so does 
ABCG2.  ABCG2 is found on the apical surface of lactating mammary epithelial 
cells (Jonker et al., 2005) and ABCG2 facilitates the accumulation of drugs in 
milk including: nitrofurantoin, cimetidine, topotecan, acyclovir, dietary 
carcinogens, ranitidine and ciprofloxicin (Oo et al., 1995; McNamara et al., 1996; 
Gerk et al., 2001a; Oo et al., 2001; Jonker et al., 2005; Merino et al., 2005a; 
Merino et al., 2006b; van Herwaarden et al., 2007; Vlaming et al., 2009).    It is 
unclear if all ABCG2 substrates will accumulate in milk.  A clinical report involving 
pantoprazole (PAN) reported a very low M/S (0.022) which would question the 
predictability of this generalization (Plante et al., 2004).   In a companion chapter, 
the disposition of PAN in rat milk was explored and revealed a clear 
stereoselective difference associated with rAbcg2.   PAN is marketed as a 
racemic mixture (Figure 5-1) and differences in the overall disposition of the two 
isomers have been reported both in man (Tanaka et al., 2001) and in rats (Xie et 
al., 2005).   It is unknown if the interaction of PAN with ABCG2 is stereoselective 
or if it could explain the human M/S report. 
In this paper, the transport of PAN isomers in monolayers consisting of rat 
(rAbcg2) and human ABCG2 expressed in MDCKII cell line was examined.  The 
first objective was to establish whether any difference in the interaction between 
PAN isomers and rAbcg2/ABCG2 was present.  Secondly, a model was 
proposed to quantify these stereoselective differences in kinetic parameters in 
order that they might be related to in vivo disposition studies.   A third objective 
was to examine the interspecies difference since the rat is frequently used as an 
animal model.  
5.3 Material and methods 
Chemicals and materials 
PAN mixture (50:50) was purchased from Wyeth (Philadelphia, PA) and the 
isomers of PAN were obtained from Altana Pharma AG (Konstanz, Germany). 
Cell culture mediums were obtained from Invitrogen (Carlsbad, CA). All the 
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organic solvents [high-performance liquid chromatography (HPLC) grade] were 
purchased from Thermo Fisher Scientific (Waltham, MA), and all of the other 
chemicals were obtained from Sigma-Aldrich (St. Louis, MO) unless specified.  
Over-expressing rAbcg2/ABCG2 in MDCK-II cell lines were used in the 
transport studies. The establishment of rat Abcg2 or empty vector (pcDNA3.1) 
alone in MDCKII was described previously (Wang et al., 2008). Human ABCG2 
or empty vector (pcDNA3.1) alone in MDCKII was previously established in our 
laboratory (Phil Empy Thesis).  The pcDNA3 plasmid construct alone (empty 
vector) and the pcDNA3 plasmid containing wild-type ABCG2 were prepared for 
transfection.  MDCKII cell transfection was performed at 50% confluence with the 
lipid-based FuGENE 6® transfection reagent at a 3:1 ratio per manufacturer’s 
protocol.  Success of transfection was initially evaluated at 48 h by Western blot 
analysis of cell lysates for ABCG2 following procedures described in the Western 
blot on page 37.  Transfected cells were then selected through the addition of 
800 μg/mL genecitin to the parent cell line media (MEM containing glutamax, 5% 
FBS, 100 U/mL penicillin, and 100 μg/mL streptomycin) (From Phil Empey’s 
dissertation).  
 
Figure 5-1 The structure of pantoprazole isomers.  
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PAN isomers transport in rat Abcg2 or human ABCG2 in Madin-
Darby Canine Kidney II cells.  
Briefly, rat /human ABCG2 or empty vector in MDCKII cells were seeded on 
microporous membrane filters (3.0-µm pore size, 24-mm diameter; Transwell 
3414; Corning Inc., Corning, NY) at a density of 1.0 x 106 cells/well. Cells were 
grown for 4 days to achieve transepithelial electrical resistance >200 · cm2, and 
medium was replaced every other day. Before the experiment, the medium at 
both the apical and basolateral side of the monolayer was replaced with 2 ml of 
OptiMEM medium (Invitrogen) without serum and  either apical or basolateral 
side was loaded with 3, 10, 30, 50 and 200 µM PAN isomers containing 0.2 
µCi/ml [3H]mannitol (Perkin Elmer, Hebron, KY). Cells were incubated at 37°C in 
5% CO2. 50-µl aliquots were collected to assess
 the paracellular flux of [3H] 
mannitol into the opposite compartment; layers restricted mannitol transport to 
<1% of the total radioactivity per hour. For PAN isomers transport, 140-µl aliquots 
were taken at 0.5 and 1 h. Samples were stored at -80°C until the time of 
analysis by HPLC assay.  
PAN HPLC 
Concentrations of PAN were assayed by HPLC on a Luna RP18 125 x 4.0-
mm column (Phenomenex, Torrance, CA) and eluted with 40% acetonitrile/60% 
10 mM potassium phosphate buffer, pH 7.2, at 0.5 ml/min. UV absorb  at 290 
nm. Aliquots of PAN in Opti-MEM medium were directly injected onto the HPLC. 
The standard curve range was from 7.8 to 2000 ng/ml. All the standard curves 
showed an intraday and interday variability of <10% and r2 > 0.999. 
Permeability 
The observed permeability (PObs, (μL/hr)/cm
2) of PAN isomers or paracellular 
marker was determined by calculating its initial transfer rate ( , pmol/hr) across 
the cell layer and dividing by the surface area (A, cm2) of the Transwell and the 
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initial concentration (C0, pmol/mL) in the donor chamber.  PAN isomers transport 
data in rat Abcg2 or human ABCG2 were expressed as mean ± S.D.  
                                                                                                   Eq. 5-1 
 
 
 
 
Figure 5-2 Three compartment model of flux across monolayer on Transwell 
system. PSD: passive diffusion; PSPC: permeability of paracellular transport; PSABCG2: 
active efflux mediated by ABCG2 on apical side.  
A three compartment kinetic model of transcellular flux across a monolayer 
system (e.g., ABCG2 – MDCKII) is shown in Figure 5-2 and has been recently 
developed to facilitate the interpretation of flux data (Theoretical part).  Briefly, 
the driving force for drug efflux from basolateral to apical side includes passive 
diffusion (PSD) across both basolateral and apical membranes, paracellular 
transport (PSPC) between cells and active transport efflux on apical side (PSAE) 
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associated with the transporter.   The model assumes the substrate does not 
interact with endogenous transporters, passive diffusion permeability (PSD) is the 
same across both membranes, there is no cellular metabolism, and rapid 
intracellular diffusion.  Substrate flux rates in three compartments can be 
described by the following set of differential equations (Eq.5-2, Eq.5-3 and Eq.5-
4).      
 
 
                                                  
                             Eq. 5-2 
 
                                                  
                             Eq. 5-3 
 
                                                  
                            Eq.5-4 
where XB, XA and XC are the mass of drug in the basolateral, apical and cellular 
compartment; CC, CB and CA are the concentration of drug in the cellular, 
basolateral and apical compartment, respectively; PSAE , PSD  and PSPC are the 
permeability-surface area products for active apical efflux, passive diffusion and 
paracellular pathways, respectively.  
Equation 5-2 and 5-3 can be further refined (Chapter 6) to describe the initial 
permeability from B to A ( ) or A to B ( ) 
 
                                                 
                                       Eq.5-5 
 
 
                                                     
                                         Eq. 5-6 
Paracellular permeability of mannitol was used as a surrogate for PAN PSPC.    
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PSD was estimated from the PAN flux in parent MDCKII (PSAE=0) by rearranging 
Equation 5-5 (or 5-6) as  
                                         Eq. 5-7 
 
Permeability associated with ABCG2 apical efflux (PSAE) was estimated from B 
to A or A to B PAN flux in rAbcg2/ABCG2 - MDCKII rearranging Equation 8 or 9, 
respectively. 
 
                                                           
                                                   Eq. 5-8 
 
 
                                                      
                                      Eq.5-9 
Initial transfer flux of from B to A (assuming CA=0) or A to B can be rewritten 
(Chapter 6) and used to solve for CC as Eq. 5-10 
 
                                                         
                                          Eq. 5-10 
ERα is defined as the ratio of the initial rate of B to A flux divided by the initial rate 
of A to B. 
 
                                                     
                                            Eq. 5-11 
Kinetic Parameter (KM and TMax) Estimation 
 The saturation kinetics of PAN isomers apical efflux transport by rAbcg2 or 
ABCG2 (PSAE) as a function of estimated cellular concentrations (Equation 5-10) 
can be modeled by Eq. 5-12 where Tmax   is the maximum transport rate and Km 
the Michaelis constant, inversely reflecting binding affinity of substrate for 
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transporter.  Non-linear regression using GraphPad Prism (5.02) was employed 
to determine Km and Tmax in Equation 5-12 from PSAE  
 
                                                      
                                                  Eq. 5-12 
5.4 Results  
Pantoprazole isomers transported in rAbcg2 or ABCG2.   The expression 
level and function of transport study of stably expressing rat Abcg2/ human 
ABCG2 cDNA or vector alone in MDCKII cell lines has been tested in a previous 
study (Wang et al., 2008) and unpublished data (Phil Empey’s Thesis). The mass 
transport of PAN isomers was studied in empty-MDCKII and rAbcg2-MDCKII 
cells as shown in Figure 5-3. There was no difference observed for flux in either 
direction (A to B or B to A) or isomer-related flux in PAN isomer transport in 
empty-MDCKII monolayers at any of the five concentrations examined.  In 
contrast, the transport of PAN isomers exhibited directional flux in rAbcg2-
MDCKII cell line. There were marked transport differences between the PAN 
isomers at 30 and 50 μM for both directions.  At lower (3 and 10 μM) 
concentrations, the difference between the isomers became negligible.  At the 
highest donor concentration (200 μM) both isomers collapsed to flux identical to 
the empty- 
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Figure 5-3 Mean (± SD, n=3) PAN isomer transport in pcDNA3.1-MDCKII (left panels) or 
rAbcg2-MDCKII cells (right panels) at 3, 10, 30, 50 and 200μM. 
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Figure 5-4 Mean (± SD, n=3) PAN isomer transport in pcDNA3.1-MDCKII (left panels) or 
human ABCG2-MDCKII cells (right panels) 3, 10, 30, 50 and 200μM. 
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MDCKII.   Parallel results were observed in empty-MDCKII and human ABCG2-
MDCKII cell line transport study (Figure 5-4).  The directional transport of the two 
isomers confirmed that PAN is a substrate for both human and rat ABCG2. 
Permeability parameters (PSobs, PSD and PSPC) and asymmetry efflux 
ratios (ERα).  Apparent permeability for PSobs, PSD, PSpc and asymmetry efflux 
ratios (Table 5-1 and 5-2) were obtained for both rat and human ABCG2.  Using 
PSobs of PAN transport in empty-MDCKII, PSD was estimated from Equation 5-7 
at different concentrations and both directions were very close (Table 5-1 and 5-
2).  Assuming the transport permeability of mannitol is similar to PAN isomer 
transport across paracellular pathway, PSpc values were small and consistent 
across studies.  PSpc values were lower for ABCG2-MDCKII compared to empty-
MDCKII.  PSobs of PAN isomers in empty-MDCKII cell lines were very similar for 
both directions at different concentrations resulting in ERα values approximating 
unity for all of the experiments.  By contrast, the PSobs of both PAN isomers in the 
transfected cell lines were very different with respect to direction, favoring strong 
basolateral to apical directional flux at lower PAN concentration.  The apparent 
flux were similar, but with subtle differences.  At the lowest PAN concentration, 
the ERα(s) of (-)-PAN was nearly double that of (+)-PAN.   Flux was decreased 
from basolateral to apical side in Abcg2/ABCG2-MDCKII and increased from 
apical side to basolateral as donor concentration increased (Table 5-1 and 5-2).  
As a result, the ERα(s) of PAN isomers in both rat and human ABCG2 
transfected cell lines decreased with increasing donor concentration (Table 5-1 
and 5-2). The direct driving force of transport is cellular concentration of 
substrate not donor concentration.  
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Table 5-1 The asymmetry efflux ratios (ERα) and permeability parameters (PSobs, PSD and PSPC) of PAN isomers transport in empty 
vs rat Abcg2-MDCKII as a function of PAN donor concentration (PS units: (μL/hr)/cm2).    
 
Isomer Parameter Direction 3uM 10uM 30uM 50uM 200uM Mean SD
A->B 118 123 116 121 130 121 5
B->A 120 130 123 126 135 127 6
1.02 1.06 1.07 1.04 1.04 1.05 0.02
A->B 116 114 110 123 142 121 13
B->A 117 121 116 135 140 126 11
1.01 1.07 1.06 1.09 0.98 1.04 0.05
231 242 226 251 271 244 18
2.30 1.14 3.54 0.72 1.39 1.82 1.12
A->B 7.4 30.1 92.5 109 127
B->A 253 224 151 137 136
34.0 7.44 1.63 1.26 1.07
A->B 12.8 20.9 33.5 79.1 126
B->A 238 229 206 194 162
18.7 11.0 6.16 2.46 1.29
0.51 0.88 3.44 0.72 1.59 1.43 1.20
n.a.
n.a.
n.a.
n.a.
n.a.
n.a.
Em
pt
y-
M
D
CK
II
Minus PSobs
ER
Plus PSobs
ER
PSD (Both Isomers)
PSPC (Mannitol)
rA
bc
g2
-M
D
CK
II 
Minus PSobs
ER
Plus PSobs
ER
PSPC (Mannitol)
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Table 5-2 The asymmetry efflux ratios (ERα) and permeability parameters (PSobs, PSD and PSPC) of PAN isomers transport in empty 
vs human ABCG2-MDCKII as a function of PAN donor concentration (PS units: (μL/hr)/cm2).   
 
Isomer Parameter Direction 3uM 10uM 30uM 50uM 200uM Mean SD
A->B 126 143 140 137 152 140 9
B->A 128 155 150 146 151 146 11
1.01 1.08 1.08 1.06 0.99 1.04 0.04
A->B 140 140 137 136 159 142 10
B->A 149 157 156 149 166 155 7
1.06 1.13 1.14 1.09 1.04 1.09 0.04
267 291 289 277 309 287 16
2.30 3.29 1.22 3.44 2.29 2.51 0.90
A->B 16.9 31.6 67.6 109 132
B->A 254 255 211 156 132
15.0 8.06 3.12 1.44 1.00
A->B 30.0 42.2 43.6 79.6 126
B->A 258 246 240 195 179
8.61 5.81 5.50 2.45 1.42
1.00 1.03 0.76 0.78 0.71 0.86 0.15
H
ua
m
n 
A
B
CG
2
Minus PSobs
ER
Plus PSobs
ER
PSPC (Mannitol)
Em
pt
y
Minus PSobs
ER
Plus PSobs
ER
PSD (Both Isomers)
PSPC (Mannitol)
n.a.
n.a.
n.a.
n.a.
n.a.
n.a.
95 
 
 
Cellular concentration profile   Simulated cellular concentrations of PAN 
isomers corresponding to donor concentrations are presented in Figure 5-5 as 
estimated from Equation 5-10 for both rAbcg2 and ABCG2-MDCKII based on 
initial estimates of permeability parameters (PSobs, PSD and PSPC) of PAN 
isomers and apparent PSAE values.   At low donor concentration (3 M), cellular 
concentration is estimated to be 3.2% of donor concentration for (-)-PAN and 
5.6% for (+)-PAN for rAbcg2 and 5.5% for (-)-PAN and 11% for (+)-PAN for 
ABCG2.  At high donor concentration (above 50 M), cellular concentration is 
predicted to approach ½ of donor concentration (Figure 5-5). 
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Figure 5-5  Predicted cellular concentration of PAN (Equation 5-10) relative to donor 
concentration based on PSD and PSPC described in Table 5-1 and 5-2 as well as fitted 
parameters TMAX and KM (Table 5-3) were used.  Squares indicate (+)-PAN, circles 
represent (-)- PAN, open symbols indicate rAbcg2-MDCKII and closed symbols 
represent ABCG2-MDCKII.  The line of identity is also illustrated. 
Kinetic parameters Km and Tmax for rat Abcg2 and human ABCG2.  The 
profile of apparent PSAE (both directions) as a function of estimated cellular PAN 
concentration is presented in Figure 5-6.   Kinetic parameters for the two 
isomers interaction with Abcg2 and ABCG2 are shown in Table 3.  The (-) isomer 
of PAN has an 8-fold lower KM compared to the (+)-PAN for both rAbcg2 (0.25 vs 
1.85 µM) and ABCG2 (0.6 vs 5.32 µM), indicating a higher affinity of 
rAbcg2/ABCG2 for the (-) isomer.   The (+) isomer of PAN has a 3-fold higher 
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TMAX compared to the (-)-PAN for both rAbcg2 (7.86 vs 2.49 nmol/hr*cm
2) and 
ABCG2 (10.2 vs 3.29 nmol/hr*cm2).  rAbcg2 had a lower KM (a higher affinity) for 
the PAN isomers compared to human ABCG2, but comparable TMax values.  The 
overall permeability (transport clearance at low PAN concentrations, PSAE) 
associated with rAbcg2 and ABCG2 was twice that for the (-) isomer compared to 
the (+) isomer of PAN. 
Modeling overall Permeability (PSObs).  Utlizing the PSD values from the 
empty –MDCKII (Table 5-1 and 5-2) as well as PSpc from the transfected cell 
lines (Table 5-1 and 5-2) and the ABCG2 related kinetic parameters (Table 5-3) 
the overall PS was modeled as a function of donor concentration (Figure 5-7).   
Donor concentrations were back calculated from the intercellular concentrations.  
The comprehensive relationships (Equations 5-5 and 5-6) were effective in 
modeling PAN flux in both directions of (-)- PAN (r2= 0.979) and (+)-PAN (r2= 
0.988) in ABCG2-MDCKII and (-)-PAN (r2= 0.985) and (+)-PAN (r2= 0.986) in 
rAbcg2-MDCKII. 
Table 5-3 The permeability parameters (PSD, PSPC and PSAE) and fitted mean (± SE) 
kinetic parameters (Km and Tmax) in both human ABCG2 and rat Abcg2.  
Parameters Unit Isomer 
Rat Abcg2 Human ABCG2 
Mean Mean 
Km μM 
(+) PAN 1.85 ± 0.66 5.32 ± 1.62 
(-) PAN 0.25 ± 0.06 0.6 ± 0.12 
Tmax nmol/hr*cm
2 
(+) PAN 7.86 ± 2.20 10.2 ± 2.43 
(-) PAN 2.49 ± 0.41 3.29 ± 0.48 
PSAE 
μL/hr*cm2 
(+) PAN 4,250 1,920 
[Tmax / Km] (-) PAN 9,960 5,480 
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Figure 5-6  Apparent apical efflux permeability (PSAE, Equation 5-12) as a function of 
simulated PAN cellular concentration (Equation 5-10). Panel A: rat Abcg2; panel B: 
human ABCG2-MDCKII cell monolayer; Squares indicate (+)-PAN, circles represent (-)-
PAN, open symbols indicate basolateral to apical PSAE and closed symbols represent 
apical to basolateral PSAE.  The initial estimates of parameters TMAX and KM (Table 5-3) 
were used to generate cellular concentration (Equation 5-10) and these concentrations 
were used in the final estimation process.  Both axes were log transformed for easier 
visualization; fitting was performed using untransformed pooled data from both 
directional PSAE.  The solid and dashed lines are the fitted results for the (-)- and (+)-
PAN isomers, respectively. 
 
98 
 
rAbcg2
1 10 100 1000
0
50
100
150
200
250
300
PSPC
Empty
PSD+PSPC
A.
Donor Conc ( M)
P
S
O
b
s
 (
u
L
/h
r*
c
m
2
)
 
ABCG2
1 10 100 1000
0
50
100
150
200
250
300
PSPC
Empty
PSD+PSPC
B.
Donor Conc ( M)
P
S
O
b
s
 (
u
L
/h
r*
c
m
2
)
 
Figure 5-7 Overall permeability (PSobs) as a function of PAN donor concentration. Panel 
A: rat Abcg2; panel B: human ABCG2-MDCKII cell monolayer; Squares indicate (+)-
PAN, circles represent (-)-PAN, open symbols indicate basolateral to apical and closed 
symbols represent apical to basolateral flux.   The simulation line represents Equation 5-
5 and 5-6 for basolateral to apical and apical to basolateral flux, respectively.  Fitted 
parameters TMAX and KM (Table 5-3) were used to generate cellular concentration 
(Equation 5-10) and simulation of overall PSobs together with PSD and PSPC as described 
in Table 5-1 and 5-2.  Model limits for basolateral to apical (PSD + PSPC), apical to 
basolateral (PSPC) and empty cell line flux are presented as reference. The small square 
box presents the range of PAN concentration in serum in rat or pharmacological 
concentration in human, respectively.  
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5.5 Discussion  
Transporters can play a role in the absorption, distribution, metabolism and 
excretion as well as a pharmacological effect of a variety of drugs.  A recent 
white paper raised several key issues for drug discovery and development, 
including which transporters are clinically important in drug absorption and 
disposition, and which in vitro approaches are predictive for studying drug 
interactions involving these transporters (Giacomini et al., 2010). Flux across a 
Caco-2 or P-gp overexpressing polarized epithelial cell lines was one of the 
prominent in vitro methods proposed in the paper.   Recently, our laboratory has 
described some of the limitations and interpretations of flux across a monolayer 
using a theoretical model (Chapter 6).  The impetus for the model arose, in part, 
from the PAN isomer flux data presented herein. PAN isomers have almost 
identical physiochemical properties. PAN isomers transported in ABCG2 
overexpressing MDCKII provided a simplified experiment model to compare 
important kinetic parameters from Transwell.  
The apparent permeabilities (PSapp) of PAN isomers transport in empty 
MDCKII cell line (parent cell line) at five different concentrations were virtually 
identical (Table 5-1 and 5-2).  There was no directional transport difference 
observed at any concentration; indicating no interaction of PAN isomers with 
endogenous transporters in the parent MDCKII cell line.  This observation is 
consistent with other reports from literature (Breedveld et al., 2004) and suggests 
that PAN is a model substrate for this commonly used polarized epithelial cell 
line.  PAN has been commonly used as an ABCG2 inhibitor in drug-drug 
interaction or ABCG2 substrate identification studies (Breedveld et al., 2004; 
Adkison et al., 2009; Oostendorp et al., 2009). In the present study, PAN was 
transported by human ABCG2 and rat Abcg2; it is particularly evident at 30 and 
50 μM (Figure 5-3 and 5-4). The results confirm that both PAN isomers are 
rAbcg2/ABCG2 substrates.  
The stereoselective interaction of PAN with rAbcg2/ABCG2 was evident at 
30 and 50 μM but was not evident at lower (3 μM and 10 μM) or higher 
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concentrations (200 μM). The model provides for a clearer interpretation of the 
isomer flux.  The rate limiting steps for PAN flux are associated with diffusion 
(PSD and PSPC) and not rAbcg2/ABCG2 associated PSAE under these 
concentrations.  Only at the intermediate donor concentrations when 
rAbcg2/ABCG2 become saturated is a change in flux observed.   Flux studies, 
including those examining stereoisomer differences, are carried out at low 
substrate concentrations in high expressing clones to optimize the opportunity for 
observing a response.   It should be noted that under such conditions, it is 
unlikely that stereoselective interactions would be reported since diffusion 
pathways dominate overall flux.    
Taken together the flux data from empty and rAbcg2/ABCG2-MDCKII cell 
lines were consistent with the three compartment kinetic model shown in Figure 
5-2, in which the passive apparent permeability on either apical or basolateral 
side (PSD), paracellular apparent permeability through tight junction between 
cells (PSPC) and the active apparent permeability of ABCG2 on apical side (PSAE) 
as shown.   Isolating the various parameters (PSD, PSPC, VMax and KM) allowed 
the overall PSObs to be successfully modeled (Figure 5-7).  PAN flux in the B to A 
direction at low PAN concentration was very rapid across the apical membrane 
and overall flux was limited by the rate of diffusional flux across the basolateral 
membrane plus diffusion via the paracellular pathway.   PAN flux in the A to B 
direction was limited paracellular diffusion since the counter flux associated with 
PSAE was so efficient that virtually none of the drug which entered the cell from 
the apical surface fluxed transcellularly to the basolateral compartment. 
Relating kinetic parameters (VMax and KM) to donor concentrations was 
problematic.  Initial attempts to fit flux to permutations of the Micahelis Menton 
equation as a function of donor concentration resulted in fits which did not mimic 
the observed data.   Fitting flux to donor concentrations would suggest an 
apparent cooperative interaction with the transporter (Hill coefficient)(Pan et al., 
2007). Clearly the driving force for an apical efflux transporter such as 
rAbcg2/ABCG2 is intracellular not donor concentration.  The apparent 
cooperativity simply reflects the fact that there is relatively more cellular drug 
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concentration as donor concentration increases due to saturation of the efflux 
transporter (Figure 5-5).  Intracellular concentrations were not measured in the 
current study, but were predicted by the model (Figure 5-5) using the apparent 
PSAE as well as estimates of PSD and PSPC.  These intracellular concentrations 
were then used to estimate VMax and KM.   The estimated KM values ranged from 
0.25 to 5.3 μM), whereas the donor concentrations around the inflection point 
(Figure 5-7) were in the 20 to 100 μM range.  The (-)-PAN had a KM value that 
was 10% of the (+) isomer indicating (-)-PAN had an almost 10 fold higher affinity 
for ABCG2 as well as rAbcg2.   The capacity (VMax) was 60% lower for (-)-PAN 
for ABCG2 and rAbcg2.   For normal therapeutic dosing, serum unbound 
concentrations are likely to be below 0.1 μM, hence cellular concentrations are 
also expected to be well below the KM.  The effective permeability (PSAE listed in 
Table 5-3) would be more than two fold greater for (-)-PAN compared to the (+) 
isomer.   In the companion Chapter 4, the M/S for (-)-PAN in rats was 1.36 and 
decreased markedly in response to GF120918 (an inhibitor of rAbcg2/ABCG2) 
when compared to 0.54 for (+)-PAN (Chapter 4).  Hence, the stereoselective 
effect of PAN and rAbcg2 in vitro did manifest itself in a measureable in vivo 
difference in disposition. 
There may be differences in the human M/S for the two PAN isomers.  The 
current in vitro or rat data does not provide sufficient insight to explain the 
observed clinical report of a low M/S for pantoprazole (Plante et al., 2004).   
Differences in the overall disposition of the two isomers have been reported; 
however most of this difference appears to be related to differences in 
metabolism.  The stereoselective metabolism of (+)-PAN was impaired to a 
greater extent than (-)-PAN in the poor metabolizers of S-mephenytoin 4'-
hydroxylase (CYP2C19) (Tanaka et al., 2001)   The stereoselective metabolism 
via sulfoxide oxidation, 4'-O-demethylation, and 6-hydroxylation results in 
enantioselective pharmacokinetics; the area under the curve value of (-)-PAN 
was 1.5 times greater than that of (+)-PAN (Xie et al., 2005). Moreover, it should 
be realized that both isomers are converted to a common metabolite before 
achieving pharmacological activity, hence, the ultimate clinical effect of 
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stereoselective differences in disposition may be limited.  As our in vivo rat milk 
studies demonstrate, stereoselective differences in disposition attributed to 
ABCG2 can result in tissue concentrations being higher despite comparable 
systemic concentrations.  
In conclusion, there was stereoselective transport of PAN isomers in 
monolayers of both rat (rAbcg2) and human ABCG2 expressed in MDCKII cell 
line with the (-) isomer possessing a greater affinity.  A mechanism based model 
was used to quantify differences in kinetic parameters between the two isomers.  
These kinetic parameters provided insights as to the extent of differences that 
might arise for in vivo studies.   The current work also provided insights into the 
species difference in ABCG2 transport.  
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CHAPTER 6:Theoretical framework for 
transcellular flux across a monolayer system 
6.1 Summary 
In-vitro cell models are utilized to assess the role of transporter proteins on the 
vectorial transfer of drug across a polarized epithelial cell monolayer.  A 
mechanistic model is presented to challenge and verify the underlying concepts 
and boundaries of this approach.   Previous investigators have demonstrated the 
limitations of the apical efflux ratio (ERA), and proposed the use of the 
asymmetrical efflux ratio (ER ) as a more robust parameter. However, the 
assumption of a nonexistent paracellular transport pathway confounds parameter 
estimation and gives rise to an underestimation of the contribution of apical efflux 
(PSA,E).   Use of donor (and not cellular) concentration gives rise to an apparent 
positive cooperativty in kinetic parameters.   Neither observed permeability 
(PSobs) nor ER  plotted as a function of substrate (or inhibitor) concentration 
provide an accurate estimation of KM or KI.   Greater appreciation of the 
consequence of using high expressing clones and the transition of rate limiting 
steps (from basolateral alone to apical and basolateral processes) provides 
insight into the interpretation of flux kinetic data (TMax or KM) as well as inhibition 
profiles (KI).  The concepts presented in this paper provide a framework for 
interpreting transcellular flux across a cell monolayer and have implications for 
the assessment of drug-drug interactions involving transporters. 
6.2 Introduction 
Approximately 50 efflux and 360 uptake transporter proteins have been identified 
in mammalian species. These proteins are localized both in intracellular 
membranes as well as on the cell membrane.  They appear to play key roles in 
homeostasis through their selectivity for ions and larger endogenous molecules, 
but they also interact with exogenous substances and drugs. Their orientation on 
either apical or basolateral faces of epithelium or endothelium can greatly control 
and facilitate substrate passage across biological membranes. This interaction 
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has led to the realization that transporter proteins can play an important role in 
the pharmacokinetics and pharmacodynamics of drugs.  Initially, much of the 
interest in transporter–drug interactions was sparked by the role of ATP-binding 
cassette (ABC) efflux transporters, such as p-glycoprotein (P-gp), multidrug 
resistance associated proteins (MRPs) and breast cancer resistance protein 
(BCRP) in resistance to chemotherapy. More recently, the role of select efflux 
and uptake transporters, which polarize on opposite sides of the same cell and 
have common substrates, has also been recognized for their capacity to 
selectively control drug transfer across a variety of epithelial and endothelial 
blood-tissue barriers.  
In the context of drug development, in-vitro expression models are being used 
extensively to characterize transporter-drug interactions. From a regulatory 
perspective, these analyses are warranted by concerns that interindividual 
variation in transporter function and drug interactions may influence 
pharmacokinetics and ultimately pharmacodynamics (Zhang et al., 2008; Zhang 
et al., 2009).  As a result, transporter effects have been included in the drug 
labeling requirements (Zhang et al., 2008; Zhang et al., 2009). Currently, efforts 
are ongoing in the industry and at the FDA to develop and evaluate models for 
predicting the relevance of interactions between drugs and efflux or uptake 
transporters. These efforts are focused on classifying individual drugs as 
transporter substrates, inhibitors, and inducers and on providing quantitative 
measures that will prompt further in-vivo studies for rigorous evaluation of clinical 
relevance.  
Widely accepted systems for such studies include cells that polarize (e.g., 
MDCKII) and overexpress a cloned transporter.  Ideally, this model system has 
tight junctions and no endogenous transporters that would interact with the drug 
of interest.   While qualitatively useful for identification of substrates, using these 
expression systems for quantitative assessments should be carefully considered 
(Kalvass and Pollack, 2007) before making conclusions based on mathematical 
modeling of the transport data.    
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Although Michaelis-Menten type relationships analysis is often used to assess 
drug-transporter interactions, there are multiple assumptions, which if not 
carefully considered could potentially yield misleading results. Some of the 
assumptions include minimum contribution by physical barriers such as the 
unstirred water layer, minimum contribution by passive diffusion, and minimum 
paracellular transport. Here we examine how these assumptions can potentially 
influence the quantitative assessments of transport parameters obtained using 
these monolayer systems and offer insights and guidelines for analyzing vectorial 
transport data. 
Comprehensive Model for Transport Pathways across a Transwell System 
Flux across a cell monolayer grown on a support filter (e.g., Transwells) can be 
represented by a series of sequential and parallel barriers (Figure 6-1, Panel A).   
The barriers include permeability across the unstirred water layer at surfaces 
(PSUWL), permeability across the filter (PSF) and ultimately permeability across 
the monolayer itself (PSM).   
An equation can be written to describe overall permeability (PSOverall) that 
includes consideration of the properties of filter itself as well as flux across the 
parent cell model monolayer (assuming no active uptake or efflux processes 
present at basolateral or apical membranes) such that  
  6-1 
Experimentally it is difficult to discern permeability through the unstirred water 
layer and the filter and these terms are generally combined to yield 
         6-2 
The contribution of diffusion through the porous filter to overall permeability is 
rather negligible. However, diffusion across the unstirred water layer may present 
a significant barrier for more lipophilic drugs, whereas the cell monolayer itself is 
the rate limiting step in the overall permeability for more hydrophilic drugs.   
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The monolayer presents two distinct parallel pathways through which drug can 
pass, transcellular (PSTC) and paracellular (PSPC) as shown in Figure 6-1, Panel 
B.  
  6-3 
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Figure 6-1 Panel A: Model of flux across monolayer on Transwell system, depicting permeability-surface area clearance 
across unstirred water layers (PUWL), the filter (PSF) and the cell monolayer itself (PSM).  The subscripts A and B denote 
the apical (AP) or basolateral (BL) compartments. Panel B:  Model of flux across a model cell monolayer with all possible 
active transport processes.   The model depicts the processes governing the transfer of drug from the basolateral to apical 
compartments across the MDCKII (cellular) compartment.  Transfer processes include diffusion (PSD), active uptake on 
the basolateral and apical membranes (PSB,U and PSA,U, respectively), active efflux on the basolateral and apical 
membranes (PSB,E and PSA,E, respectively) as well as paracellular diffusion (PSPC). Transcellular transport processes are 
denoted as PSTC. 
CellularBasolateral Apical
PSD
PSB,U
PSD
PSA,E
PSA,UPSB,E
B C A
PSPC
Tight
Junction
PSTC
APBL
Filter Cell
Unstirred Water Layer
,UWL BPS ,UWL APS
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FPS
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The latter depends largely on the molecular size and the integrity of tight 
junctions. The former is comprised of two distinct barriers, the basolateral and 
apical membranes, with each containing multiple pathways that restrict or 
facilitate passage.  At a minimum, diffusion occurs across both membranes (PSD) 
and drug must cross these barriers in series. 
  
6-4 
 
Careful consideration must be given to passage across the unstirred water layer 
since it may present the rate limiting barrier for some drugs.   While the above 
analysis is restricted to diffusion (i.e., parent cell line), there are implications for 
expression systems as well.  The observations of Balakrishnan et al 
(Balakrishnan et al., 2007) suggest that a similar phenomena may occur for less 
lipophilic drugs for which flux across empty or parent cell monolayers is 
controlled by diffusion.  Their flux in overexpression systems, however, may be 
so rapid that the unstirred water layer becomes rate limiting.   Hence, variation in 
transporter expression or substrate affinity can readily influence which barrier is 
rate limiting (Balakrishnan et al., 2007). 
For the remainder of the paper, the contribution of the unstirred water layer will 
be assumed to be negligible. 
Integrated Monolayer Model  
While the resistance approach is simple and direct, there are limitations in its 
application and a broader model is warranted to explore the contributions of the 
two membranes to overall flux.  Assuming no endogenous transporters, passive 
diffusion permeability (PSD) is the same across both membranes, no cellular 
metabolism, and rapid intracellular diffusion, a kinetic model (Figure 6-1, Panel 
B) can be described by the following set of differential equations.  
Substrate flux into and out of the basolateral compartment, B, can be described 
by the following equation 
109 
 
 
 
6-5 
where XB is the mass of drug in the basolateral compartment; CC, CB and CA are 
the concentration of drug in the cellular, basolateral and apical compartment, 
respectively; PSB,E , PSB,U and PSPC are the permeability-surface area products 
for basolateral efflux, basolateral uptake and paracellular pathways, respectively. 
Substrate flux into and out of the cellular compartment, C, can be described by 
the following equation  
 
 
6-6 
where XC is the mass of drug in the cellular compartment; PSA,U and PSA,E are 
the permeability-surface area products for apical uptake and apical efflux 
pathways, respectively. 
Substrate flux into and out of the apical compartment, A, can be described by the 
following equation 
 
 
6-7 
where XA is the mass of drug in the cellular compartment. 
Flux Across an Untransfected Cell Line 
Assuming the absence of both active uptake into and efflux out of the cell, initial 
permeability for the basolateral to apical direction in the parent untransfected cell 
line ( ) can be written as 
  6-8 
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An identical equation can be written for flux in the apical to basolateral direction.  
Fluxes via parallel pathways, like diffusion through the cell and between 
cells are summed, while flux via pathways in series (i.e., diffusion across 
basolateral and apical membranes) is the reciprocal of the sum of the 
reciprocals . 
Initial Rate of B-to-A flux across a Monolayer 
For most experiments, an initial directional flux rate is often used.  The initial flux 
or appearance in the apical compartment for drug transferred from B→A 
(assuming CA=0), Equation 6-7 can be written as  
  6-9 
If rapid equilibrium between the basolateral and cellular compartment is 
assumed , then Equation 6 can be rewritten as 
  6-10 
Substituting Equation 10 into Equation 9 yields 
  6-11 
Hence, the initial permeability for the basolateral to apical direction ( ) can 
be described by the following equation  
 
 
6-12 
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Initial Rate of A-to-B flux across a Monolayer 
Likewise the directional flux rate in the apical to basolateral direction (assuming 
CB=0) can be written as 
  6-13 
Assuming rapid equilibrium between the apical and cellular compartments 
, Equation 6-6 can be rewritten as 
  6-14 
Substituting Equation 6-14 into Equation 6-13 yields the initial permeability for the 
apical to basolateral direction ( ) 
 
 
6-15 
 
Flux Across a Transfected Cell Line 
In order to understand the limitations of models describing flux across a 
monolayer, a broadly encompassing model that includes all of the flux processes 
can be utilized (Figure 6-1, Panel B).  Such an approach may be required to 
explore the relative contributions of the two membranes to overall transcellular 
flux as well as the contribution of paracellular flux.  However, this paper will focus 
attention on the most frequent analysis and on what is the current focus of the 
Drug-Drug Interaction Draft Guidance at the FDA; a monolayer in which an apical 
efflux transporter (i.e., P-gp, ABCG2, MRPs) has been expressed.   Table 6-1 
contains various scenarios to describe flux across such a model system.   
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In a single transfected system like ABCG2 (or MRPs), the other pathways are 
assumed to be negligible    and Equation 6-12 can be 
rewritten as  
  6-16 
 
Table 6-1 Scenario 2 describes the PSObsl for the ABCG2 transfected cell line in 
which passage across both membranes and between cells are contributing to the 
overall flux. 
PSA,E is determined by the properties of the substrate and the transporter, and 
can be written as in Equation 6-17 
  6-17 
where TMax is the maximum transfer rate associated with the active transport 
process, KM is the Michaelis-Menten constant (inversely related to affinity) for the 
transporter substrate complex and CC is the intracellular drug concentration 
available to interact with the transporter. 
As defined, PSA,E can vary according to inherent substrate characteristics (KM 
and TMax) or due to transporter expression level (scaling of TMax).  During the 
development of transfected cell lines, clones with high transporter expression 
levels are selected in order to develop a positive response model for identifying 
substrates and predict the role of the transporter in the drug’s disposition (i.e., 
significant change in B→A rate).  Thus, this process is inherently biased for 
selecting clones that can achieve a much greater PSA,E  (e.g., 10-fold) than PSD. 
Hence,  increases with increasing PSA,E  until it achieves a maximal flux 
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that is the upper boundary (PSD + PSPC), as defined by Equation 6-18, which 
evaluates Equation 6-16 at high PSA,E values relative to PSD.    
 
1
1
4
 
 
Table 6-1 Models depicting initial flux rates for parent and cloned cell model with diffusion across membranes (PSD), diffusion via paracellular 
pathway (PSPC) and active transport via an apical efflux transporter (PSAE) as well as the determinants of overall permeability (PS) for parent cell 
line as well as low and high expressing clones. 
Scenario B→A Flux A→B Flux 
Model Determinants of  overall 
PS 
Model Determinants of overall 
PS 
1.  Empty or 
Parent Cell 
Line 
 
 
 
 
 
 
 
 
 
 
2.  Apical 
Efflux 
Transporter 
Low 
Expression 
 
 
 
 
 
 
 
 
 
 
 
 
3.  Apical 
Efflux 
Transporter 
High 
Expression 
(PSAE>>PSD) 
 
 
 
Upper Boundary   
Apical membrane ceases to 
be a barrier; passage across 
basolateral membrane is rate 
limiting for transcellular flux. 
 
 
 
 
Lower Boundary  
All drug entering the cell is 
pumped back into apical 
compartment; only drug 
appearing in B is associated 
with paracellular pathway. 
ApicalBasolateral Cellular
PSD PSD
B C A
PSPC
Tight
Junction
ApicalBasolateral Cellular
PSD PSD
B C A
PSPC
Tight
Junction
PSD PSD
B C A
PSPC
PSA,E
PSD PSD
B C A
PSPC
PSA,E
Basolateral Cellular Apical
PSD PSD
B C A
PSPC
Tight
Junction
PSA,E
ApicalBasolateral Cellular
PSD PSD
B C A
PSPC
Tight
Junction
PSA,E
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  6-18 
In this limiting case, it becomes increasingly difficult to distinguish the role of 
PSA,E in the overall transport.  Flux across the apical membrane becomes so 
rapid such that overall vectorial flux across the monolayer is controlled by 
diffusion through the basolateral membrane (PSD) as well as by the paracellular 
pathway (Table 6-1, Scenario 3).  Clearly the B→A flux rate has a fixed dynamic 
range (2 fold) which is bounded and scaled by PSD. 
In a similar fashion, A→B flux for single transfected system like ABCG2 
(Equation 6-15) can be rewritten as 
 
 
     6-19 
Likewise as PSA,E increases, flux in the A→B direction reaches a lower limiting 
value.   
   6-20 
All drug mass that enters the cell by diffusion across the apical surface is 
pumped back into the apical compartment and does not cross the basolateral 
membrane (Table 6-1, Scenario 3).  Hence, only drug diffusing via the 
paracellular pathway reaches the basolateral compartment.   
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Figure 6-2 Panel A: Effect of increasing permeability-surface area clearance attributed to apical efflux (PSA,E) on observed flux 
(PSobs).  B to A flux increases as PSA,E increases to a maximum of diffusion across the basolateral membrane (PSD) and paracellular 
pathway (PSPC).  A to B flux (dX/dt) decreases as PSA,E increases to a minimum of diffusion across the paracellular pathway (PSPC).   
As the apparent permeability and permeability-surface area product are proportional to flux, substituting any of these parameters on 
the y-axis would yield the same relationship.  Panel B: The influence of PSA,E relative to PSD on permeability flux (PSobs) for 
situations where PSD is two (squares), five (diamonds) or greater than 10 times (circles) the paracellular flux (PSPC).  Panel C: Data 
from Panel B is normalized by adjusting for the dynamic range; all of the data from B to A (open circle) or A to B (closed circle) 
collapse to the identical line. 
A B
B to A
A to B
C
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Numerous published reports utilize the initial B→A vectorial transfer of drug 
to determine the influence of an apical efflux transporter.  While a logical 
approach, its limitations as a quantitative tool are rarely appreciated (Kalvass and 
Pollack, 2007).   From a practical perspective it is useful to consider those 
conditions under which an apically expressed transporter contributes to the 
overall flux of a series of drugs (or a given drug in a series of clones that vary in 
expression levels of the transporter).   Figure 6-2 Panel A shows the influence of 
PSA,E (relative to PSD) on the mass transfer of drug across a monolayer.   As 
PSA,E increases, the directional flux reaches an upper (B→A) and lower (A→B) 
boundary that is controlled by the diffusion properties of the basolateral 
membrane and paracellular passage.  Such data could experimentally arise due 
to clonal selection, i.e., comparing transcellular flux of one drug in different 
clones (PSA,E varies due to increasing transporter expression) or in comparing 
various drugs in a single clone (varied PSA,E or PSD).  For either situation, overall 
flux (PSObs) is bounded between the flux observed in the parent cell line 
(Equation 6-8) and the flux observed in the clone when PSA,E>>PSD (Equation 6-
18).  At lower PSA,E to PSD ratios (PSA,E / PSD < 0.2), contributions of active efflux 
is less apparent.   The appearance of drug in the apical compartment is governed 
by diffusion across both basolateral and apical membrane with contribution from 
paracellular diffusion.  At much higher PSA,E to PSD ratios ((PSA,E / PSD > 20.), 
flux approaches the boundary (i.e., diffusion across the basolateral membrane 
and paracellular pathway become rate limiting).  Figure 2 Panel B further 
illustrates this phenomena by plotting the measured flux as a function of PSA,E 
normalized to PSD.   Kalvass and Pollack (Kalvass and Pollack, 2007) presented 
a similar figure (Figure 6-2 in their reference) however, their model assumed 
paracellular to be nonexistent (PSPC=0).  For drugs which have poor diffusion 
permeability (PSD<10*PSPC) it is clear that paracellular flux cannot be ignored.   If 
the observed permeability surface area product (PSobs) is normalized for the 
dynamic range (influenced by PSPC) then all of the curves in Figure 6-2 Panel B 
collapse into a one B→A and one A→B flux graph can be seen as in Figure 6-2 
Panel C.   The inflection point in PSObs (50% in A to B and 150% for B to A) 
118 
 
occurs when PSAE / PSD = 2.    When this ratio is much less than 2, both 
basolateral and apical membranes contribute to controlling the appearance of 
drug in the receiver side.   When the ratio is much greater than 2, passage 
across the apical membrane ceases to be a barrier for B→A flux and drug 
appearance in the donor side is controlled by diffusion across the basolateral 
membrane and diffusion via paracellular route.  For A→B flux (PSA,E / PSD >> 2) 
the drug appearance in the receiver side is limited to drug arriving via 
paracellular passage.   Hence, the region near the inflection point is the most 
sensitive to changes in PSAE and has important implications when considering 
clonal selection, saturation and inhibition of the transporter (changes in apparent 
PSAE) and these concepts will be utilized later on in the paper.  Normalization 
(Figure 6-2 Panel C) provides a more universal application (a single graphical 
representation); however, it may also be somewhat misleading.   Data 
transformation as advocated by a number of groups (Kalvass and Pollack, 2007; 
Giacomini et al., 2010; Lumen et al., 2010), including efflux ratios (ERA, ER ) or 
the ratios of ratios (ER inhibitor / ER inhibitor)), can distort the experimental error 
and may result in a loss of critical insight between the experimental observation 
and its determinants, e.g., role of PSPC in parameter estimation (see below).    
While PS has its limitations (Kalvass and Pollack, 2007), PS, like systemic 
clearance, can be more readily related to underlying principles (i.e., rate limiting 
steps). 
ERA 
Frequently the rate of flux in B→A direction in the transfected cell line is 
compared to the parent cell line to quantitate the contribution of an apically 
expressed transporter.  This ratio is termed ERA and is estimated by  
  6-21 
Substituting Equation 6-16 and 6-19 and assuming , Equation 21 
yields 
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  6-22 
Equation 6-22 would imply that this ratio is independent of the very parameter of 
interest, namely PSA,E.   
Moreover, as PSPC approaches 0 (or is low relative to PSD), ERA approaches a 
limit  
  6-23 
This limitation was pointed out in the work by Kalvass and Pollack (Kalvass and 
Pollack, 2007).   Table 6-2 illustrates this point with ERA for both murine (Abcg2) 
and human (ABCG2) derived from the literature.  ERA approaches the limitation 
of 2 for most drugs, especially for the Abcg2 clones and supports the earlier 
assumption that for many of these substrates  largely due to the 
high transporter expression level for these clones.   Hence, ERA is not a 
discriminating parameter since it has limited dynamic range and the numerical 
value is independent of ABCG2 flux (PSA,E).   Rather ERA reflects the fact that 
flux across the system has changed from one controlled by diffusion across two 
barriers arranged in series (PSD/2) to diffusion across one barrier (PSD), the 
basolateral membrane. 
ER  
In contrast to ERA, a more robust parameter is the ratio of the rate of flux in one 
direction (B→A) over the opposite flux (A→B) in the transfected cell line (Kalvass 
and Pollack, 2007).  This ratio is termed the asymmetrical ER (ER ) and is 
estimated by 
  6-24 
Equation 6-24 can be rewritten using Equations 16 and 18 and experimentally 
setting  
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Moreover, as PSPC approaches 0 (or is low relative to PSD), ER approaches a 
limit  
  6-26 
It would appear that ER can be more readily related to PSA,E (Equation 27) and 
this relationship has been explored in the work of Kalvass and Pollack (Kalvass 
and Pollack, 2007).   
  6-27 
The magnitude of ER  estimates obtained in mouse and human ABCG2 
expressing cells is much greater; hence, it appears to be more discriminating 
compared to ERA (Table 6-2).  The ER  for the empty or parent cell is close to 
unity (+/-20%) for most substrates suggesting that endogenous transporters in 
MDCKII cells are playing a minor role in the flux of these molecules.  Exceptions 
to this assumption would include cimetidine, estradiol, nitrofurantoin, riboflavin 
and topotecan; indicating a likely interaction with endogenous MDCKII 
transporters.    
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Table 6-2 Comparison of the ERA and ERα of several Abcg2/ABCG2 substrates in 
murine and human Abcg2/ABCG2-transfected MDCKII cell lines in the literature.  Apical 
efflux ratios (ERA), asymmetry efflux ratios (ERα), and the ratio of the asymmetry ratios in 
Abcg2/ABCG2-transfected vs. empty vector-transfected cells (ERα Ratio) in mouse 
(mAbcg2) or human (ABCG2) transfected MDCKII cells were calculated using flux data 
compiled from the literature.  Drugs where the mean of ERα Empty was not within 20% of 
unity were identified (shaded rows). 
Substrate 
Empty  mAbcg2  ABCG2  
Reference  
ERα ERA ERα ERA ERα 
Aflatoxin  1.12 1.58 9.32 1.15 1.91 
(van Herwaarden et al., 
2006) 
Albendazole  1.14 1.70 18.3 1.36 2.11 (Merino et al., 2005a) 
Cimetidine  1.26 3.01 7.14 2.44 3.11 (Pavek et al., 2005) 
Ciprofloxacin  0.88 2.52 4.37 1.18 2.13 (Merino et al., 2006a) 
Estradiol  0.68  -  - 0.83 0.66 (Pavek et al., 2005) 
Imatinib  1.03 2.39 35.3 -  -  (Breedveld et al., 2005) 
IQ  1.09 1.84 16.7 1.30 2.47 
(van Herwaarden et al., 
2006) 
Nitrofurantoin  0.64 2.63 8.70 2.66 3.21 (Merino et al., 2005b) 
Norfloxacin  0.91 2.92 3.26 1.29 1.32 (Merino et al., 2006a) 
Ofloxacin  0.90 2.22 6.17 1.29 1.56 (Merino et al., 2006a) 
Oxfendazole  1.14 2.35 5.70 0.87 1.17 (Merino et al., 2005a) 
Pantoprazole  1.00 1.34 5.05  -  - (Breedveld et al., 2004) 
PhIP  1.20 1.27 16.43 1.89 12.7 
(van Herwaarden et al., 
2003; Pavek et al., 2005) 
Riboflavin  0.13 2.33 1.65 -  -  
(van Herwaarden et al., 
2007) 
Topotecan  2.23 3.13 14.85 1.46 5.79 
(Breedveld et al., 2004; 
Pavek et al., 2005) 
Trp-P-1  1.09 2.89 4.25 1.64 1.39 
(van Herwaarden et al., 
2006) 
 
While valuable, there are limitations to the use of ER .  In order to use ER  as 
depicted in Equation 6-26, PSPC was assumed to be negligible.  In our lab (as in 
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others), PSPC in MDCKII cells is relatively low, but not zero (1-2% of the amount 
initially in the donor per hour).  PSPC contributes significantly to passage of drugs 
with lower lipophilicity, the very drugs for which transporters would appear to be 
most critical.   As indicated by the ratio of Equations 6-18 and 6-20, at the limit 
(i.e., assuming that PSA,E>>PSD when clones are overexpressing the 
transporter), ER , much like ERA,  reflects the ratio of fluxes that are independent  
of the transporter protein (Equation 6-28). 
  6-28 
Hence, evaluating the vectorial transport of high affinity substrates in 
overexpressing clones may generate ER  values that do not correlate with PSAE. 
The influence of PSPC on ER is demonstrated in Figure 6-3 Panel A.  When 
PSPC is zero there is a linear relationship between the ER and PSA,E regardless 
of the PSD value.    However, in the presence of a typical PSPC there is a 
deviation from linearity such that ER  is no longer proportional to PSA,E.  The 
deviation becomes more problematic as PSD decreases since the paracellular 
pathway contributes more to the overall flux in either direction.   At high ratios of 
PSAE / PSD  ER reaches the experimental boundary defined by Equation 6-28.  
The impact of PSPC on the estimation of PSAE (Equation 6-27) is illustrated in 
Figure 6-3, Panel B.  As PSPC approaches zero then PSA,E is accurately 
estimated.  However, in the presence of a typical PSPC, estimates of PSA,E 
diverge from their true values, and substrates with the lower PSD are most 
affected. 
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Figure 6-3 Panel A Asymmetrical flux ratio (ERα) as a function of increasing PSA,E relative to PSD (10, 25, 50 and 250 uL/hr*cm
2) 
when PSPC is 1.5 uL/hr*cm
2. Dashed line represents the case for all values of PSD when PSPC is 0.  Panel B  Estimated apical efflux 
permeability (PSA,E ; Equation 27 ) relative to the true value of PSA,E as a function of increasing PSA,E relative to PSD (10, 25, 50 and 
250 uL/hr*cm2) when PSPC is 1.5 uL/hr*cm
2. Dashed line represents the case for all values of PSD when PSPC is 0. 
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Saturable PSA,E 
A number of investigators have characterized the influence of increasing donor 
concentration on the basolateral to apical flux of drug across a cell monolayer 
when characterizing an apical efflux transporter (Breedveld et al., 2004; Kitamura 
et al., 2008).   The interpretation of such analysis has several limitations.   
If PSA,E is assumed to be a saturable process (Equation 6-17), then Equation 16 
can be rewritten to describe the flux of drug from basolateral to the apical side 
  6-29 
As similar fashion, flux from apical to the basolateral side, Equation 6-19, can be 
written as 
  6-30 
In order to assess an accurate KM the concentrations to be characterized are 
cellular and not donor concentration (basolateral or apical compartment).   These 
concentrations are not equivalent; nor is the relationship between them fixed for 
a saturable efflux system.   Earlier in considering the initial flux rates, it was 
assumed that the cellular concentration comes to rapid equilibrium and can be 
defined by the model parameters as in Equation 6-10 for (B→A flux) and 
Equation 6-14 (A→B flux); hence, it is possible to simulate CC for the initial rate 
calculation.  For a single transfected apical efflux transporter model examining 
B→A flux (as well as A→B flux), the relationship for CC approximates the 
following. 
  6-31 
A more complex relationship arises when considering saturation of the efflux 
transporter as in Equation 6-32 
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  6-32 
that can be rearranged to yield an expression which equates donor concentration 
(CB) to a given cellular concentration 
  6-33 
Hence, simulations using cellular concentrations can be performed and donor 
concentrations derived from Equation 6-33.   A much greater challenge is to 
assess cellular concentrations in an experimental setting; nonetheless 
simulations provide useful insights that guide experimental design and 
interpretation of the results.   
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Figure 6-4: Panel A Internal cellular concentration (CC) as a function of external donor concentration (CD) for a drug modeled in 
which PSD is fixed at 250 uL/hr*cm
2, TMax is fixed at 5,000 pmol/hr/cm
2and KM varies from 0.05 M to 5 M (hence, PSAE varies from 
100,000 to 1,000 uL/hr*cm2, respectively). Dotted line represents line of unity.  Panel B Concentration relationship between apparent 
PSobs and cellular (CC, open symbols) or donor (closed symbols) concentration for a drug with PSD of 250 uL/hr*cm
2, PSPC of 1.5 
uL/hr*cm2,TMax of 5,000 pmol/hr/cm
2 and KM  of 0.5 M.  The simulation was performed using CC and equations 29 and 30.  
Subsequently corresponding donor concentrations were solved for using the influence of saturating the apical efflux transporter 
(Equation 33).
A B
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Figure 6-4 Panel A illustrates the predicted relationship between cellular (CC) 
and basolateral donor concentration (CD) for a model system containing an apical 
efflux transporter.  At low donor concentrations, the intercellular concentration is 
considerably lower for larger PSA,E (i.e., when KM is smaller) since drug is 
pumped out of the cell more effectively.  At higher donor concentrations, the 
transporter becomes saturated and the cellular concentration approaches a limit 
of half the donor concentration (i.e., same concentration achieved in parent cell 
line).  While intuitively obvious, the full impact of this observation is realized when 
examining the Panel B in Figure 6-4 which illustrates the relationship between 
observed flux and cellular or donor concentration.  The nonlinear function relating 
cellular and donor concentration causes the relationship between flux and donor 
concentration (squares Panel B Figure 6-4) to be steeper than a simple 
saturation model.   Without an appreciation for the need to model cellular 
concentration, a saturable model with a positive Hill coefficient (estimated near 
2.5) would need to be invoked in order to describe the relationship between flux 
and donor concentration.  If the cellular concentrations could be used, a simple 
saturation model is sufficient to characterize the model (circles Figure 6-4 Panel 
B).   
Another limitation of this type of data is the interpretation of the inflection point on 
the plot of apparent PS and concentration (donor or cellular).   As described 
earlier (Figure 6-2, Panel B) the 50% (A→B flux) and the 150% (B→A flux) 
value of the PSObs occurs when the value of PSA,E approaches twice that of PSD.  
Typically this inflection point (CC,inf pt) has been interpreted as being 
representative of KM; however, this is inaccurate for flux across a monolayer.   
The concentration corresponding to this inflection point, CC,inf pt can be defined as  
 
 
6-34 
which can be rearranged to yield  
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Figure 6-5 Apparent permeability-surface area clearance (PSobs) A→B directional flux 
(Panel A and C) and ER  (Panel B and D) as a function of substrate concentration 
(cellular: open symbols; donor: closed symbols).  PSPC is 1.5 uL/hr*cm
2 and PSD is 50 
uL/hr*cm2 . Panel A and B Substrates vary in KM with both substrates having a TMax of 
2.500 pmol/hr/cm2.   Substrate 1 (circles) has a KM of 0.2 M and Substrate 2 (squares) 
has a KM of 2.0 M.  Panel C and D Substrates vary in TMax with both substrates having 
a KM of 0.2 M.  Substrate 1 (circles) possessing TMax of 2.500 pmol/hr/cm
2, and 
Substrate 3 (squares) has a TMax of 10,000 pmol/hr/cm
2. 
As evident from Equation 6-17, PSAE (at low CC) is the ratio of TMax to KM. 
  6-36 
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Hence, the greater the ratio of apical active efflux to diffusion permeability 
(PSA,E/PSD>>2) the greater CC,infpt  will deviate from KM.   The mechanistic 
understanding of this deviation can be illustrated for the apical efflux transporter 
scenario depicted in Table 6-1.   For high affinity transporter substrates tested in 
high expression cell monolayers, flux across the apical membrane at 1/2 PSA,E 
(when CC = KM) results in apical flux which is many fold greater than PSD.   
However, flux across the apical surface will not be rate limiting under those 
conditions.   PSA,E will only begin to approach 2PSD when the CC is much greater 
than KM as defined by Equation 6-36.  Figure 6-5 Panel A illustrates the change 
in A→B flux as a function of cellular and donor substrate concentration.  [To 
simplify presentation, only A→B flux is depicted; however, B→A flux is a mirror 
image of A→B flux relative to the location of the inflection point].  The inflection 
point of PSObs (A→B or B→A) as a function of CC does not correspond to KM 
(Figure 6-5 Panel A).  The cellular CC, infpt values were virtually identical at close 
to 25 M for the two substrates despite the tenfold difference in KM (0.2 and 2.0 
M, respectively).  As predicted by Equation 6-36, the inflection point for PSObs 
occurs at a cellular concentration which is much larger than the KM (125-fold for 
Substrate 1 and 12.5-fold for Substrate 2).  Moreover, the corresponding donor 
concentrations (plotted in most flux experiments) were close to 100 M for both 
substrates and the steepness of the relationship is again evident.   Kalvass and 
Pollack (Kalvass and Pollack, 2007) advocate using ER rather than PSObs to 
estimate kinetic parameters.   As can be seen in Figure 6-5 Panel B the 
inflection point is closer to KM when plotting ER  as a function of concentration; 
however, it is not equivalent to KM even if the cellular concentrations were known 
(open symbols).   The overall flux rate (or ratio of fluxes, ER ) is dominated by 
the slow step, i.e., diffusion across the basolateral membrane.  For the two 
examples depicted in Figure 6-5 (Panel A and B) flux across the apical 
membrane at CC=KM is 10 to 100 greater than flux across the basolateral 
membrane.  This influence of PSA,E/2PSD on inflection point for apparent PS can 
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also be seen in Figure 6-5 Panel C, in which KM is common, but TMax differs for 
the substrates.  The cellular CC,infpt values were different at 25 and 95 M for the 
two substrates despite having identical KM values (0.2 M).   Equation 36 
predicts an inflection point which would be 125-fold greater than KM for Substrate 
1 and 500-fold for Substrate 4 under the specified conditions.  Again, the 
inflection point is closer to KM when plotting ER  as a function of concentration 
(Figure 6-5 Panel D) but far from identical. Again, the saturation of the apical 
efflux transporter becomes evident only when its flux rate slows considerably and 
approaches the diffusion permeability of the drug.  Interpretation of monolayer 
flux data must be done with considerable appreciation for the limitations of the 
system and an understanding of those factors controlling flux. 
Parameter Estimation for Saturable PSA,E 
Given the complexity of the donor to cellular concentration relationship (Figure 6-
4, Panel A) and the fact that PSObs is a hybrid parameter, estimation of kinetic 
parameters from Transwell flux data is problematic, but not intractable.   Table 6-
3 outlines an approach that can provide estimates of TMax and KM using 
Transwell flux data.   Several key assumptions underpin the analysis such as (1) 
paracellular flux of the drug can be modeled using the flux of a marker substrate 
(e.g., mannitol or sucrose), (2) no endogenous transport processes, (3) no 
cellular metabolism and (4) cellular concentration can be modeled as described. 
Our laboratory has investigated the interaction of pantoprazole isomers with 
ABCG2 in a transfected MDCKII cell model using this approach (Wang and 
McNamara, 2010).   Pantoprazole isomers exhibited many of the properties 
illustrated in the current analysis; i.e., boundaries illustrated in Figure 6-4 Panel 
B at low and high pantoprazole donor concentrations, inflection point related to 
TMax not KM, kinetic analysis with donor concentrations suggesting positive 
cooperativity.  Using the approach outlined in Table 6-3, reasonable parameter 
estimates were obtained (Wang and McNamara, 2010). 
 
1
3
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Table 6-3 Iterative approach for the estimation of TMax and KM using transcellular flux data. 
Parameter Substrate/Cell Eq Rearranged to Comments 
Paracellular 
Permeability
 
Mannitol (or 
sucrose) / Parent 
cell line 
6-8 
 
1. Solve for PSPC using mannitol data. 
2. Assume that paracellular flux is similar 
for drug and marker (mannitol or 
sucrose). 
Diffusion 
Permeability
 
Drug / Parent cell 
line 
6-8 
 
3. Confirm drug is not a substrate for 
endogenous transporter,  ER  is unity 
for parent cell line. 
4. Solve for PSD using drug data and PSPC 
from mannitol data. 
Transcellular 
Permeability
 
Drug / Transfected 
cell line 
 
 
5. Solve for transcellular permeability 
PSTC,B→A.  
6. Similar case for A to B flux  
Apparent 
Apical Efflux 
Permeability
 
Drug / Transfected 
cell line 
6-16 
 
7. Approximate apparent apical efflux 
for B to A direction using 
, PSD and PSPC). 
8. Approximation is more accurate near 
the inflection point; error is significant 
near the boundaries (contribution of 
PSAE is masked). 
Apparent 
Apical Efflux 
Permeability
 
Drug / Transfected 
cell line 
6-19 
 
9. Approximate apparent apical efflux 
 for A to B direction using 
, PSD and PSPC) 
Initial Cellular 
Concentration 
 
Drug / Transfected 
cell line 
6-31 
 
10. Approximate initial cellular concentration 
(CC) using CD, PSD and . 
Kinetic 
Parameters 
 
Drug / Transfected 
cell line 
6-17 
 
11. Nonlinear regression analysis of PSAE, 
apparent as a function of CC to fit the 
parameters (TMax and KM). 
12. Steps 4-9 may be repeated to refine 
estimates of CC and PSAE, apparent 
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Inhibition of PSA,E 
As mentioned earlier, there is considerable interest in assessing drug-drug 
interactions involving transporters.   Inhibition of transcellular flux has been 
advocated as a viable approach for screening, however, there is considerable 
concern regarding the ability to compare results obtained using different model 
substrates or different cell lines or clones (Giacomini et al., 2010).  At low cellular 
concentrations of substrate (CC<<KM), the influence of a competitive or non-
competitive inhibitor on permeability-surface area product associated with the 
active transport component can be written as: 
  6-37 
where IC is the cellular concentration of the inhibitor and KI is the Michaelis-
Menten constant (inversely related to affinity) for the transporter inhibitor 
complex. 
As discussed by Kalvass and Pollack (Kalvass and Pollack, 2007) the use of 
B→A flux data or ERA alone can be misleading, resulting in inaccurate estimates 
of inhibition constants (KI).   Figure 6-6 Panel A illustrates the influence of 
increasing inhibitor concentration on the apparent permeability-surface area 
A→B flux for a substrate.  If the inhibitor is also a substrate for the transporter 
then the nonlinear nature of the relationship between cellular and donor 
concentration of the inhibitor needs to be considered (Equation 6-33, Figure 6-4 
Panel A).   As cellular inhibitor concentration increases, the efflux pump 
becomes inhibited and the substrate flux returns to that of the parent cell line.   
The difference between the two inhibitors (KI values of 0.1 and 0.5 M) is evident 
in Figure 6-6 Panel A; however, it should be noted that the inflection point for 
these cellular concentration inhibition curves (0.9 and 4.5 M, respectively) do 
not correspond to the KI values.  
Again as described earlier (Figure 6-2, Panel B) the 50% (A→B flux) and the 
150% (B→A flux) value of the PSObs occurs when apparent PSAE approaches a 
133 
 
value which is twice that of PSD.  A drug could be defined as an effective inhibitor 
if it causes the flux of a known substrate to decrease to half of its maximum for 
B→A (150%) transport or minimum for A→B (50%).   The cellular inhibitor 
concentration corresponding to this inflection point,CC,inf pt can be defined as  
 
 
 6-38 
Rearranging this equation to yield a relationship which defines the concentration 
of inhibitor required to cause a 50% decrease in the apparent flux in a 
transmembrane system relative to the actual KI and the substrate’s active apical 
efflux (PSA,E) and passive diffusion (PSD) characteristics. 
  6-39 
Equation 6-38 would imply that the concentration of inhibitor needed to cause a 
substantial change in flux is dependent on the characteristics of the substrate 
(PSA,E and PSD) in addition to properties of the inhibitor (KI).   Use of ER  does 
not provide an accurate estimation of KI (Figure 6-6 Panel B) for either donor or 
cellular concentration.   Again, the influence of an inhibited PSA,E is not evident 
until it’s numerical value approaches twice that of PSD. 
Figure 6-6 Panel C expands on this issue in that a better efflux substrate (higher 
PSAE) is more difficult to inhibit causing a shift to the right of the inhibition profile 
(IC,infpt increases from 0.9 to 9.9 M for the tenfold higher PSA,E).  In a similar 
fashion (Equation 6-39), inhibition of a substrate with a higher diffusion 
permeability (PSD) occurs at lower inhibitor concentration (IC,infpt decreases as 
substrate PSD increases). Again ER  plotted as a function of inhibitor 
concentration (donor or cellular) reveals inflection points which are influenced by 
PSA,E of the substrate (Figure 6-6 Panel D). 
The influence of the BCRP inhibitors FTC and GF120918 on the B→A flux for 
nitrofurantoin, cimetidine and PhIP in BCRP-MDCKII cells were examined in our 
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laboratory (Philip Empey Thesis, Figure 6-7).   At a concentration of 10 M, FTC 
was shown to be effective at inhibiting flux of all three substrates; however, 
GF120918 (1 M) was effective in inhibiting nitrofurantoin and cimetidine, but did 
not inhibit PhIP B→A flux.   One interpretation of such data might be that there 
are multiple binding sites for BCRP.  Giri et al (Giri et al., 2008) suggested that 
similar inhibition profiles supported evidence for the involvement of multiple 
binding regions for BCRP.   In the context of the current model analysis 
(Equation 6-38), another interpretation could also be put forth.   For the same 
inhibitor (same KI), a much higher concentration will be required to see a change 
in overall flux rate when substrates have a higher PSA,E to PSD ratio.  The 
concentration needed to cause the apparent PSObs to decrease by 50% (between 
the transfected with no drug and the parent cell flux), is greater than KI.   The 
greater the PSD at the basolateral surface the less transport at the apical surface 
has to change in order for overall PSObs to be altered.   Subsequent experiments 
in our lab (Philip Empey Thesis, data not shown) revealed that higher 
concentrations of GF120918 (10 M) decreased the B→A flux of PhiP.  Hence, 
this inconsistency in altering flux of different substrates with a common inhibitor 
may not be a result of multiple binding sites, but rather a consequence of data 
interpretation in light of the complexity of the model system. 
 
 
 
1
3
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Figure 6-6 Apparent permeability-surface area clearance (PSobs) A→B directional flux (Panel A and C) and ER  (Panel B and D) for 
a substrate (PSA,E = 500 uL/hr*cm
2 and PSD of 25 uL/hr*cm
2 at low substrate concentration) as a function of inhibitor concentration 
(cellular: open symbols; donor: closed symbols) with a PSPC of 1.5 uL/hr*cm
2.  Panel A and B Inhibitors vary in KI with both inhibitors 
have a PSD, and TMax of 25 uL/hr*cm
2 and 500 pmol/hr/cm2 respectively.   Inhibitor 1 (circles) and Inhibitor 2 (squares) have KI values 
of 0.1 and 0.5 M, respectively. Panel C and D Same inhibitor but substrates vary in PSA,E; both substrates having PSD of 25 
uL/hr*cm2.  Substrate 1 (squares) has a PSA,E of 500 uL/hr*cm
2 and Substrate 2 (circles) has a PSA,E of 5,000 uL/hr*cm
2.  Inhibitor 
has PSD, TMax and KI values of 25 uL/hr*cm
2, 500 pmol/hr/cm2 and 0.1 M, respectively.
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Figure 6-7 Apparent permeability-surface area clearance (PSobs) B→A directional flux for (Panel A) Nitrofurantoin at 10 M, (Panel 
B) Cimetidine at 5 M and (Panel C) PhiP at 2 M in MDCKII cells transfected with human ABCG2 in the absence or presence of 1 
M GF120918 or 10 M FTC. 
A B C
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Discussion 
Interactions between transporters and drug substrates are of great interest in 
drug development and in-vitro cell models are constructed to study the 
importance of a given transporter protein on the vectorial transfer of drug from 
one side of a polarized epithelial cell barrier to the other.  An example includes 
the use of MDCKII cells into which a transporter gene has been cloned and the 
protein is usually expressed at high levels.   While the experimental paradigm is 
widely utilized, the limitations and interpretations of the results of such studies 
are not broadly understood (Bentz et al., 2005; Balakrishnan et al., 2007; Kalvass 
and Pollack, 2007; Korjamo et al., 2007; Lumen et al., 2010).   An appreciation of 
the underlying conceptual framework and assumptions that provide insights into 
the mechanisms of drug uptake and efflux when using such in-vitro models is 
needed in order to make broader inferences regarding drug absorption, 
disposition and for predicting the potential for drug-drug interactions.   The goal 
of the present analysis was to provide the framework for systematically 
examining data from such models.   An appreciation of controlling (rate limiting 
steps) or boundary conditions provides insights as to the interpretation of 
resulting observations. 
The work of Kalvass and Pollack (Kalvass and Pollack, 2007) represented an 
important conceptual step forward illustrating some of the complexities with 
modeling and interpreting vectorial transport data.   They clearly demonstrated 
the limitations of ERA, recognizing that transporter overexpression on one 
surface (e.g., apical) results in diffusion across the opposite surface (i.e., 
basolateral) being the rate limiting transport process across the monolayer. 
Hence when studying the role of an apical transporter in B→A flux, in comparison 
to the untransfected parent cell line, the ERA metric is an unreliable index for the 
magnitude of the transporter’s contribution to the overall flux because this rate 
limiting situation yields asymptotic values for a range of affinities.  Table 6-2 
provides further experimental evidence supporting the concern that ERA is not a 
discriminating parameter.   ER  or the asymmetrical flux, on the other hand, was 
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thought to be more robust and would more readily correlate with the extent of 
transporter drug interaction.  Again, the current analysis (Table 6-2) supports that 
ER  is a more robust parameter.   However, the discriminating power of this 
parameter relies on the assumption that the paracellular transport pathway 
contributes negligibly to the overall flux across the membrane, which can be 
invalid for many experimental paradigms (e.g., MDCKII cell models) and can 
confound parameter estimation and the values of ER .   The degree to which 
paracellular flux influences ER or PSA,E appears to be greatest for those 
substrates with lower passive diffusion, i.e., substrates for which a transporter 
would seem most critical for membrane flux.   
The current analysis suggests that kinetic parameters (e.g., KM) derived from 
vectorial flux data must be interpreted with caution.  Kitamura et al (Kitamura et 
al., 2008) examined the role of multiple transporters in the hepatobiliary transport 
of rosuvastatin.   The KM values for rosuvastatin uptake into HEK293 cells for 
OATP1B1 (0.80 M) was considerably different from those attributed to 
OATP1B1 obtained using a double transfected (OATP1B1/MRP2) MDCKII model 
(29.9 M), and the authors concluded that the transcellular transport of 
rosuvastatin might not be determined solely by the uptake clearance.   Breedveld 
et al (Breedveld et al., 2004) estimated a K1/2 for the B→A flux of pantoprazole in 
an MDCKII-mBcrp model system of 0.1-1.2mM.  Experimental work in our 
laboratory (Wang and McNamara, 2010) would suggest a much higher affinity 
(lower KM) for mBcrp and pantoprazole than might be inferred from the K1/2 value.    
The active site for an efflux transporter is likely to be intracellular, although the 
active site for p-GP may be imbedded in the inner membrane itself.   Hence, the 
driving force for efflux transporters is the concentration in a compartment other 
than the donor.  The present examination illustrated that the nonlinear 
relationship between cellular and donor concentration gives rise to an apparent 
positive cooperatively relationship when examining flux as a function of donor 
substrate (or inhibitor) concentration.  Several groups have reported positive 
cooperatively in transcellular flux for p-GP (Keogh and Kunta, 2006b) and BCRP 
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(Pan et al., 2007).  Clearly an alternative explanation is the differential between 
the internal and external concentration gradients.  It is likely this phenomenon of 
positive cooperatively is also observed for cellular uptake studies.   
Giri, et al (Giri et al., 2008) has examined the inhibition of substrate (prozosin, 
zidovudine, abacavir and imatinib) flux in BCRP overexpressing MDCKII cells by 
a number of inhibitors.   At a fixed concentration, Ko143 inhibited the flux of all of 
the substrates whereas GF120918, nelfinavir and Pluronic P85 exhibited 
differential inhibition depending on the substrate.  The authors suggested that 
these observations supported evidence for the involvement of multiple binding 
regions for BCRP (Giri et al., 2008).   Another interpretation of the data might be 
related to the relative magnitude of active transport and passive diffusion flux for 
the substrates relative to the KI for the inhibitors.   Again, parameters arising from 
flux experiments needs to be interpreted with caution. 
The concepts presented in this paper provide a framework for interpreting 
data arising from flux across a cell monolayer.   Without the appropriate context, 
quantitative and qualitative (mechanistic) errors arise that ultimately can 
misinform our understanding of transporter function and their influence on 
pharmacokinetics and pharmacodynamics (Zhang et al., 2008; Zhang et al., 
2009). 
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CHAPTER 7: Summary and conclusion 
Drug accumulation in milk is a rising concern for the strategy of 
breastfeeding. Understanding the mechanism of active drug transport into milk is 
a key step to provide guidance for drug use in lactation.  ABCG2 is highly 
expressed in mammary gland during lactation in mouse, cow and human studies 
and is responsible for the active transport of some xenobiotics into milk.  
In this dissertation, we confirmed that Abcg2, but not P-gp, is highly 
expressed in rat lactating mammary gland by western blot and 
immunohistochemistry. Abcg2 was upregulated during lactation compared with 
non-lactation as shown by Real-time PCR. A rAbcg2-MDCKII cell line has been 
characterized as functional one by Flow Cytometry and the transport of 
nitrofurantoin. Utilizing GF120918 as an effective inhibitor of rAbcg2, a “chemical 
knockout” rat model has been established for milk active transport study.   The 
M/S for nitrofurantoin was decreased dramatically in this viable alternative to the 
genetic knockout mouse model.  
Half of all drugs are marketed as chiral substances. While there are some 
studies of stereoselective interaction with P-gp transport or chiral metabolism, 
there is no report demonstrating stereoselective interaction between drugs and 
ABCG2.  From our investigation, pantoprazole is a prototypical substrate of 
human ABCG2 as well as of rat Abcg2. There is stereoselective interaction 
between Abcg2/ABCG2 and pantoprazole as demonstrated in both in vitro and in 
vivo experiments. ABCG2 recognizes pantoprazole enantiomers differently which 
resulted in significant differences in M/S ratios for the two isomers in the rat 
study. M/S ratios of pantoprazole isomers in rat mediated by passive diffusion 
were determined and predicted by a passive diffusion model. Since chirality does 
not alter basic physical and chemical properties, no difference was observed 
between predicted M/S ratios of pantoprazole isomers.  The ratios of 
(M/SObserved)/ (M/SPredicted) of plus and minus pantoprazole were 4.43 and 11.95, 
respectively, which supported a role for a transporter in the high M/S ratios of 
pantoprazole isomers. GF120918 decreased M/S ratios of both isomers but had 
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a more significant effect on the minus isomer of pantoprazole. Both pantoprazole 
isomers form an identical active metabolite that does not have a chiral center, so 
the stereoselective interaction between pantoprazole and ABCG2 is unlikely to 
result in any significant clinical consequences. However, this stereoselective 
recognition may have consequences for other chiral drugs. The M/S ratio of 
either isomer of pantoprazole in rat was much higher (25 time or 68 times) than 
one human case report (M/S=0.02). The reason for this species difference has 
not been resolved.  
Five concentrations of pantoprazole isomers were transport by either rat 
Abcg2 or human ABCG2. Having identical chemical properties (diffusion 
controlled) as well as no interaction with endogenous transporters of the MDCKII 
cell line, the pantoprazole isomers provided an ideal platform to compare the 
kinetic parameters derived from Transwell experiments, e.g., PSD, PSAE, PSPC, 
Km and Vmax. The results demonstrated a consistent trend for pantoprazole 
transport across these two species. Km and Vmax of pantoprazole enantiomers in 
rat Abcg2 or human ABCG2 were estimated from fitting data with very modest 
differences between species.  
Cell monolayer flux across Transwell or Snapwell is a broadly used method 
for studying drug transporter or for screening new molecule entity in drug 
development. Three compartment models instead of a single barrier model have 
been established by different groups in order to explain the complex 
observations. Transport of pantoprazole isomers in Abcg2/ABCG2 
overexpressing MDCKII cell line provided solid evidence for a mathematic model 
of the monolayer system. Paracellular transport of a hydrophilic compound may 
not be assumed negligible compared with transcellular transport. Cellular 
concentration and not donor concentration is the direct driving force of 
transcellular transport for an apical efflux transporter like ABCG2.  The model 
confirmed the importance of assessing the data from the context of rate limiting 
barriers in series or in parallel.  For good substrates in highly expressing cell 
clones passive diffusion on the basolateral side is the limiting step in efflux 
transporter on the apical side in a monolayer system, so that the ERA does not 
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reflect PSAE. ERα is a more robust parameter than ERA but the expression level 
of efflux transporter and cellular concentration can still affect the value of ERα. 
Due consideration should be taken when setting up criteria in drug screening 
based on the value of ERα. The estimation of Km, Ki or IC50 from monolayer 
system is not directly related to a property or function of a transporter, but is 
related to the transition from one rate limiting step (flux across the basolateral 
membrane) to multiple barriers (flux across both basolateral and apical 
membranes).  
In conclusion, transporters are broadly expressed in barriers (i.e., blood brain 
barrier, intestine epithelial barrier, renal epithelial barrier, mammary gland 
epithelial barrier and so on), playing an important biological role for the regulation 
of endogenous and exogenous substrate concentrations across cells, tissues 
and systems.   A mechanistic three compartment monolayer model with 
appropriate expression of transporters is critical to our understanding of these in 
vivo biological barriers.   Specific transporter expressing cell lines grown in 
monolayer systems can provide invaluable insights into their function provided 
that an appropriate expression level of transporter can be correlated with function 
and flux assessment can be put into the context of limitations of the model 
system. 
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APPENDICES 
Appendix A: List of Abbreviations 
A Membrane surface area 
ABC ATP-binding cassette transporter superfamily 
ACV Acyclovir 
ADME Absorption, Distribution, Metabolism and Excretion 
AUC Area under the concentration-time curve 
BCRP Breast cancer resistance protein 
CA Concentration in the apical (milk) compartment 
CB Concentration in the basolateral (serum) compartment) 
CC Concentration in the cellular (LMEC) compartment 
Cmilk, unbound Unbound concentration in the milk 
 
Cserum, unbound Unbound concentration in the serum 
 
CDC 
 
The Centers of Disease Control and Prevention 
CM 
 
Cimetidine 
CP 
 
Ciprofloxicin 
DMSO 
 
Dimethyl sulfoxide 
ERα 
 
Asymmetry efflux ratio; ratio of the initial rate of B→A flux 
divided by the initial rate of A→B flux 
FACS 
 
Fluorescence-activated cell sorting 
fm 
 
Fraction protein bound in the milk 
 
fs 
 
Fraction protein bound in the serum  
 
GF120918 
 
N-(4-[2-(1,2,3,4-tetrahydro-6,7-dimethoxy-2-isoquinolinyl)ethyl]-
phenyl)-9,10-dihydro-5-methoxy-9-oxo-4-acridine carboxamide  
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NF 
 
Nitrofurantoin 
PAN 
 
Pantoprazole 
Papp, 
(μL/hr)/cm2 
 
The apparent permeability 
PDR 
 
The Physician’s  Desk Reference 
PSAE 
 
Permeability-surface area products of apical efflux 
 
PSD Permeability-surface area products of passive diffusion  
PSPC 
 
Permeability-surface area products of paracellular flux 
between cells 
MRP 
 
Multiple resistance protein  
M/S 
 
Drug concentration in milk to drug concentration in serum 
MXR Mitoxantrone resistance-associated protein 
MTX Methotrexate 
NIS 
 
The National Immunization Survey 
RER 
 
Rough endoplasmic reticulum 
RLMS 
 
Ross Laboratory Mother Survey 
RN 
 
Ranitidine 
SA 
 
Salicylic acid 
TEB 
 
Terminal end buds 
XA The mass of drug in the apical compartment 
 
XB, The mass of drug in the basolateral compartment 
 
XC The mass of drug in the cellular compartment 
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Appendix B: Glossary 
ATP 
 
ATP is a molecule which consists of the nitrogenous base 
adenine linked to the sugar ribose and which has a chain of 
three phosphate groups attached to the ribose in a linear 
fashion. ATP is present in all living cells and serves as an 
energy source for many metabolic processes; energy is 
released when ATP is hydrolyzed into ADP. It is the single 
most important molecule in all living things since it serves as 
the currency for energy in biological systems. 
 
ATPase 
 
Enzyme that catalyzes a process involving the hydrolysis of 
ATP. A large number of different proteins, including ABC 
transporters, have ATPase activity. 
 
Baculovirus 
vectors 
 
They are used for expression of foreign genes in insects. 
Caco-2 The Caco-2 cell line is an immortalized line of heterogenous 
human epithelial colorectal adenocarcinoma cells. 
Monolayers of Caco-2 cells are widely used to predict the 
absorption of compounds. This tool is also suitable to study 
active transport processes. 
 
cDNA Single-stranded complementary DNA synthesized from an 
RNA template by the action of RNA-dependent DNA 
polymerase. cDNA (i.e., complementary DNA) is used in a 
variety of molecular cloning experiments as well as serving 
as a specific hybridization probe. 
 
Cloning, 
Molecular 
The insertion of recombinant DNA molecules from 
prokaryotic and/or eukaryotic sources into a replicating 
vehicle, such as a plasmid or virus vector, and the 
introduction of the resultant hybrid molecules into recipient 
cells without altering the viability of those cells. 
 
DMPK Drug metabolism and pharmacokinetics 
 
Drug interactions 
 
 
The action of a drug (termed perpetrator) that may affect the 
activity, metabolism, or toxicity of another drug (termed 
victim). 
Drug 
 
Any substance which when absorbed into a living organism 
may modify one or more of its functions. The term is 
generally accepted for a substance taken for a therapeutic 
purpose, but is also commonly used for abused substances. 
Synonymous with medicine, pharmaceutical. 
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Efflux transporter Proteins, located in the cell membrane, which transport 
molecules out of the cell. 
Endogenous Produced inside an organism or cell. 
 
Endothelial cell of 
the brain 
capillaries 
Monomolecular cell layer separating the blood and brain 
tissue. Play a major role in blocking xenobiotic and some 
endogenous substances from entering the brain. 
 
Epithelial cells 
 
Cells that line the inner and outer surfaces of the body. 
 
 
Flow-cytometry An instrument that allows one to gather information from 
single cells by light scattering or fluorescence properties. 
These provide information on the size and internal complexity 
(forward scatter and side scatter, respectively) as well as 
"markers", identified by staining with fluorescent probes such 
as conjugated antibodies in the case of immunophenotyping, 
or nucleic acid dyes in the case of reticulocyte enumeration 
and DNA content analysis. 
 
In vitro A biological or biochemical process carried out in a test-tube, 
culture plate or similar vessel. 
 
In vivo  
 
A biological or biochemical process occurring in a living 
organism. 
PCR Polymerase chain reaction (PCR) is a rapid, inexpensive and 
simple method for producing relatively large numbers of 
copies of DNA molecules from minute quantities of source 
DNA material--even when the source DNA is of relatively 
poor quality. It has rapidly become one of the most widely 
used techniques in molecular biology and molecular 
pathology. 
 
Sf9 
 
An insect ovarian cell, Spodoptera frugiperda (Sf9), has been 
widely used to express recombinant proteins, as a host cell in 
the baculovirus expression system. 
 
Vesicle 
 
A relatively small and enclosed compartment, separated from 
the cytosol by at least one lipid bilayer. Vesicles store, 
transport, or digest cellular products and wastes. 
 
Xenobiotic Chemical substances those are foreign to the biological 
system. They include naturally occurring compounds, drugs, 
environmental agents, carcinogens, insecticides, etc. 
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Appendix C: Chemical Structures 
 
1. GF120918 
 
 
2. Cimetidine 
 
 
3.Pantoprazole 
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4. Methotrexate 
 
 
5.Nirofurantoin 
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6. Riboflavin  
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Appendix D: Standard curves for HPLC assay 
1.  The standard curve of NF in rat serum   
Range: 62.5-8000ng/ml; Y=0.0017x; r2=0.9999 
0 2000 4000 6000 8000
0
5
10
15
NF Conc. (ng/ml)R
a
ti
o
 (
H
e
ig
h
t 
o
f 
N
F
 t
o
 h
e
ig
h
t 
o
f 
F
Z
)
 
2. The standard curve of NF in rat milk:  
Range: 0.725-29 μg/ml; Y=0.6272x; r2=0.9993 
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3. The standard curve of NF in cell culture media  
Range: 3.9-8000 ng/ml; Y=16.921x; r2=0.9999 
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4. The standard curve of pantoprazole in cell culture media (this is one 
Std curve for 10μM PAN experiment) 
Range: 15.6-8000 ng/ml; Y=130.3093x; r2=0.9998 
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Appendix E-1: Chromatogram of PAN and internal standard of LC-MS 
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1. Chromatogram of PAN in phosphate buffer: A: 1250 ng/ml PAN mixture; B: 
1500ng/ml (-) PAN; C: 1500ng/ml (+) PAN; D: blank.  
  
 
 
 
 
 
 
 
 
A 
B 
C 
D 
(+)PAN (-)PAN 
(-)PAN 
(+)PAN 
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2. Chromatogram of PAN and internal standard in milk sample: A and B: 
1250ng/ml PAN and IS in milk sample; C and D: blank milk sample. 
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3. Chromatogram of PAN and internal standard in serum sample: A: IS; B: PAN 
isomers. 
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Appendix E-2: Standard curves for LC-MS assay 
E-2-1: The standard curve of PAN isomers in phosphate buffer.  
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E-2-2: The standard curve of PAN isomers in milk. 
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E-2-3: The standard curve of PAN isomers in serum. 
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Appendix F: The expression of Abcg2 RNA Ontogeny   
Material and Methods 
Tissue collection: 
Eight adult female Sprague-Dawley rats (four lactating and four non-lactating) 
were purchased from Harlan Laboratories (Indianapolis, IN). The mammary 
glands were harvested in lactating rats on day 16 to 18 post partum and all 
tissues from non-lactating and lactating rats were fresh frozen in liquid nitrogen 
and then stored at -80 °C until the time of analysis by real time PCR.  
RNA isolation and quantitative PCR 
Isolation of total RNA from mammary gland was performed using the RNeasy® 
Micro Kit per manufacturer protocol with sample disruption using Qiashredder® 
and on-column DNAse treatment.  The total RNA concentration was determined 
by the measurement of optical density at 260 nm with a small volume UV-Vis 
Spectrophotometer (ND-1000, NanoDrop, Wilmingon, DE). Total RNA integrity 
was verified by an OD260/OD280 absorption ratio greater than 1.9.  Reverse-
transcription of 1μg RNA to cDNA was performed with the SuperScriptTM First-
Strand Synthesis System for RT-PCR kit following manufacturer’s protocol using 
oligo(dT) to prime the reaction preferentially for mRNA. The total cDNA samples 
of liver and intestine ontogeny were from Maggie Abbassi (Maggie Abbassi 
Thesis).  
Quantification of the expression level of rat Abcg2 was performed using the 
quantitative polymerase chain reaction (qPCR) on the iCycler Multicolor Real-
Time PCR Detection System (Bio-Rad, Hercules, CA).  The primer sequences 
were obtained from published literature and double checked with reference 
sequences deposited in NCBI’s Entrez Gene with the software assistance of 
Primer3 (Whitehead Institute for Biomedical Research, Cambridge, MA) and 
Oligo Tool Kit (Operon, Huntsville, AL). The primers utilized were confirmed to 
generate unique products using NCBI’s BLAST. Reference accession numbers, 
primer sequences, and product sizes are provided in table 6-1 
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Table 0-1 The primer sequences of rat Abcg2 for Qualitative PCR 
Gene Reference 
Sequence 
Forward Primer (5’→3’) Prod. 
Size  
(bp) 
Mg 
Conc 
(mM) 
Anneal 
Temp 
(ºC) 
Ref. 
Reverse Primer (5’→3’) 
Rat 
Abcg2 
AB105817 TAT GAG GTT CTT GCC AAG 
TGT TAT 
181 3.5 60 (Bergman 
et al., 
2005) 
CTA ACA TGA AGT ACA ATA 
AAC AAG 
 
qPCR reaction master mixes (50 µL) were made using the SYBR® Green PCR 
Core Reagents kit and contained 200 nM of each primer, 1.25 mM dNTPs, 1x 
SYBR Green buffer, 0.025 U/μL Taq polymerase, optimized concentrations of 
magnesium chloride for each primer pair, 20 nM fluorescein, and 0.10 μg of 
sample cDNA. The protocol for thermal cycling was: 
Cycle  1: (  1X)  
 Step  1:   95.0ºC for 05:00 
Cycle  2: ( 50X)  
 Step  1:   95.0ºC for 00:45 
 Step  2:   60.0ºC for 01:00 
 Step  3:   72.0ºC for 01:00 
 Data collection and real-time analysis enabled. 
Cycle  3: (  1X)  
 Step  1:   95.0ºC for 02:00 
Cycle  4: (100X)  
 Step  1:   95.0ºC for 00:30 
 Decrease setpoint temperature after cycle 2 by 0.5ºC 
 Melt curve data collection and analysis enabled.  
Cycle  5: (  1X)  
 Step  1:    4.0ºC HOLD 
163 
 
 
The mammary gland from a lactating rat 16 days post-partum was used as the 
comparator for relative quantification (to generate the standard curves). The 
standard curve of each qPCR has correlation coefficients > 0.99 and PCR 
efficiencies of 95-100%. 
Finally, to confirm the generation of a single product of appropriate size, all 
amplification products were separated by 3% agarose gel electrophoresis in 1 x 
TBE running buffer for 50 min at 150 mV, visualized by staining with ethidium 
bromide, and imaged on an Image Station 2000 MM (Eastman Kodak, New 
Haven, CT).  
Results 
 Expression of Abcg2 in non-lactating vs lactating mammary gland 
qPCR was performed to determine if the transcripts for Abcg2 in mammary gland 
was increased  during lactation. Rat Abcg2 amplification curve, standard curve, 
single products on the melt curve analysis and agarose gel electrophoresis are 
shown in Fig. A-1. After amplification Abcg2 could be detected and the product 
was confirmed by agarose gel electrophoresis. The RNA expression in mammary 
gland was increased almost 8 times than non-lactating rats. However one non-
lactating rat had relative high Abcg2 level which is close to lactating mammary 
gland.  
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Figure 0-1 Rat Abcg2 amplification curve, melt curve analysis, standard curve, and 
agarose gel electrophoresis generated from standards over a 4-log10 dilution series for 
Abcg2 expression in lactating and non-lactating mammary gland.    
 
Table 0-2 mRNA of Abcg2  expression level in lactating and non-lactating mammary 
gland. 
200 bp 
125 bp 
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Animal #       1 2 3 4 Ave. 
Lac 0.141 0.433 0.0657 0.0909 0.183 
Non-lac 0.00192 5.39E-05 0.0863 0.00708 0.024 
Ratio(Lac/non-lac)       7.662 
 
 
 
Expression of Abcg2 in intestine and liver ontogeny 
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Figure 0-2 Rat Abcg2 amplification curve, melt curve analysis, standard curve, and 
agarose gel electrophoresis generated from standards over a 4-log10 dilution series for 
Abcg2 expression in intestine at different age.    
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Figure 0-3 The expression level of rAbcg2 in intestine at different ages. Data were 
obtained from four rats in each group and the values that do not share the same letter 
are significantly (P < 0.05) different from each other. 
 
 
 
 
 
 
200 bp 
125 bp 
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Figure 0-4 Rat Abcg2 amplification curve, melt curve analysis, standard curve, and 
agarose gel electrophoresis generated from standards over a 4-log10 dilution series for 
Abcg2 expression in liver at different age.  
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Figure 0-5 The expression level of rAbcg2 in liver at different ages. Data was obtained 
from four rats in each group and the values that do not share the same letter are 
significantly (P < 0.05) different from each other. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
169 
 
Appendix G: Inhibition of pantoprazole isomers on cimetidine transport across 
MDCKII empty and MDCKII-Abcg2 monolayer.  
Material and Methods 
Cells were seeded on microporous membrane filters (3.0-μm pore size, 24-
mm diameter; Transwell 3414; Corning Inc., Corning, NY) at a density of 1.0 × 
106 cells/well. Cells were grown for 4 days to achieve transepithelial electrical 
resistance >200 Ω ∙ cm2, and medium was replaced every other day. Before the 
experiment, the medium at both the apical and basolateral side of the monolayer 
was replaced with 2 ml of OptiMEM medium (Invitrogen) without serum and 
either 100μM each pantoprazole isomer or OptiMEM only with 5 μM cimeditine 
traced with 0.1μM 3H cimetidine containing 0.2 μCi/ml [14C]sucrose. Cells were 
incubated at 37°C in 5% CO2. We required that layers restricted sucrose 
transport to <1% of the total radioactivity per hour. 150-μl aliquots were taken 
and accounted at 0.5, 1 and 2h for cimetidine and sucrose transport.  
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Figure 0-6 Inhibition of pantoprazole isomers on cimetidine transport across MDCKII 
empty and MDCKII-Abcg2 monolayer. A: Cimetidine transports in empty and rAbcg2-
MDCKII cell lines; B: Cimetidine transports in rAbcg2-MDCKII cell line in absence or 
presence of PAN isomers.  
  
A 
 
 
 
 
 
 
 
 
 
 
 
B 
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Appendix H: Rat Abcg2 expressed in Sf9 system: the structure of vector, 
screening procedure, expression level and function study.  
Establishment of rAbcg2 in Sf9 system 
The total RNA was isolated from rat liver. Specific RNA of Abcg2 was 
amplified to cDNA which was purified and identified in DNA gel. Both the cDNA 
of Abcg2 and pENTR vector were digested by enzyme Not I and Asc I.  Abcg2 
was inserted into pENTR vector. The structure of pENTR vector and combined 
pENTR-Abcg2 are shown in Figure A-7. Combined pENTR-Abcg2 was amplified 
in Ecoli. DNA was extracted and purified. After digested at attRI and attRII 
positions, it was inserted into pIB/V5- His-DEST vector (Figure A-8). The pIB/V5- 
His-DEST vector-rat Abcg2 was transfected into Sf9 cells.  
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Figure 0-7 The structure of pENTR vector (Left) and combined pENTR-Abcg2 (Right).  
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Figure 0-8 The structure of pIB/V5- His-DEST vector (upper) and pIB/V5- His-DEST-rat 
Abcg2 (lower).  
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Establishment of rAbcg2 in Sf9 system 
Population screening of rAbcg2-Sf9 
The rAbcg2-Sf9 population with higher Abcg2 expression level was sorted by 
Flow-Cytometry. The population was selected according to the comparison of 
fluoresce intension from Hoechst 33342 in vector and Abcg2-Sf9 combined with 
the result absence or presence of GF120918 in rAbcg2-Sf9. In order to get better 
rAbcg2-Sf9 population, they were grew and sorted after first sorting (Figure A-9). 
We tried to grow single clone rAbcg2-Sf9 by growing one cell but it was failed. So 
at last we chose to grow them as a population.  
First sorting 
 
 
Second sorting 
 
 
Figure 0-9 The rAbcg2-Sf9 population with higher Abcg2 expression level was sorted by 
Flow-Cytometry. Upper: first sorting. Lower: second sorting. A: Grey: vector; blue: 
rAbcg2. B: Grey: vector; blue: Vector+ GF120918. C: Grey: rAbcg2; blue: rAbcg2+ 
GF120918. R4: sorted rAbcg2 population.  
R4 R4 
R4 
A                                              B                                          C 
A                                            B                                         C 
175 
 
Expression level of rAbcg2 in Abcg2-Sf9 
Crude membrane fractions were prepared from vector only or rAbcg2-Sf9 
cells, rat lactating mammary gland and kidney. The western blot was performed 
to test the expression level of Abcg2. The result was shown in Figure A-10.  
 
 
 
 
Figure 0-10 The Western result of rAbcg2 expression in Sf9 cells.  
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Function of rAbcg2 in Sf9 
The plasma vesicles were prepared by the method in Leier’s paper (Leier et 
al., 1994). ATP dependent methotrexate (1000μM) accumulation in vesicles at 20 
minutes was performed according to the methods in Gerk’s paper (Gerk et al., 
2007). Forty μg vesicle proteins were used for each reaction of experiment. The 
results are shown in Figure A-11and time dependent experiment is shown in 
Figure A-12. 
 
 
 
 
 
 
 
 
 
 
 
Figure 0-11 Methotrexate accumulated in presence of ATP or AMP in vesicle of vector 
or rAbcg2 in Sf9 cells (left panel). ATP dependent methotrexate transport by membrane 
vesicle from vector or rAbcg2 in Sf9 cells (right panel). Data are presented as mean±S.D 
(n=3). 
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Figure 0-12 Time dependent of methotrexate accumulation in presence of ATP or AMP 
in vesicle of vector or rAbcg2 in Sf9 cells.  
 
The problem of ABCG2/Abcg2-Sf9 vesicle experiment 
In vesicle experiment the time dependent and concentration dependent 
experiments were performed for the estimation of Km and Vmax of Abcg2/ABCG2. 
The linear range of “uptake” of Abcg2/ABCG2 has been observed in time 
dependent experiment. Thus, the best incubation time could be determined. 
However, the saturation could not be clearly observed in concentration 
dependent experiment. The variability is big and could not see a smooth plateau. 
One of the possible reason is the Abcg2-Sf9 is a population not monoclonal cell 
line. Some of cells might have low Abcg2 expression and increased passive 
diffusion so that the active efflux mediated by Abcg2 can be masked.  
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Appendix I: The mass transport of pantoprazole isomers in human ABCG2 
expressing in MDCKII cell lines at 3-200μM concentrations. (Note: this is the 
same data as shown in chapter 5. In this part, the data is shown as mass transfer 
rate from both directions vs donor concentration.Figure A-13 and A-14) 
Note: Mass transport of a drug mediated by an active transporter vs donor 
concentration is a common method to describe the transport profile. From it, the 
kinetic parameters can be estimated, such as Km and Tmax. However, Transport 
data by Transwell model is different from that in vesicle transport studies. In 
order to get a direct picture and see how different between Transwell data and 
vesicle data, the mass transport of pantoprazole isomers in human ABCG2 
expressing in MDCKII cell lines at 3-200 µM concentrations are shown as bellow.  
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Figure 0-13 PAN isomers are transported in empty (upper) and ABCG2(lower) in 
MDCKII cells from 3-200μM concentrations.  
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Figure 0-14 PAN isomers are transported from A to B or B to A direction in empty and 
ABCG2 in MDCKII cells at each concentration.  
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